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Nonalcoholic fatty liver disease (NAFLD) has become one of the most common hepatic 
diseases worldwide, making the diagnosis and management of NAFLD an emerging 
public health issue. Theories associated with NAFLD surmise that inflammation may be 
the root cause, along with the complex interplay of other chronic conditions such as 
obesity, metabolic syndrome, diabetes, dyslipidemia, and cardiovascular disease (CVD). 
It is unknown if other inflammatory conditions such as rheumatoid arthritis (RA), along 
with the use of methotrexate (MTX), might confer increased risk for NAFLD. 
Longitudinal data collected from a retrospective cohort of 17,481 adult RA patients in the 
United States were used to determine the incidence and factors associated with the 
development of NAFLD using a noninvasive tool (Fibrosis-4 score). Results of the 
Kaplan Meier analysis showed that 31% of this cohort developed NAFLD, in about 7 
years from baseline, with most having mild to moderate disease and only 1.4% with 
advanced disease. RA patients also had a prevalence of chronic conditions associated 
with NAFLD, as seen in the general population. In the Cox proportional hazard 
multivariate analysis, age (middle and elderly), hypertension, CVD, dyslipidemia, 
metabolic syndrome, exercise, use of MTX, and non-MTX antirheumatic drugs were 
independent predictors for the development of NAFLD. This research could improve 
early diagnosis of NAFLD using a novel noninvasive tool. Increase awareness of the 
prevalence and causes of NALFD inform clinical practice and management of the disease 
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Chapter 1: Introduction to the Study  
Nonalcoholic fatty liver disease (NAFLD) is predicted to be the next global 
epidemic of liver disorders, mostly as a result of obesity (Ray, 2013). Prevalent comorbid 
conditions rooted in inflammation such as metabolic syndrome, obesity, diabetes mellitus 
, cardiovascular disease (CVD), and dyslipidemia appear to accelerate the development 
of NAFLD (Argo & Caldwell, 2009; Lonardo, et al., 2015). Rheumatoid arthritis (RA) is 
a chronic inflammatory condition, also associated with similar risk factors such as 
obesity, metabolic syndrome, hypertension, hypertriglyceridemia, low levels of high 
density lipids (HDL), diabetes, insulin resistance and CVD (Chung et al., 2008; Crowson 
et al., 2011). What is unknown is if other chronic illnesses such as RA might confer a risk 
for NAFLD given the overlap of these factors associated with inflammation. 
Additionally, a known hepatotoxic drug, methotrexate (MTX) often used to treat RA has 
been associated with increased elevation of liver enzymes, and the development of 
NAFLD (e.g. fibrosis) of the liver (Arena et al., 2012; Sakthiswary, Chan, Koh, Leong, & 
Thong, 2014). In this study, I investigated whether NAFLD is present among patients 
with RA, given the overlap of several risk factors related to inflammation and exposure to 
MTX. This association has not been documented or well characterized in the literature for 
this potentially at risk population.  
Increasing rates of obesity and metabolic syndrome and the anticipated parallel 
increases in the occurrence of NAFLD makes the diagnosis, management, and prevention 
of NAFLD an emerging public health challenge (Fabbrini, Sullivan, & Klein, 2010; 





approach by biopsying the liver is a challenge, as it is an invasive and costly procedure 
associated with discomfort and even the risk of death (Shah et al., 2009a). Additionally, it 
is not always clear when a biopsy is necessary, hence there is a need to identify patients 
at risk using convenient and noninvasive tools (McPherson, Stewart, Henderson, Burt, & 
Day, 2010). Fibrosis 4 Score (FIB-4) is such a tool: an index is calculated corresponding 
to the various stages of NAFLD using commonly available laboratory measures such as 
alanine aminotransferase levels (ALT), aspartate aminotransferase levels (AST), platelet 
counts and age as shown in Table 7 (Shah et al., 2009a). Using such a tool makes the 
diagnosis of NAFLD more feasible.  
There is a paucity of information about NAFLD for the population with RA. 
There is a need to disseminate information about the incidence, prevalence, and factors 
associated with NAFLD. To address this gap in knowledge, retrospective data collected 
from an observational cohort of patients with RA in the United States (U.S.) was used to 
determine the incidence and factors associated with NAFLD using FIB-4. This chapter 
provides a brief review of the background and statement of the problem, followed by the 
purpose of the study and the research questions. The next section in this chapter includes 
a brief review of the theories related to NAFLD, the design and methodology, definition 
of the study variables, the scope of the study and the related assumptions and limitations. 
Finally, this chapter describes the significance of this study and its potential contributions 







The dependent variable for this study is the presence of NAFLD. NAFLD 
encompasses a spectrum of fatty liver disease that starts with the development of simple 
fatty liver, progressing to steatohepatitis, fibrosis, cirrhosis, and, for some, can lead to 
cancer. However, these disorders occur in the absence of significant alcohol use 
(Chalasani et al., 2012). Each stage of the disease is associated with histological changes 
in the liver (Kleiner et al., 2005). Liver biopsy is best able to elucidate these subtle 
pathological changes, however, its scalability in general practice is limited (Chalasani et 
al., 2012).  The FIB-4 index is a validated noninvasive tool that corresponds with the 
various stages of NAFLD (Shah et al., 2009a; Vallet-Pichard et al., 2007). An FIB-4 
score of  <1.3 indicates the absence of advanced disease and the presence of NAFLD is 
denoted by a score of ≥ 1.3 (McPherson et al., 2010; Shah et al., 2009a). More details 
about the validity and reliability of the tool are described in Chapter 3.  
There were no studies in the literature that reported on the incidence rate of 
NAFLD in the RA population or the U.S. general population. However, outside of the 
U.S. studies reported NAFLD incidence of 15% to 20% as shown in Figure 5. There were 
a few studies addressing the prevalence of NAFLD in the U.S. Evidence of prevalence 
rates of NAFLD in the RA population was limited to one small study reporting a rate of 
23% in the U.S. (Bhambhani, Amin, Gutierrez, Cuppari, & Disla, 2006). A second study 
reported lower rates (4.7%) but only included RA patients with elevated liver 
transaminase levels while on MTX (Sakthiswary et al., 2014). NAFLD prevalence in the 





Independent risk factors associated with NAFLD are age, gender, and 
race/ethnicity along with clinical features such as metabolic syndrome, obesity, diabetes, 
and dyslipidemia (Chalasani et al., 2012). These factors were used as the independent 
predictor or explanatory variables in this study. Other potential confounders associated 
with NAFLD but not considered as independent risk factors were MTX use, liver enzyme 
elevation, alcohol use, and liver disorders (Chalasani et al., 2012; 171; Nascimbeni et al., 
2013). NAFLD rates appear to increase with age, peaking at the middle ages of life. 
Hispanics and men appear to be at higher risk for NAFLD. NAFLD rates steadily 
increased with age for women also, with higher rates reported in the latter years of life 
(Chalasani et al., 2012; Vernon et al., 2011). Also presented in Chapter 2 are the risk 
factors related to NAFLD in the general population, given the paucity of such 
information in the RA population. RA has some unique as well as common risk factors. 
The overlapping NAFLD related risk factors are related to high levels of systemic 
inflammation and are also prevalent in the RA population including: obesity, metabolic 
syndrome, hypertriglyceridemia, hypertension, dyslipidemia, and insulin resistance 
(Ahmed, 2006).  
This study used retrospective data collected from an observational cohort of 
patients with RA in the U.S. to determine the incidence, prevalence, and the factors 
associated with NAFLD using FIB-4. This study has the potential to make significant 
contribution to the body of knowledge related to NAFLD, inform clinical practice and 
improve the lives of patients with RA, already burdened with challenges of the 






In the last ten years, NAFLD has emerged as the leading cause of chronic liver 
disorders, notably unrelated to significant alcohol use (Preiss & Sattar, 2008).  In the U.S. 
during the period between 1980 and 2010, about 30% of the population had NAFLD, 
rates paralleling the prevalence of metabolic syndrome and obesity (Browning et al., 
2004; Lazo et al., 2013, Smits Ioannou, Boyko, & Utzschneider, 2013; Vernon et al., 
2011). Patients with NAFLD are more likely to develop chronic liver diseases, such as 
cirrhosis of the liver, and are at increased risk for hepatocellular carcinoma (Farrell & 
Larter, 2006). 
Patients with RA have higher rates of comorbidities similar to those with 
NAFLD, such as metabolic syndrome, and are also at increased risk for cardiovascular 
disease compared to those without RA (Chung et al., 2008; Crowson et al., 2011). MTX 
is used as the standard treatment for RA. It is a known hepatotoxic drug that can increase 
elevation of liver enzymes and has been associated with NAFLD and fibrosis of the liver 
(Arena et al., 2012; Sakthiswary et al., 2014). Given the overlap of several risk factors for 
NAFLD and RA, it can be presumed that NAFLD may be prevalent among patients with 
RA.  
Purpose of Study 
The purpose of this quantitative research study was to determine the incidence 
and factors associated with NAFLD using observational data collected from a cohort of 
patients with RA. The primary objective of this study was to first establish the occurrence 





the study is, to determine if there are significant clinical and demographic factors that 
independently predict the development of NAFLD after adjusting for relevant 
confounders. These include several factors such as age, gender, race/ethnicity, metabolic 
syndrome, obesity, diabetes, dyslipidemia, MTX use, liver enzyme elevation, alcohol use, 
and liver disorders. All patients who met the eligibility criteria and were without NAFLD 
at the index baseline visit were grouped into the incident cohort. Since the incident cohort 
sample size was sufficiently powered to conduct the primary analysis for the study, the 
alternate plan for using the prevalent cohort analyses was dropped. 
Research Questions and Hypotheses 
This was a quantitative, nonexperimental, retrospective cohort study that sought 
to answer the following research questions:  
RQ1 Quantitative: What is the incidence rate of NAFLD among patients with RA 
from January 2001 - November 2014 in a RA registry in the U.S. using the FIB-4 
test? 
RQ2 Quantitative: What is the prevalence of NAFLD among patients with RA for 
one year (e.g. from January 2012-December 2012) in a RA registry in the U.S. 
determined by using the FIB-4 test? 
RQ3: Among patients in the RA incident cohort, what are the baseline differences 
in clinical and demographic characteristics among those with NAFLD compared 





RQ H0: Among patients in the RA incident cohort, there are no significant 
baseline differences in the clinical and demographic characteristics among those 
with NAFLD compared to those without. 
RQ3 Ha: Among patients in the RA incident cohort, there are significant 
differences in the baseline clinical and demographic characteristics among those 
with NAFLD compared to those without. 
RQ4 Quantitative: For the RA incident cohort, what are the significant baseline  
factors (clinical and demographic) that predict the development of NAFLD after  
adjusting for relevant confounders? 
RQ4 H0: For the RA incident cohort, there are no significant baseline factors   
(clinical and demographic) that predict the development of NAFLD after 
adjusting for relevant confounders. 
RQ4 Ha: For the RA incident cohort, there are significant factors (clinical and  
demographic) that predict the development of NAFLD after adjusting for relevant  
confounders. 
Theoretical Framework 
The two hit theory postulated by Day and James (1998) is the most frequently 
referenced theory to explain NAFLD (Lim, Mietus-Snyder, Valente, Schwarz, & Lustig, 
2010). This theory proposes that there is an accumulation of lipids in the liver that leads 
to the formation of triglycerides, insulin resistance, the onset of hyperglycemia, and 
eventually inflammation of the liver. These are thought to be precursors in the process for 





central to the development of NAFLD. Specifically, as the result of high levels of 
intrahepatic triglycerides and the subsequent alteration in the metabolism of fatty acids, 
glucose, and lipoproteins leading to systemic inflammation (Fabbrini, et al., 2010). RA is 
also a disease associated with systemic inflammation and appears to have similar 
pathogenic changes that are associated with chronic inflammation (Ahmed, 2006). 
Additionally, liver enzyme elevation due to MTX use has been associated with an 
increased risk for NAFLD (Arena et al., 2012; Visser & Heijde, 2009). It is most likely 
that the development of NAFLD may be due to the confluence of several factors. All 
related to inflammation and altered lipid metabolism, metabolic syndrome, obesity, 
alteration of glucose metabolism, and for patients with RA, the use of MTX. 
Conceptual Framework 
Theories, pathways, and relationships related to the development of NAFLD are 
still evolving (Erickson, 2009). NAFLD is a chronic disease with many complex 
interacting obesity and metabolic related pathways, as well as environmental and genetic 
factors (Erickson, 2009). According to Erickson’s NAFLD conceptual framework, any 
and all factors related to the metabolic pathway play a significant role in the development 
of NAFLD as shown in Figure 1 and further explained in Chapter 2. Some theorists 
suggest that these relationships may be bidirectional, that NAFLD maybe in the causal 
pathway of inflammation, hyperlipidemia, obesity, and insulin resistance; however, this 
assertion lacks substantial evidence and is considered hypothetical (Azad & Quayum, 





Erickson’s conceptual framework helps explain the relationships between factors 
associated with NAFLD and provides the theoretical context for this study. 
Nature of the Study 
Retrospective data enabled access to a concurrent cohort of patients with data 
collected over many years, and also provided a large enough sample size, with specific 
data points, to reasonably answer the research questions. This approach accommodated 
an important element in the study: the ability to measure risk factors associated with 
NAFLD that may take years to develop and are key to identifying the predictors of 
NAFLD. The analysis for this study included determining the incidence and prevalence 
rates of NAFLD, descriptive analyses to characterize the study population, Kaplan Meier 
and adjusted Cox proportional hazard analysis to determine the incidence rate, time to 
event, and the predictors associated with the development of NAFLD. 
Definitions of Terms 
Variables were defined for this study using guidelines for NAFLD and MetS 
(Fabbrini et al., 2010; Alberti et al., 2009; Grundy, et al., 2005) and were also based on 
the definitions used in the registry to capture the data. In this study the following 
variables were defined as follows: 
Age: The amount of time a person has lived was categorized based on the age 
related prevalence rates of NAFLD reported in the literature (Chen, et al., 2006; Lazo et 
al., 2013; Yan et al., 2013). Age was operationalized into the following categories: 





Alcohol use: Defined as the use of alcohol in the following manner, if used on a 
daily, weekly or monthly basis (Corrona Rheumatoid Arthritis, 2015). 
Diabetes: Refers to type 2 diabetes mellitus, the most common form of diabetes 
associated with NAFLD (Chalasani et al., 2012). 
Dyslipidemia:  Defined as alterations in the lipid panel; specifically elevations in 
total cholesterol, LDL and triglyceride and reduced levels of HDL as shown in Table 8. 
(Grundy et al., 2005).  
Gender: Gender was defined as either as male or female.  
Liver Disorders: History of liver disorder was defined as those with liver related 
disorders, hepatic events and also history of liver biopsy excluding NAFLD (Corrona 
Rheumatoid Arthritis, 2015). 
Metabolic Syndrome (MetS): MetS was defined as the presence of any three of the 
following obesity related risk factors: elevated waist circumference, elevated 
triglycerides, blood pressure, glucose and reduced high density lipids (HDL)(Alberti et 
al., 2009; Grundy, et,al., 2005). Specific criteria for each of these measures are outlined 
in Table 8 (Grundy et al., 2005). 
MTX Use: MTX was defined as current use of the drug, a standard treatment for 
patients with RA (Arena et al., 2012). 
NAFLD: Was defined as the presence or absence of NAFLD, measured by using 
FIB-4 score corresponding to the various stages of fibrosis and was defined as: no 
advanced NAFLD, presence of NAFLD, mild/moderate NAFLD and advanced NAFLD 





Obesity: Obesity was measured using Body Mass Index (BMI). BMI is a ratio of 
an individual’s weight (kg) / [height (m)]2 adjusted for gender and are categorized into 
four groups: underweight, normal weight, overweight, and obese, criteria used by the 
Center for Disease Control (CDC, 2014). Elevated BMI score of ≥ 30 was used to 
determine the presence of obesity, a definition similar to studies conducted by Lazo et al. 
2011, Lazo et al. 2013, Ong et al. 2008 and Williams, 2011.  
Race/ Ethnicity: Information about race/ethnicity was collected from patients in 
the registry and was defined by the patients. Patients were asked to check all applicable 
categories: Caucasian (White), Hispanic or Latino, not Hispanic or Latino, African 
American (Black), American Indian, or Alaska Native, Asian, other (specify) and, 
multiracial. 
Scope and Delimitations  
This study was limited to determining the incidence, prevalence, and factors 
associated with NAFLD among adults regardless of gender, or race/ethnicity in the U.S. 
using longitudinal data collected in a registry of patients with RA. Excluded from the 
analysis are those for whom the FIB-4 information was not available or those with 
secondary causes of NAFLD (e.g. Hepatitis C, B, polycystic ovarian disease), and other 
conditions that are not routinely collected in the registry. Factors associated with NAFLD 
are limited to those captured in the registry, such as age, gender, race/ethnicity, metabolic 
syndrome, obesity, diabetes, and dyslipidemia (Chalasani et al., 2012). A limited data set 
from patients meeting the study inclusion and exclusion criteria during the years of 





study outlined here and the use of a limited dataset based on the inclusion and exclusion 
criteria specific to this study yielded a highly selected sample, and thus threatens the 
generalizability of the results to the general RA population. 
Limitations  
The main threat to internal and external validity for this study was the study 
design. This was a nonrandomized study that uses secondary data and utilizes a 
nonprobability sample of convenience (Szklo & Nieto, 2013, pp. 109-150). One of the 
inherent limitations of this study was the potential for systematic selection bias, since the 
cohort was primarily selected based on availability of laboratory parameters (liver 
enzyme and platelet counts) in the registry. The impact of this limitation was addressed in 
the analysis plan outlined in Chapter 3, where the comparability of NAFLD study cohort 
and the overall registry population was assessed and is reported in Table 9. Using real 
world data increased the external validity of the study; however, there remain many 
unmeasured confounders that threaten internal validity and thereby diminish the 
inferential power of the study ( Szklo & Nieto, 2014. pp. 153-182). Using a large sample 
size, as in this study, helped decrease overall variability and allowed assessment of the 
impact and adjustment of the measured confounders; these are factors that can help 
mitigate some of the threats to internal validity ( Szklo & Nieto, 2014. pp. 313-363). 
Outlined below are other limitations using secondary data, however these cannot 
be addressed methodologically. Data for the registry were collected as part of routine 
clinical practice and may not have been a good fit for the research question. There may 





pertinent time points or patients may have been lost to follow up (Hofferth, 2005). 
Laboratory measures may not necessarily be captured for every patient on MTX in the 
registry. Since this was a retrospective study, misclassification of either the exposure or 
the outcome variable was also a potential risk. In this study misclassification of exposure 
was of greater concern, as there could be variations in RA practices and subsequently 
how the data was captured in the registry.  However, this risk was less for the outcome 
variable as a uniform definition for NAFLD was applied to all cases in a similar manner.  
While this was a large registry of RA patients across the U.S., there are some 
potential sources of bias. Patients can volunteer to participate in the registry and all 
patients at a site are not entered into the registry. There could be variation from site to site 
as to how participants are chosen and who is selected for the registry. Selection bias could 
pose a potential threat to the generalizability of the results. Regarding the incident 
analysis, another limitation may be that the observational time available in the registry 
may not be sufficiently long to identify incident cases of NAFLD. A third limitation was 
long term outcomes related to NAFLD were not available to corroborate the outcome 
findings of this study. 
Significance 
It is well established that RA patients have lower life expectancy and are at 
increased risk of death, especially those patients with other comorbid conditions such as 
diabetes, metabolic syndrome, hypertension, and cardiovascular disease (Nurmohamed, 





chronic conditions, thus it is important to identify if NAFLD may be prevalent among 
other related chronic diseases such as RA. 
The overall burden from the confluence of many chronic conditions along with 
the emergence of NAFLD is yet unknown, though anticipated to significantly impact the 
health care system and the associated health care costs (Loomba & Sanyal, 2013). The 
results of this study may help inform future studies by identifying factors associated with 
increased risk for NAFLD among patients with RA, along with providing incidence rates, 
time to development of NAFLD, and rates of prevalence.  This study is intended to help 
confirm the harmful effects of NAFLD and its interplay with many chronic conditions, 
including RA (Lazo & Clark, 2008). 
Patients treated with MTX for RA are at risk for the development of NAFLD and 
fibrosis of the liver (Arena et al., 2012; Kneeman, Misdraji, & Corey, 2011). Biopsies, 
while a reliable approach to confirm NAFLD are not always feasible nor a sustainable 
strategy given the increased prevalence of NAFLD (McPherson et al., 2010). It is 
estimated that using non-invasive tools such as FIB-4 could reduce unnecessary liver 
biopsies by 50%, thereby saving the invasive procedures only for those with advanced 
disease thus reducing physical harm and overall costs (McPherson et al., 2010). Early 
identification and characterization of NAFLD is essential to improve long-term 
prognosis, potentially averting the development of chronic liver disease in this at risk 
population (McPherson et al., 2010). Prevention, diagnosis, and management of NAFLD 
have been identified as an emerging public health issue (Fabbrini et al., 2010; Ray, 2013; 





awareness of NAFLD, support public health practitioners and clinicians, and inform 
policy, particularly for chronic conditions such as RA associated with significant disease 
burden (Fabbrini et al., 2010; Ray, 2013; Vernon et al., 2011). Policies are needed to 
support surveillance programs and also those that foster interdisciplinary approaches for 
the management of chronic conditions. The potential for social change includes early 
diagnosis of NAFLD using a novel, less expensive, noninvasive tool and increased 
awareness of this chronic condition along with the other prevalent chronic diseases.  
Summary 
NAFLD is a chronic condition that is emerging as a public health challenge in the 
U.S. (Argo & Caldwell, 2009). Obesity and metabolic dysfunction are central to the 
development of NAFLD and this is due to systemic inflammation (Fabbrini et al., 2010). 
The presence of these and other prevalent conditions associated with NAFLD, such as 
diabetes, CVD, and dyslipidemia appears to accelerate the development of NAFLD 
(Argo & Caldwell, 2009). Patients with RA also have a prevalence of these risk factors 
(Ahmed, 2006; Chung et al., 2008; Crowson et al., 2010). Use of MTX for the treatment 
of RA has been associated with increased elevation of liver enzymes and fibrosis of the 
liver (Arena et al., 2012; Sakthiswary et al., 2014). Hence, this study hypothesized that 
NAFLD may be prevalent in patients with RA, given the overlap of several NAFLD 
related risk factors and exposure to MTX. However, this association has not been 
documented or well characterized in the literature for this potentially at risk population. It 
is most likely that the development of NAFLD may be due to the convergence of several 





In the next chapter, I cover the research strategies used for the literature review, 
the theories related to NAFLD, and an extensive review of the literature pertaining to the 





Chapter 2: Literature Review 
NAFLD is described as the next global epidemic and poses an emerging public 
health challenge in the U.S. (Argo & Caldwell, 2009). NAFLD is a common chronic 
condition, primarily associated with other prevalent conditions such as obesity and 
metabolic syndrome, along with diabetes, cardiovascular disease (CVD), and 
dyslipidemia (Argo & Caldwell, 2009). Patients with rheumatoid arthritis (RA) also have 
a prevalence of many of these risk factors associated with inflammation (Chung et al., 
2008; Crowson et al., 2011; Crowson et al., 2010 ). Additionally, MTX, a standard 
treatment for rheumatoid arthritis, is a known hepatotoxic drug that can cause increased 
elevation of liver enzymes and has been associated with the development of NAFLD and 
fibrosis of the liver (Arena et al., 2012; Sakthiswary et al., 2014). However, this 
association has not been documented or well characterized in the literature for this 
potentially at risk population.  
This chapter covers research strategies used for the literature review. An extensive 
review of the literature was conducted pertaining to the theories, incidence, prevalence, 
and factors associated with NAFLD. In this review the primary focus of the search was 
for studies conducted in the U.S. however, if such information was not available or was 
inadequate, then studies from other countries were included to supplement the 
information. Similarly, NAFLD-related risk factors were presented mostly for the general 
population and also when this information was available for the RA population.  
The purpose of this study was to determine the incidence, prevalence, and factors 





population was limited, thus many of the constructs of this study are based on literature 
available in the general population. The information about the incidence, prevalence, and 
risk factors associated with NAFLD in the general population became the basis for this 
study. Peer-reviewed journal articles were retrieved using the Google Scholar search 
engine, the CINAHL & MEDLINE databases, and references from guidelines and review 
articles were also used. 
The key search term used was NAFLD, along with several thematic terms such as 
prevalence, incidence and risk factors related to NAFLD. Other terms included were: 
fatty liver and or NAFLD plus natural history, theories, epidemiology of NAFLD and RA, 
metabolic syndrome, obesity, diabetes, hyperlipidemia, CVD, and MTX associated 
laboratory abnormalities. Studies conducted between 2009 and October 2015 was 
reviewed. Older publications were included if they were original works or were empirical 
or significant publications that were referred to in the more recent literature, or provided 
some information not available in the recent studies. Inclusion criteria for the literature 
review were publications related to NAFLD in the adult general population, RA 
population, clinical studies, observational studies, treatment guidelines, and review 
articles. Excluded from the review were studies related to NAFLD where alcohol use was 
eluded to but was not clearly defined, research in the pediatric population, and 
publications about other secondary causes of NAFLD as identified in the clinical 
guidelines for the diagnoses, treatment and management of NAFLD (Chalasani et al., 
2012). Also excluded were studies in languages other than English, and laboratory 






Theories related to NAFLD are seated in principles of biological plausibility, of 
which the two hit theory (Day & James, 1998) is the most frequently referenced theory to 
explain NAFLD (Lim et al., 2010). This theory postulates that accumulation of fatty acids 
incites the development of fatty liver (first hit) which then sensitizes the liver (second hit) 
leading to inflammation and subsequently to hepatic injury and development of fibrosis 
of the liver (Day & James, 1998; Lim et al., 2010). The first hit is presumed to occur as a 
result of metabolism of fructose leading to the production of de novo lipogenesis and 
intrahepatic lipids, which inhibits the mitochondrial β-oxidation process of the long-chain 
fatty acids (Lim et al., 2010). The second hit proposes that the accumulation of these 
hepatic lipids interacts with hepatic antioxidants leading to molecular instability causing 
reactive oxidation and inflammation. The end result of this process is the formation of 
triglycerides, insulin resistance, the onset of hyperglycemia, and eventually liver steatosis 
(Lim et al., 2010). 
Obesity and metabolic dysfunction are two factors central to the development of 
fatty liver, specifically, due to the increased levels of intrahepatic triglycerides (IHTG) 
(Fabbrini et al., 2010).The result of high levels of IHTG is theorized to alter the 
metabolism of fatty acids, glucose, and lipoproteins leading to systemic inflammation 
(Fabbrini et al., 2010). Development of NAFLD is complex and appears to be rooted in 
these processes, specifically in the second phase when the liver is overwhelmed with an 
overabundance of fatty hepatic lipids leading to inflammation (Lim et al., 2010). Thus, 





intrahepatic lipids and the subsequent cellular changes in the liver due to inflammation is 
central to the development of NAFLD. Similar pathogenic changes in the liver are seen in 
alcoholic patients, but with NAFLD, these changes are unrelated to alcohol use (Chen et 
al., 2011; Comar & Sterling, 2006; Lim et al., 2010). The pathophysiological alterations 
in the liver are thought to be due to the oxidative process due to metabolic syndrome and 
obesity along with the coexistence of other interdependent chronic conditions such as 
diabetes, dyslipidemia and CVD among others (Chitturi & Farrell, 2001; Lim et al., 2010; 
Utzschneider & Kahn, 2006). Thus, alterations in lipid and glucose metabolism, 
metabolic dysfunction along with many other chronic conditions are culprit pathways 
central to systemic inflammation associated with NAFLD.  
RA is a chronic disease associated with systemic inflammation and has also been 
associated with NAFLD (Arena et al., 2012). Similar theories relating to inflammation 
have been hypothesized to explain the relationship between NAFLD and RA (Ahmed, 
2006). Specifically proposed is the notion that the overlapping pathogenic changes seen 
in these two chronic diseases are due to inflammation (Ahmed, 2006). The result of these 
changes is manifested as hyperlipidemia, insulin resistance, as well as other altered 
inflammatory pathways unique to RA (Ahmed, 2006). Pathways unique to RA are also 
related to inflammation; these are fibrogenic and apoptotic responses expressed by 
specific inflammatory cytokines, such as tumor necrosis factor alpha (Ahmed, 2006). 
Such responses are presumed to contribute to the development of NAFLD (Ahmed & 
Byrne, 2005; Kitade, Yoshiji, & Kojima, 2008). An additional proposed link to NAFLD 





(Svenson, Lundqvist, Wide, & Hällgren, 1987).  This alteration in glucose metabolism 
may be due to the intensity of the underlying inflammatory burden of chronic conditions 
such as RA resulting in insulin resistance and diabetes (Ahmed, 2006).   
Another line of reasoning linking RA and NAFLD relates to treatment of RA with 
MTX. MTX is a standard treatment for patients with RA, and has been associated with 
liver enzyme elevation, and may also play a role in the development of NAFLD (Arena et 
al., 2012). Visser and Heijde (2009) conducted a systematic review of the literature from 
1950 to 2007 and assessed the risk of liver toxicity associated with MTX use in patients 
with RA and psoriatic arthritis. During a period of three years the incidence rate was 
13/100 per patient-years. About a third of the patients had elevated liver enzymes after 
initiation of treatment with MTX (Visser & Heijde, 2009) A more recent study of 978 
subjects with long term exposure to MTX also supports these findings (Sakthiswary et 
al., 2014). This study reported that the cumulative MTX dose was associated with 
elevated liver enzymes and was an independent predictor for NAFLD. Visser and Heijde 
(2009) also reviewed studies that reported NAFLD results from liver biopsies for RA 
patients treated with MTX. During a period of four years, the risk of mild fibrosis was 
15.3%, 1.3% for severe fibrosis, 0.5% for cirrhosis of the liver, and the risk prior to 
treatment was 9%, 0.3% and 0.3% respectively. For these reasons, it can be concluded 
that liver enzyme elevation due to MTX use was associated with an increased risk for 
NAFLD, and that there may also be an underlying risk for RA patients and this may be 





Theories related to NAFLD are complex and appear to be linked to chronic 
inflammation affecting the liver. It is most likely that NAFLD may be due to a 
confluence of several factors related to inflammation and altered lipid metabolism, 
metabolic syndrome, obesity, alteration of glucose metabolism, and for patients with RA 
the use of MTX. These factors and relationships are supported by the two hit theory and 
provides the core theoretical framework for this research study. 
Conceptual Framework 
Understanding of the theories, pathways, and relationships related to the 
development of NAFLD is still evolving (Erickson, 2009). NAFLD is a chronic disease 
with many complex interacting obesity and metabolic related pathways, as well as 
environmental and genetic factors. Erickson diagrammatically depicted these 
relationships in an attempt to summarize the current understanding of these complex 
interactions based on the strength of available evidence (see Figure 1). According to 
Erickson’s framework, any and all factors related to the metabolic pathway play a 
significant role in the development of NAFLD. Some theorists suggest that these 
relationships may be bidirectional; that NAFLD is thought to be in the causal pathway of 
inflammation, hyperlipidemia, obesity, and insulin resistance; however, this assertion 
lacks substantial evidence and thus is considered hypothetical (Azad & Quayum, 2007; 
Erickson, 2009; Vanni et al., 2010).  
Factors such as genetics, gender, diet, and environmental factors are illustrated in 
the diagram with unidirectional arrows as they have been uniquely linked to NAFLD 





the predisposition to NAFLD within families, certain ethnic groups, and some specific 
variant genes have been linked to NAFLD (Erickson, 2009; Puppala et al., 2013). The 
relationship between NAFLD and factors such as insulin resistance and diet are related to 
obesity, and are thought to be a result of diets rich in simple carbohydrates, saturated fats, 
and the consumption of highly processed foods, coupled with the sedentary lifestyle 
(Thoma, Day, & Trenell, 2012). Other factors associated with NAFLD such as 
inflammation, hyperlipidemia, insulin resistance, and obesity are thought to be 
bidirectional(Erickson, 2009). Erickson’s conceptual model has been applied in several 
studies. Alisi et al. (2011), sought to identify determinants of diet-induced NAFLD and 
uses the Erickson’s conceptual model to explain the complex interrelationships between 
NAFLD related factors. Similarly Chung et al. (2012) and Lin, Chou, Huang, & Chiou, 
(2011) assessed NAFLD rates and cited Erickson in their research studies. 
This study was fundamentally based on the hypothesis that NAFLD and RA have 
shared risk factors associated with inflammation such as metabolic syndrome, 
hyperlipidemia and insulin resistance. Thus the interplay between these factors and 
NAFLD seen in the general population may also be present in the RA population.  There 
is a gap in the literature establishing NAFLD in the RA population, the risk factors and 
the relationships between these risk factors. In summary, Erickson’s conceptual model 
provides a framework to establish these relationships between the risk factors identified 
for this study and the nature of their relationships with NAFLD. Thus, the two hit theory 
further clarified by Erickson’s conceptual framework helps explain these relationships 






Figure 1. Erickson’s NAFLD conceptual model (2009). Reprinted with permission. 
Background 
The purpose of this study was to determine the incidence, prevalence, and factors 
associated with NAFLD among patients with RA. RA is a chronic disease associated with 
systemic inflammation. RA is characterized by joint swelling, joint tenderness, and 
destruction of the synovial joints (Aletaha et al., 2010). RA disease activity is measured 
by using several clinical measures such as swollen and tender joint counts, patient and 
physician global assessment of disease activity, patient assessment of pain, and also may 
include laboratory tests for acute phase response to inflammation (Aletaha, Funovits, 
Keystone, & Smolen, 2007).  
In contrast, NAFLD is an asymptomatic condition, commonly associated with 
liver enzyme elevation (AST and ALT) and some may have non-specific vague right 





Harrison, 2012). NAFLD is diagnosed using clinical and pathological criteria for liver 
injury or disease, that can range from the presence of fatty liver, simple steatosis, 
nonalcoholic steatohepatitis (NASH), liver cirrhosis to hepatocellular carcinoma (Torres 
et al., 2012).  
RA and NAFLD have some shared risk factors such as age, gender, and 
race/ethnicity, along with clinical features such as metabolic syndrome, obesity, diabetes, 
and dyslipidemia (Ahmed, 2006; Chalasani et al., 2012). Several of these clinical risk 
factors are associated with inflammation (Lim et al., 2010). Additionally, patients using 
MTX may be at an increased risk for NAFLD. It is not known if NAFLD may be 
prevalent among patients with RA. 
Liver biopsy is the conventional technique used to decisively confirm NAFLD. 
However, this is an invasive procedure associated with discomfort and even the risk of 
death (Shah et al., 2009a). Additionally, it is not always clear when a biopsy is needed. 
Given this inherent risk and the increasing prevalence of NAFLD, biopsies are not always 
feasible nor a long term sustainable strategy (Shah et al., 2009a).  
Thus, there is a need to identify patients at risk for NAFLD using easily available 
non-invasive tools such as FIB-4 score (McPherson et al., 2010). FIB-4 is a noninvasive 
tool developed to identify NAFLD. It is validated to ascertain the various stages of 
NAFLD using laboratory liver function tests (AST, ALT levels) and platelet counts along 
with age (Shah et al., 2009a). The key feature of this composite score is that it uses 
commonly available measures, thus enabling clinicians to incorporate this tool easily into 





This study addressed this gap using this novel noninvasive tool (FIB-4) to 
determine the incidence, prevalence, and factor associated with NAFLD using 
retrospective data collected from a well established registry of patients with RA (Curtis et 
al, 2013; Curtis et al., 2010; Kremer, 2005). The rationale for using this registry includes 
its rich history of epidemiological studies conducted to address a variety of research 
questions that range from establishing prevalence rates to characterizing safety, 
effectiveness, and treatment patterns. As of April 2015, there have been over 50 
manuscripts and 140 abstracts published using data from this registry (Corrona.org. 
2015). There have been several studies conducted similar to this study. Furst et al. (2009) 
conducted a study to determine the prevalence of low hemoglobin. Whereas Greenberg 
et.al (2011) conducted a study to determine cardiovascular risk among patients with RA, 
and Fisher et.al (2012) validated malignancy rates by adjudicating the rates in the registry 
with the patient charts. Additionally, this is the only registry in the U.S. that has 
longitudinal data for close to 40,000 patients, where ascertainment of the incidence, 
prevalence, and risk factor for NAFLD is feasible (Corrona.org. 2015). 
The literature was reviewed for the rates and factors associated with NAFLD and 
this review reflects information from studies conducted in diverse populations and 
countries using an assortment of tools to determine the presence of NAFLD. Aside from 
the challenges posed by the various tools used, a variety of standards were used to 
ascertain the presence of the disease. Some of these tools are more sensitive than others, 
for example, using the gold standard (biopsy) a more sensitive approach for the diagnosis 





related to NAFLD proved to be a pervasive challenge throughout this literature review. 
Thus, to provide clinical perspective and ensure alignment with the standard of care, 
evidence and expert opinions provided for the diagnosis and management of NAFLD 
offered in the guidelines for clinicians was used as a guiding reference (Chalasani et al., 
2012).  
Given the gap in the literature for NAFLD in the RA population, information 
from the general population was reviewed. The following sections in this literature 
review describe the tools and measures used to stage NAFLD, followed by a brief review 
of the epidemiology of RA, prevalence of overlapping NAFLD risk factors in the RA 
population.  An extensive review of the literature on the incidence, prevalence of NAFLD 
and NAFLD risk factors in the general population was conducted. 
Tools and Measures for Nonalcoholic Fatty Liver Disease  
NAFLD fits into a spectrum of fatty liver disease that starts with the development 
of simple fatty liver, progressing to steatohepatitis (NASH), fibrosis, cirrhosis, and for 
some, leading to cancer (Chalasani et al., 2012). However, these disorders 
characteristically occur in the absence of significant alcohol use (Chalasani et al., 2012). 
Each stage of the disease is associated with histological changes in the liver (Kleiner et 
al., 2005). Fibrosis is staged from 0 to 4: with stage 0 = absence of fibrosis; stage 1 = peri 
sinusoidal or portal changes; stage 2 = peri sinusoidal and doorway/peri portal changes; 
stage 3 = septal or bridging fibrosis; and stage 4 = cirrhosis of the liver (Kleiner et al., 
2005). A number of diagnostic tools can be used to identify the presence of NAFLD. 





such as ultrasound (U.S.), computerized tomography (CT), magnetic resonance 
spectroscopy (MRS), and magnetic resonance imaging (MRI), biopsies or in a 
combination of these tools (Chalasani et al., 2012). There are significant variations in the 
rates of NAFLD depending on the tools used. Highest rates for NAFLD was reported 
using histological criteria from liver biopsies  (20% to 51%), followed by liver ultrasound 
with rates that ranged 17% to 46%; and MRS was about 31% (Chalasani et al., 2012). 
The lowest rates [7% to 11%] were reported when liver enzyme levels were used alone 
without including imaging or histological criteria (Chalasani et al., 2012).  
The FIB-4 index is another tool that is used to determine the NAFLD. It uses 
commonly available measures such as age, liver enzymes (AST, ALT), and platelet 
counts to determine the presence of NAFLD. FIB-4 score is calculated by using the 
following formulae: age [years] × AST [U/L]) / (platelet [109] × √ALT [U/L] (Shah et al., 
2009a). FIB-4 score corresponds with the various stages of fibrosis as shown in Table 7 
(Shah et al., 2009a; Vallet-Pichard et al., 2007).  
Liver biopsy is best able to elucidate these subtle pathological changes in the 
liver (Chalasani et al., 2012). However, its scalability is limited and is associated with 
procedure related morbidity, mortality, costs and sampling error, and thus highlights the 
need to use reliable and valid non-invasive tools to diagnose NAFLD (Chalasani et al., 
2012; Shah et al., 2009a). There are several noninvasive tools available; seven of these 
tools were compared for their reliability and validity to determine the presence of fibrosis 
(Shah et al., 2009b). Based on results of sensitivity, specificity, positive predictive value, 





other markers and deemed it as a valid and reliable tool to measure the absence or 
presence of advanced fibrosis. Specifically, FIB-4 index had an 80% positive predictive 
value for advanced fibrosis with FIB-4 score ≥ 2.67 and 90% negative predictive for FIB-
4 index ≤ 1.30.  Others have evaluated the accuracy of the FIB-4 index in other chronic 
liver conditions, corroborating the FIB-4 score to liver biopsies and deemed that the tool 
was reliable (Mallet et al., 2009; Vallet-Pichard et al., 2007).  
The dependent variable for this study is the presence of NAFLD, determined by 
using the FIB-4 index. A FIB-4 score of  <1.3 indicates the absence of disease and the 
presence of NAFLD with a score of ≥ 1.3. FIB-4 index uses commonly available clinical 
measures (ALT, AST, platelet counts, and age), and since these measures are collected in 
the RA registry, this was the tool used to determine the presence of NAFLD for this 
study.  
Epidemiology of Rheumatoid Arthritis (RA) 
A review of the literature found only two studies that reported on the prevalence 
of NAFLD in the RA population, of which one was an abstract.  This was a small study 
of 100 RA patients in the U.S. and the researchers used ultrasound to determine the 
presence of NAFLD (Bhambhani et al., 2006).The prevalence rate for the RA group was 
23% compared to 15% among those without RA; the significance of this difference was 
not reported. The other study was conducted in Singapore during the years of 2006 to 
2013 and also used ultrasound to determine NAFLD (Sakthiswary et al., 2014). The 
intent of this study was to determine the risk factors associated with MTX use and 





on MTX use were included in the analysis (N = 978). The NAFLD prevalence rate was 
4.7% in this study. This rate was much lower compared to the Bhambhani et al., (2006) 
study, which was conducted in U.S. and in a broader RA population. No studies were 
found that reported on the incidence of NAFLD in this population. Given the paucity of 
studies in RA, information about the prevalence of NAFLD in the RA population remains 
a gap in the literature. 
Prevalence of NAFLD Related Risk Factor: RA Population 
There are certain risk factors associated with NAFLD seen in the general 
population were also prevalent in the RA population. For example, some of the 
demographic factors such as age, gender, and ethnicity are also risk factors for RA. 
Likewise, there is increased prevalence of obesity, MetS, hypertension, dyslipidemia, 
hypertriglyceridemia, and insulin resistance in this population also (Chung et al., 2008; 
Crowson et al., 2011). Following is a review of the prevalence for each of these factors in 
the RA population. 
Obesity a known risk factor for NAFLD is also prevalent in the RA population. 
Studies that reported on the prevalence of obesity in the RA population ranged from 21% 
to 65% and almost three times more among those with RA compared to those without the 






Figure 2. Prevalence in the RA Population (%): Obesity  
Of the many NAFLD related risk factors, MetS plays a key role in the 
development of NAFLD (Chalasani et al., 2012). The presence of one or more of the 
many Mets related factors could contribute to the development of NAFLD (Erickson, 
2009). Patients with RA appeared to have higher rates of MetS compared to those 
without the disease as illustrated in Figure 3. Prevalence rates of MetS ranged from 18 % 
to 45 % among those with a diagnosis of RA. Most studies reported higher rates in the 
RA group, with the exception of two studies. These studies reported higher rates for the 
control group, however, both were conducted outside of the U.S. (Karimi, 
Mazloomzadeh, Kafan, & Amirmoghadami, 2011; Sahebari et al., 2011). Studies carried 
out in the U.S. comparing RA patients to a control group reported higher rates in the RA 






Figure 3. Prevalence in the RA Population (%): Metabolic Syndrome  
Hypertension is a prevailing problem for patients with RA and is also a key 
contributing factor associated with MetS (Grundy et al., 2005). Rates were consistently 
higher for patients with RA compared to those in the control group as shown in Figure 4. 






 Figure 4. Prevalence in the RA Population (%): Hypertension  
Dyslipidemia or hypercholesterolemia, terms often used interchangeably, is 
another risk factor associated with NAFLD and also prevalent in the RA 
population(Chalasani et al., 2012; Chung et al., 2008; Crowson et al., 2011). Gerli et al. 
in 2005 reported a dyslipidemia rate of 12.9% among patients with RA compared to 8% 
in the control group, however this difference was not significant. A second study reported 
a similar rate of 16% among patients with RA (Avouac et al., in 2014 ). Of the lipid 
parameters, hypertriglyceridemia and low levels of HDL are of interest as they are used 
to define the presence of MetS and also because they have been uniquely associated with 
NAFLD (Chalasani et al., 2012; Grundy et al., 2005). 
Rates for hypertriglyceridemia in the RA population ranged from 16% to 38% as 





and without RA (Crowson et al., 2011; da Cunha et al., 2012) . Even though the rates of 
hypertriglyceridemia were higher for patients with RA in both the studies, these 
differences were not significantly different compared to the control group. One study 
conducted in Iran showed that the control group had statistically significant higher rates 
of hypertriglyceridemia compared to the RA group (Karimi et al., 2011). This study also 
reported a statistically significant higher prevalence of low HDL levels in the control 
group. Prevalence rates for low HDL ranged from 24% to 44.6% (see Figure 5). Those 
with the RA group had higher prevalence of low HDL, but these rates were not 
significantly different from the control group (Crowson et al., 2011; da Cunha et al., 
2012). Based on this review, most studies reported higher prevalence of 
hypertriglyceridemia and low levels of HDL among patients with RA when compared to 
patients without the disease. 
 





Insulin resistance is another NAFLD risk factor related to high levels of systemic 
inflammation and is also associated with RA (Dessein, Woodiwiss, Joffe, & Norton, 
2007). Several studies have reported higher rates of insulin resistance in the RA 
population, a factor associated with metabolic syndrome, and also thought to be a 
precursor for diabetes (Dessein, Joffe, Stanwix, Botha, & Moomal, 2002; Svenson et al., 
1987). Despite the recognition of insulin resistance in the RA population (Dessein et al., 
2006), more often the prevalence rates of diabetes was reported in most studies. Rates for 
diabetes ranged from 4.7% to 16.1% as shown in Figure 6. Two studies compared rates of 
diabetes for those with and without RA and reported mixed results. Del Rincón & 
Williams (2001) reported higher rates of 16.1% for RA compared 9.5% for those without 
(p  <0.001). However, Solomon et al., (2003) reported similar rates of diabetes for both 
groups (4.7% vs. 4.9%) respectively.  
 





Epidemiology of NAFLD: General Population  
Unlike the review of literature related to NAFLD in the RA population, there was 
a wealth of information available in the general population. The majority of the studies 
reviewed were cross-sectional observational studies. Some were carried out in large 
populations, and others were smaller regional studies or studies conducted in select 
populations (e.g. patients from liver or lipid clinics). Tables 1 through 3 lists the studies 
that reported on the NAFLD prevalence rates in U.S. (Table 1), followed by Asia (Table 
2) and then the rest of the world (Table 3). Table 4 covers studies that reported on the 
incidence rates and factors associated with NAFLD. The tables also include the details of 
the location where the studies were conducted, the study design, sample size, population, 
and the tools used to diagnose the presence of NAFLD. The results on the incidence and 
prevalence rates from these studies are graphically shown under each of the topic 
sections. 
General Population NAFLD Prevalence Rates: United States 
Most of the studies conducted in the U.S. that reported NAFLD prevalence rates 
were cross-sectional observational studies with sample sizes that ranged from 70 to 
20,050 (see Table 1). Most of the studies were conducted in the general population; 
several of the larger studies used nationally representative samples  (e.g., Third National 
Health and Nutrition Examination Survey from 1988 -1994). As shown in Table 1, these 
studies included a variety of assessment tools: CT scan, MRI, MRS, ultrasound, liver 
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The prevalence rates for NAFLD for the general population in the U.S. are 
illustrated in Figure 7, and the rates ranged from 11% to 46%. Several of the larger more 
recent studies were conducted using data from Third National Health and Nutrition 
Examination Survey, data collected from 1988 to 1994 (NHANES III). Some of these 
studies also included additional follow up data through 2010 as shown in Table 1. The 
NAFLD prevalence rates were varied using the NHANES III data, most likely due to the 
varying definitions used to ascertain presence of NAFLD. For example, Lazo et al.  in 
2013 with a sample of 12,454 participants reported a rate of 19%, (95% CI [17.5, 20.6]). 
Smits et al. (2013) reported higher NAFLD rates of 30%. Some of the earlier studies 
reported similar rates to the Smits et al., (2013) study. For example, in 2004 from a large 
cross-sectional population-based sample of adults (N = 2287) using proton nuclear 
magnetic resonance spectroscopy reported a NAFLD rate of 31% (Browning et al., 
2004). Tran et al.,  (2006) reported slightly higher rate of 38.5% in 2006; however this 
was a small study of living liver donors (N = 70) and used biopsy to determine NAFLD. 
Williams et al. (2011) reported the highest NAFLD prevalence rate of 46% in the U.S. 
Rates derived from a small prospective cohort study of middle-aged adults using 
ultrasound to determine NAFLD (N = 328). The lowest NAFLD prevalence rates of 11% 
was reported by Church et al., in 2006, however, this study only included non-Hispanic 
healthy men (N = 238). In summary as shown in Figure 7, prevalence of NAFLD was 
wide with about 10% to 50 % of the general population at risk for NAFLD in the U.S. It 
is not clear if this variation was due to the tools or criteria used to determine the presence 






Figure 7. NAFLD Prevalence Rates in the General Population (%): U.S. 
 
General Population NAFLD Prevalence Rates: Asia  
Similar studies were conducted in Asia as shown in Table 2. However, there was 
a mix of large population and small regional level studies, with sample sizes that ranged 
from N = 768 to 29,994. Unlike the studies conducted in the U.S., most of these studies 
used ultrasound, including one study in Japan where FIB4-score was used to determine 





Table 2  





Location Study Design Sample Population Age (years) Diagnosis of 
NAFLD 




Kwon 2012 Korea 
Retrospective 
Oct 2003 - Dec 2010 




Oh 2006 Korea Jan - Dec 2004 40196 General population Adults Ultrasound 
Lee 2010 Korea 
Population Cohort 





Zhou 2007 China 
Cross-sectional 
Apr - Nov 2005 




Fan 2007 China 
Prospective Cohort 





Fan 2005 China October 2002 to April 2003, 3175 General population >16 years Ultrasound 








Xu 2013 China 
Prospective 
5 Year follow up 
6905 Employee Population Adults Ultrasound 










Table 2  
NAFLD Prevalence Studies in the General Population: Asia  (table continues) 
First Author Year 
Published 
Location Study Design Sample Population Age (years) Diagnosis of 
NAFLD 
Li 2009 China 
Cross-sectional 
Jan  - Dec 2007 




Shi 2011 China Cross-sectional 6 043 General Population Adults Ultrasound 
Wong 2011 China Cross-sectional 1013 General Population Adults MRS 
Chen 2008 China Jan 2005 to Jul 2007 26527 General Population) Adults Ultrasound 
Chen 2006 Taiwan Cross-sectional 3245 General population Adults Ultrasound 




(22 - 65) 
Ultrasound 
Hamaguchi 2005 Japan 
Prospective observational     
Jan - Dec 2001 
4401 General population 
Adults 
(21 - 80) 
Ultrasound 




Eguchi 2012 Japan 2009- 2010 8352 General population Adults FIB-4  




NAFLD prevalence rates for studies carried out in Asian countries ranged from 
7% to 40%, as illustrated in Figure 8. More studies reported rates greater than 18%, the 
lowest rate was reported by Xu et al., (2013) of 7%. This prevalence rate is closer to the 
rate reported by the study conducted in Singapore in the RA population by (Sakthiswary 
et al., 2014) of 4.7%. Eguchi et al., (2012) study, used FIB-4 score to determine the 
presence of NAFLD and reported a prevalence rate of 29.7%, similar rates to several of 
the other studies that used ultrasound. It is not known if the wide variation in rates seen in 
the Asian countries were due to the tools and definitions used to measure NAFLD, 
regional differences or the underlying study populations. Nevertheless, the spread of 
prevalence rates in Asia was similar to the rates seen in the U.S. (see Figure 7). FIB-4 
yielded results similar to other tools when used to determine the presence of NAFLD. 
 




General Population NAFLD Prevalence Rates: Rest of the World 
Compared to the studies conducted in the U.S., studies from the rest of world 
were smaller (N of 134 to 3012) as shown in Table 3. NAFLD prevalence rates ranged 
from 17% up to 78.8% as depicted in Figure 9. The highest rate of NAFLD was 78.8% 
from a study conducted in Israel (Soresi et al., 2012). The authors attributed the rate to 
higher background prevalence rates of metabolic syndrome and hyperlipidemia in this 
population. The spread of prevalence rates for NAFLD in the rest of the world was 
mostly similar to the rates seen in the U.S. 
 






NAFLD Prevalence Studies in the General Population: Rest of the World  
First Author Year 
Published 
Location Study Design Sample Population Age (years) Diagnosis of 
NAFLD 
Zelber-Sagi 2007 Israel 
Prospective cohort 
 2003–2004 








Kagansky 2004 Israel 
Prospective study    





> 80 years Ultrasound 










Amarapurkar 2007 India 
Cross-sectional  











Mohan 2008 India Cross-sectional 
    










Frith 2009 UK 
Retrospective Cohort 
2005 to 2007 




Bedogni 2005 Italy 
Cross-sectional  




12 to 65 years Ultrasound 







Kotronen 2010 Finland 
Cross sectional 









In summary, a review of the literature from 1980 to 2010 reported an average 
NAFLD rate of 30 % in the U.S. (Vernon et al., 2011). This rate was similar to the range 
in rates from the review of the literature for this study, which also included more recent 
studies (Browning et al., 2004; Lazo et al., 2013, Smits et al., 2013)  
NAFLD Incidence Rates 
There were several studies that reported on the incidence of NAFLD in the 
general population as described in Table 4. All these studies were conducted outside of 
the U.S., and the follow-up periods were from 3 years up to 8.5 years. The reported 
incidence rates in the general population ranged from 9.3% to 36.7% as illustrated in 
Figure 10. All the studies used ultrasound to ascertain NAFLD except for one study that 
used liver enzyme elevations (Suzuki et al., 2004). 
 
Figure 10. NAFLD Incidence Rates in the General Population (%) 
   There were four studies that reported NAFLD incidence rates that ranged from 




around 10%; however there was variation in the follow-up period. Three of the four 
studies used ultrasound to determine the presence of NAFLD and had similar incidence 
rates, around 19%. Zelber-Sagi et al., (2012) reported an incidence rate of 19% with a 
follow-up period of 7 years. Bedogni et al., (2007) reported similar rates also using 
ultrasound, 18.5 % and 18.5 per 1,000 person-years (PY) developed NAFLD over the 
observational period of 8.5 years. Likewise, Tsuneto et al., (2010), also using ultrasound 
reported a rate of 20% and incidence rate of 19.9/1000 person-years (22.3 PY/1000 for 
men, 18.6 PY/1000 for women).  In this review, the highest cumulative incidence rate of 
36.5% using ultrasound to diagnose NAFLD was reported by Zhou et al., (2007); the 
participants in this study were followed up for 4.8 years. The lowest rate was about 10%, 
all using ultrasound to determine the presence of NAFLD (Hamaguchi & Kojima, 2007; 
Omagari et al., 2002; Xu et al., 2013). However, there was one study that used liver 
enzyme elevation as proxy for NAFLD and reported a rate of 15%; the follow-up period 
for this study was five years (Suzuki et al., 2004). This study also reported the highest 
incidence per patient year (PY) rate of 31 cases per 1000 PY. Similar rates were reported 
from a study in the UK that used retrospective data from a catchment area of 200,000 
adults and reported 29 cases per 100,000 PY (Whalley, Puvanachandra, Desai, & 
Kennedy, 2007). However this study used a variety of parameters to attribute presence of 
NAFLD such as liver biopsy, liver imaging, laboratory blood tests, endoscopy for 
screening or management of esophageal varices, and paracentesis of ascites.  
In summary for the general population, most studies reported rates between 15% 




incidence rates varied by region, modality used to diagnose NAFLD, and cumulative 
incidence rates were also confounded by varied follow-up periods. It is not known if 
these rates are under-reported, given these issues and the absence of large long-term 
prospective population level studies; these are concerns also raised by others reviewing 
the literature for NAFLD incidence rates (Argo & Caldwell, 2009; Lazo & Clark, 2008; 






NAFLD Incidence Studies in the General Population 
First Author Year 
Published 




Zhou 2012 China 
Prospective cohort 
Nov 2005 - Nov 2009 







Xu 2013 China 
Prospective 





Zelber-Sagi 2006 Israel 
Prospective cohort 
2003–2004 







Tsuneto 2010 Japan 
Prospective 
1990 – 2007 






Hamaguchi 2007 Japan 
January 2001 -2003 















Bedogni 2007 Italy 
Prospective study  




12 to 65 
years 
Ultrasound 




Risk Factors Associated with Nonalcoholic Fatty Liver Disease 
This literature review focused on risk factors related to NAFLD in the general 
population, given the paucity of such information in the RA population. This review of 
the literature identified a plethora of risk factors associated with NAFLD, and reported 
prevalence rates from cross sectional studies. The process taken to derive the final list of 
risk factors was determined by identifying factors that were consistently reported in the 
literature. This list was triangulated against the list provided by the consensus guidelines 
for the diagnosis and management of NAFLD (Chalasani et al., 2012). Guidelines are an 
accepted source of information in the medical community, used to help standardize and 
inform clinical practice. The result of this exercise was a list of risk factors independently 
associated with NAFLD and these factors was used as independent predictor variables for 
this study. 
Risk factors associated with NAFLD are age, gender, and race/ethnicity along 
with clinical features such as metabolic syndrome, obesity, diabetes, and dyslipidemia 
(Chalasani et al., 2012). However, there are other factors such as hypertension and liver 
enzyme elevations that have been associated with NAFLD but were not considered as 
independent risk factors and thus may act as potential confounders (Chalasani et al., 
2012). These risk factors associated with NAFLD occur in the absence of significant 
alcohol use or other secondary causes of NAFLD, for example hepatitis C, Wilson’s 
disease, and Reyes syndrome (Chalasani et al., 2012). The following sections in this 




Age. NAFLD appears to affect people of all ages. Studies in the general 
population recognized age as a significant risk factor for NAFLD, noting that the risk 
increased as age increased (Chalasani et al., 2012; Vernon et al., 2011). Age brackets 
used to measure the prevalence of NAFLD varied by study.  Frith, Day, Henderson, Burt, 
& Newton, (2009), Hu et al., (2012), Wong et al., (2011), and Yan et al., (2013), all 
reported that NAFLD rates increased with age and the risk peaked for those in the 50 to 
65 year age group. Chen et al., (2007), reported a prevalence rate of 33.7% for those in 
the middle ages of 40 - 64 years of age with similar rates for those more than 65 years of 
age (32.6 %) and 17.7% for those 18-39 years. In the adjusted analysis, the risk for 
NAFLD was significant for the age bracket 40–64 years (odds ratio [OR] 1.58, 1.25 - 
2.01 (p <0.000) and also for those older than 65 years of age [OR 1.45, 1.08, 1.95, p = 
0.013] (Chen et al., (2007). Similar patterns was also reported by Amarapurkar et al., 
(2007),with the highest prevalence rates in this study of 27.7% for the age of 40 to 49 
years, followed by 24.5% (60 -69 years) and then 23.5% (50-59 years), 18.9% (>70 
years) and lowest rates between 20-29 years of 8.8%. Lazo et al. (2013) also reported that 
those aged 40 years and older had higher rates compared to 20 to 39 years, and this was 
regardless of gender or race. Similar results were reported by Chen, et al., 2006 and Yan 
et al., (2013); these studies also reported statistically significant trends over time, the risk 
for NAFLD increased as age increased. Chen, (2006) in an adjusted analysis reported 
increase risk for those between 40-64 years with OR 1.59, 95% CI [1.25, 2.01] and 
similar risk for ages older than 65 years, OR 1.46, 95% CI [1.08, 1.96] compared to those 
less than 40 years of age. 
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However, some studies reported the reverse trend, with the younger group at 
increased risk for NAFLD. Ong, Pitts, and Younossi (2008) reported higher rates for the 
younger group, those less than 40 years of age versus those 40 years (50.4% vs. 34% 
respectively) and lower rates (15.6%) for those more than 60 years of age.  The study did 
not report if there was significant differences between these age groups. Park et al., 
(2006) also reported similar patterns for NAFLD rates but used different age brackets; 
with those 30 years with a rate of 45.9%, followed by 33.4% for those 25-30 years and 
9.8% for those less than 25 years of age.   
Age was also associated with increased risk for progression of disease, poor 
hepatic related outcomes such as hepatic fibrosis, hepatocellular carcinoma, diabetes, and 
mortality (Adams et al., 2005; Ascha et al., 2010; Hashimoto et al., 2005; Kichian, 
Mclean, Gramlich, Bailey, & Bain, 2003; Ong et al.,2008; Vernon et al., 2011). Ong et 
al., (2008), identified age (older) along with other confounders (e.g. gender, race, higher 
body mass index [BMI] and metabolic syndrome) to be significantly associated with 
higher risk of overall mortality with OR 1.11, 95% [1.11, 1.12]) and for liver related 
mortality OR 9.22, 95% CI [9.11, 9.33]).  Lee et al., (2007) used a combination of 
ultrasound and biopsy to diagnose NAFLD and reported similar results; age (>30 years) 
was an independent risk factor for significant hepatic disease (>30% stenosis of the liver).  
While most studies found age to be a significant risk factor, only one small study 
conducted in China followed 17 patients over a period of 6 years and compared those 
who progressed versus those who did not progress (Hui et al., 2005). In this study, age 
was not statistically significant (p = 0.27), when older individuals with a mean age of 46 
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years were compared to younger individuals with an average age of 36 years. In 
summary, most studies reviewed in the general population reported that the risk for 
NAFLD was associated with age and the risk increased over time, peaking in the middle 
ages of life.  
Gender. Gender is another well recognized risk factor for NAFLD, however this 
association is related to age in the general population (Chalasani et al., 2012). NAFLD 
rates varied by gender, men were at higher risk for NAFLD and regardless of gender the 
risk increased with age (Chalasani et al., 2012; Vernon et al., 2011). As illustrated in 
Figure 11, all the studies reviewed in the general population showed that men were at 
higher risk for NAFLD except for three studies conducted  by Dassanayake et al., (2009); 
Kotronen et al., (2010); and Zhou et al., (2007). 
 
Figure 11. NAFLD Prevalence in the General Population (%): Gender  
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For studies conducted in the U.S., men appear to be at a higher risk for NAFLD 
than women as shown in Figure 11. Men had significantly higher rates of NAFLD 58.9% 
versus 41.1% for women, p < .001 (Williams et al., 2011). Other studies reported higher 
rates among men but did not report if these differences were significant (Lazo et al., 
2011; Stepanova & Younossi, 2012). In adjusted analyses also, men were at significantly 
higher risk of developing NAFLD compared to women with hazard ratio (HR) of 1.26, CI 
95% [1.264, 1.266], p < 0.001 (Ong et al., 2008). When rates was compared among men, 
the proportion of men with NAFLD compared to those without was significantly higher; 
52.4 % versus 45.6%, p <0.001 (Lazo et al., (2011).  Similar analysis of rates among men 
with NAFLD compared to those without was 58.8% versus 40.7% (p  < 0.001) was 
reported by Williams et al., (2011). 
There were many more studies conducted outside of the U.S. that detailed 
differences and relationship between gender and age. Hu et al., (2012) reported that the 
prevalence of NAFLD in males was significantly higher than females, and this risk was 
seen across all age groups (p < 0.001). When men were compared to women the rates 
were respectively: 25% versus 3.89% in the less than 30 year old age group; 50% versus 
13.29% in 30-39 age group; 56.06% versus 24.27% in 40-49 age group, and 57.35% 
versus 45.79% in 50-64 age group. The prevalence increased steadily over time among 
these age groups for women.  In a large study of 9094 adults conducted by Li et al., 
(2009), the prevalence rate was three times higher among males then women  (18.9% vs. 
5.7%, P <0.001). The prevalence rates among men gradually increased by age; 9.4% in 
less than 30 years, 24.4% up to the age of 50 and then decreased over the next several 
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decades of life. However, this trend differed for women. For women there was a gradual 
increase in prevalence rates over time, with a rate of 0.4% in those aged less than 30 
years, and the highest rates of NAFLD were seen in the latter years of life, for those more 
than 70 years of age with a rate of 18.6% (Li et al., 2009).  Park et al., (2006) also 
reported similar differences between men and women (23% vs.13.7% respectively, 
significance was not reported) and trend patterns of increased risk for women with age. 
Notably, in this study there was little variation in rates for men for the various age groups 
between 30 and those more than 70 years of age (about 25%) except for those in the age 
group of 20-29 had a lower rate of about 16%. 
There were three studies conducted in the general population that reported higher 
rates of NAFLD in women. Zhou et al., (2007) reported higher overall NAFLD rates for 
women (16.1%) compared to men (13.1%) with a p <0.05. The trends over time were 
similar for men and women with increasing rates up to the age of 60-70 years for both 
genders (P < 0.01). However, in this study when stratified by age the NAFLD prevalence 
rates for men less than 50 years, the rates was significantly higher than women (22.4 % 
vs. 7.1%, P < 0.001). Like other studies, rates increased for women aged older than 50 
years of age and this rate was significantly greater for women 27.6% versus 20.6% for 
men (P < 0.05).  Two other studies also reported lower rates among men, 31.1% versus 
37.4% for women (Dassanayake et.al. 2009) and 40% versus 60% respectively for the 
study conducted by Kotronen et.al. (2010). 
In several adjusted analyses, men were at higher risk for NAFLD. (Chen, et al., 
(2006) reported that men were at a 44% increased risk for NAFLD compared to women 
62 
 
(OR 1.44, 95% CI [1.09, 1.90], P= 0.011). This increased risk was also reported by Shi et 
al., (2011), with OR 1.04, 95% CI [1.03, 1.05]) for men. In a study by Lazo et al. (2013), 
after adjusting for age and other confounders, men remained at a significant higher risk 
for NAFLD 20.2%, 95% CI [18.0, 22.5]) compared with 15.8%, 95% CI [14.3, 17.2]) for 
women (P < 0.001). In summary, men appeared to be at higher risk for NAFLD in the 
general population. However, during the course of life, NAFLD rates steadily increased 
with age for women, with higher rates reported in the latter years of life.  
Race/Ethnicity. Race and ethnicity is another independent NAFLD risk factor. 
This literature review focused on studies in the U.S., the country where this study was 
conducted. NAFLD prevalence rates by race and ethnicity for the general population are 
illustrated in Figure 12. 
 
Figure 12. NAFLD Prevalence in the General Population (%): Race/Ethnicity  
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Most studies conducted in the U.S. reported differences in prevalence rates of 
NAFLD by race and ethnicity. The highest rates were reported among Hispanics 
followed by Caucasians with the lowest rates among African Americans (Stepanova & 
Younossi, 2012; Vernon et al., 2011).  Williams et al., (2011), in a study conducted in 
Houston Texas of 328 individuals using liver biopsies to identify the presence of NAFLD 
reported the highest rates among Hispanics (58.3%), followed by Caucasians (44.4%) and 
then African Americans with 35.1%. There was a significant difference in the prevalence 
of NAFLD between Hispanics compared with Caucasians (19.4% versus 9.8%; P = 0.03). 
These race/ethnic differences were also confirmed by a study conducted by (Browning et 
al., 2004). This was a study of individuals with advanced NAFLD (cirrhosis of the liver) 
and used biopsy ICD-9 diagnosis code to determine the presence of NAFLD; they 
reported a rate of 68 % for Hispanic patients, followed by 22% for European Americans 
and 7% for African Americans. Similar patterns were reported by Browning et al., in 
2004. This study assessed NAFLD (hepatic steatosis) using proton magnetic resonance 
spectroscopy and reported similar trends with 45% prevalence in Hispanics, 33% in 
whites, and 24% were blacks, and noted that there was higher underlying prevalence of 
obesity and insulin resistance among the Hispanics in this study. 
However, when liver enzymes were used as a surrogate marker for NAFLD the 
differences in prevalence among the various races were similar to other studies but the 
overall rate was slightly lower. Kallwitz et al., (2008), conducted a study with a 
population of 547 obese individuals. Hispanics continued to have the highest rates (39%), 
28% for Caucasians, and 12% for African Americans. These differences were significant 
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between the three groups. Hispanics had higher rates than African Americans (P < 0.001) 
and Caucasians were also at greater risk compared to African Americans [P = 0.030]. 
Two other studies also reported lower risk for NAFLD among African Americans 
(Caldwell, Harris, Patrie, & Hespenheide, 2002; Solga et al., 2005). 
However in this literature review, there were several studies that reported higher 
NAFLD rates for Caucasians. Two studies were conducted using the NHANES database. 
Stepanova & Younossi, (2012), reported prevalence rates of 75.6% for Caucasians and 
8% and 8.4% for Hispanics and African Americans respectively. The second study was 
conducted by Ong et al., in 2008, but included only two race/ethnicity categories (Non 
Hispanic Whites and other) and reported similar rates for Non Hispanic Whites (72.1%) 
and 27.9 % for all other races. However, another study also using NHANES data reported 
higher rates for Hispanic Americans (referred to in the study as Mexican Americans) by 
Lazo et al. (2013). In this adjusted analysis resulted in significantly higher rates for 
Mexican Americans of 24.1%, 95% CI [20.8%, 27.5%] compared to 17.8% 95% CI [6.1, 
19.5] for Non Hispanic whites and 13.5%, 95% CI [1.3, 15.7] for Non Hispanic blacks 
(Lazo et al., 2013).  Other studies that reported higher rates of NAFLD for Caucasians 
were small regional studies or conducted in select populations (e.g. liver clinic) and 
hence the rates may not be representative of the overall general population (Mohanty et 
al., 2009; Weston et al., 2005). For example, Mohanty et al., (2009) used biopsy samples 
from the University of Chicago hospital pathology database and reported NAFLD rates of 
64.7% for Caucasians, 15.1% for African Americans and 13% for Hispanic Americans. 
Weston et al., (2005), also reported higher rates for Caucasians 64.7%, 13% and 15.1% 
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for Hispanics and African Americans respectively.  However, this study only included 
patients from a regional liver clinic. In summary, this literature review of prevalence of 
NAFLD differed by race and ethnicity in the U.S.  There were more studies that reported 
increased rates for Hispanics, followed by Caucasians, with African Americans 
consistently having the lowest risk for NAFLD. 
Obesity. The link between NAFLD and obesity coupled with metabolic syndrome 
has been well established in the literature and has been accepted as central to the 
development of NAFLD in the general population (Chalasani et al., 2012; Lazo & Clark, 
2008a; Vernon et al., 2011b). For this literature review, studies reviewed reported 
NAFLD rates related to obesity that ranged from 14.3% to 99.1% in the general 
population as depicted in Figure 13. The most recent guidelines recommends using waist 
circumference to evaluate the presence of obesity related to metabolic syndrome (Alberti 
et al., 2009). However, some studies used BMI if waist circumference was not available, 
for example Lazo et al. (2011), Lazo et al. (2013),Ong et al. (2008) and Williams et al. 
(2011). Rates of NAFLD varied by regions, populations, and also by the criteria used to 
measure obesity (e.g. with BMI > 30, or elevated waist circumference (≥40 inches in men 
and ≥35 inches in women). These rates are further confounded by the measure used to 
determine the presence of NAFLD (e.g., biopsy or ultrasound).  Some of the studies 
conducted prior to 2005, reported higher NAFLD rates (>90%), and used biopsy results 
from severely obese patients undergoing bariatric surgery. Others were carried out in 
subpopulations with higher prevalence of metabolic syndrome or diabetes. These were 
unlike studies that were conducted in the general population, where ultrasound was used 
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most often to determine the presence of NAFLD, and which reported lower rates of 
obesity as seen in Figure 13.  
In the U.S., NAFLD rates related to presence of obesity as measured by BMI or 
elevated waist circumference ranged from 25.8% to 99%, with most studies reporting 
prevalence rate greater than 65% (see Figure 13). The population level study conducted 
by Lazo et al. in 2013, compared all the various BMI categories to normal BMI. After 
adjusting for confounders there was a two-fold increase risk for NAFLD (OR 2.17, 
95%CI [1.81, 2.60]) for those with a BMI of 25 –29.9 and the OR was 3.31, 95%CI 
[2.74, 4.0] for those with a BMI 30–34.9. However, there was a five-fold increase risk 
(OR 5.05, 95%CI [4.15, 6.14] for those with a BMI ≥35. Even those below normal 
weight with a BMI <18.5 had a two fold increase risk for NAFLD (OR 2.01, 95%CI 
[1.23, 3.27]. Similar results were also reported for those with abdominal obesity by 
Mohan, Farooq, Deepa, Ravikumar, & Pitchumoni, (2009); there was a two fold 
increased risk for NAFLD for those with a BMI ≥ 25 (OR 2.4, 95% C.I. [1.6, 3.5] p < 
0.001), and a four-fold increased risk for those with BMI ≥ 30  (OR 4.0, 95% C.I. [1.9, 
8.3] p < 0.001). Several other studies after adjusting for confounders also reported 
significant risk of NAFLD associated with increased BMI (Babusik, Bilal, & Duris, 
2012; Chen et al., 2007; Jimba et al., 2005; Li et al., 2009; Shi et al., 2011).  
Obesity is a significant risk factor for NAFLD and some studies suggest increased 
risk even among those with normal BMI. There appears to be a dose response in the 
prevalence of NAFLD associated with obesity, with the prevalence being highest among 
the severely obese. Most of the literature and recent guidelines recommend using waist 
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circumference as the measure for obesity when evaluating metabolic syndrome(Alberti et 
al., 2009). However, this measure is not collected in the RA registry, hence BMI was 
used in a similar manner to studies conducted by Lazo et al. (2011), Lazo et al. 
(2013),Ong et al.(2008) and Williams et al. (2011) where elevated BMI was used to 
determine the presence of obesity. 
 
Figure 13. NAFLD Prevalence in the General NAFLD Population (%):Obesity 
Metabolic Syndrome. Metabolic syndrome (MetS) is a significant risk factor for 
NAFLD (Chalasani et al., 2012). This syndrome is a collection of risk factors related to 
obesity, such as increased waist circumference, elevated triglycerides, blood pressure, 
and plasma glucose levels, and reduced HLD levels (Grundy et al., 2005). The most 
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recent consensus guideline defines MetS as the presence of any three of these risk factors 
(Alberti et al., 2009). There is a belief that the presence of any and all factors related to 
MetS could potentially place individuals at risk for NAFLD (Erickson, 2009). A variety 
of definitions were used in the literature and it appears that criteria used for MetS in the 
studies also evolved over time. For example, elevated blood glucose levels were a 
mandatory requirement according to the earlier guidelines. This was reflected in the 
earlier studies, while more recent studies used broader definition such as history of use or 
current use of diabetic medications. More studies reported on the rates of NAFLD using 
the individual components of MetS; only a few studies used the composite MetS 
definition. 
 Prevalence rates of NAFLD in the general population with MetS varied. Studies 
included diverse populations, sample sizes, and the criteria used to determine MetS and 
presence of NAFLD also varied by study. The overall MetS rates among those with 
NAFLD ranged from 15.7 % to 70%, with one study in the U.S. reporting a rate of 43.5% 
(Ong et al., 2008) and another of 20.5% (Smits et al., 2013). Studies included in Figure 




Figure 14. NAFLD Prevalence in the General Population (%): Metabolic Syndrome 
There was a proportional increase in prevalence rates for NAFLD as the number 
of the individual criteria used to determine MetS increased. In a large U.S. study 
conducted by Smits et al. (2013) of 3846 individuals in the general population reflected 
this pattern. NAFLD rates were 90.8% for those who met all five criteria for MetS, and 
58.8% for those with three criteria, however there was 17.2% of the population without 
MetS that had NAFLD. Marchesini et al. reported similar findings in an earlier but 
smaller study in 2003 (N = 304). This study evaluated the prevalence of NAFLD and 
MetS stratified by weight. NAFLD prevalence rate was 36% for the  group with three or 
more MetS criteria, and about 18% among those within the normal weight group, 29% 
for the overweight group, and 67% in the obese group had NAFLD (Marchesini et al., 
2003). In the group with at least one MetS criteria and normal weight, the rate for 
NAFLD was 70%; almost 90% in the overweight and nearly 99% for the obese group. In 
another study, 80% of individuals with NAFLD met all five of the MetS criteria, 63% 
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met three, with 5% of the population that did not have any of the criteria (Wong et al., 
2011). However a study conducted by Chen, et.al. (2008) reported lower overall rates 
associated with the number of MetS criteria (0=11.22%, 1=29.40%, 2 =25.55% and ≥ 3 
=33.83%).  
Several studies showed MetS as an independent predictor for NAFLD. One study 
showed a two fold risk for NAFLD (OR 2.0, 95% C.I [1.3, 3.1] (p < 0.001) after 
adjusting for confounders (Mohan et al., 2009). However, another adjusted analysis 
reported a threefold increase risk for NAFLD-related diseases (OR 3.2, 95% CI [1.2-8.9] 
(Marchesni et al., 2003).  In summary, the presence of any and all indications of MetS 
increased the risk for NAFLD in the general population. Secondly, there appeared to be a 
dose-response effect by the number of MetS component criteria and increased risk for 
NAFLD. 
Diabetes. Diabetes is a well-established risk factor for NAFLD and often 
associated with insulin resistance (Chalasani et al., 2012). Insulin résistance is surmised 
to play a significant role in the pathogenesis of NAFLD (Jakobsen, Berentzen, Sørensen, 
& Overvad, 2007). Most studies accounted for it as one of the criteria for MetS (e.g. 
glucose levels, use of diabetes medication). Others measured it separately as an 
independent variable using measures such as homeostasis model assessment (HOMA) or 
insulin levels (Bajaj et al., 2009; da Cunha et al., 2012; Dessein, Christian, & Solomon, 
2009).  
Overall the prevalence of diabetes in the general population with NAFLD was 
wide and ranged from 4.8% to 87%. These rates reflect regional variations, with higher 
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rates in India and lower rates in studies conducted in China (see Figure 15). In the U.S., 
two studies were conducted in the general population with NAFLD; these studies 
reported rates of 15.8% to 26.3% for diabetes (Lazo et al., 2011; Williams et al., 2011).  
Likewise a study conducted by Mohan et.al (2009) in India reported a rate of 54.5% for 
diabetes. These were patients with NAFLD in the general population. In the multivariate 
analysis, diabetes was associated with almost a three fold increased risk for NAFLD (OR 
2.9, 95% C.I [1.9–4.6], p < 0.001). However, the rates for NAFLD were significantly 
higher in studies conducted in the diabetic population, these rates ranged from 63% - 
69.65% (Gupte et al., 2004; Kelley, McKolanis, Hegazi, Kuller, & Kalhan, 2003; Targher 
et al., 2007). Even though the overall diabetes-related prevalence might be lower in the 
general population in the U.S., those with a history of diabetes appear to be significantly 
at higher risk for NAFLD.  
 




Dyslipidemia. Dyslipidemia or hypercholesterolemia is another risk factor 
associated with NAFLD (Chalasani et al., 2012). Dyslipidemia is defined as alterations in 
the lipid panel; specifically elevations in total cholesterol, low density lipid (LDL) and 
triglyceride (TG) and reduced levels of HDL (Grundy et al., 2005). Review of the 
literature found that dyslipidemia and hypercholesterolemia were used interchangeably. 
The definitions and or cutoff criteria to define dyslipidemia used varied by study. For 
example, Lazo et al. (2013), identified hypercholesterolemia as those with total 
cholesterol levels >240 mg/dL, while Hu et al., (2012), defined it as having either 
elevated total cholesterol level (≥5.2 mmol/L) or triglyceride level (≥1.7 mmol/).  
Consequently, a wide range of prevalence rates for dyslipidemia was seen in the 
literature. The focus of this literature review was limited to those studies that reported on 
the overall rates of dyslipidemia, hypertriglyceridemia and low levels of HDL, as these 
factors are among others are used to define the presence of MetS and also because of 
their unique association with NAFLD (Chalasani et al., 2012; Grundy et al., 2005).  
Prevalence rates for NAFLD associated with dyslipidemia in the general 
population were varied in the U.S. Rates that ranged from 20% to 92% and similar rates 
were reported in other countries (see Figure 16).  This wide range of prevalence rates 
maybe indicative of when these studies where conducted. Some of them were carried out 
before the 1990s and may reflect an era prior to increased prevalence of obesity and 
metabolic syndrome. Obesity and metabolic syndrome are two known key factors 
associated with the development of NAFLD (Erickson, 2009). About half of the 
individuals with NAFLD appear to have dyslipidemia, characteristically presenting with 
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high serum TG and low serum HDL levels (Chalasani et al., 2012). Since the recognition 
of high serum TG levels and low serum HDL levels as key predictors of NAFLD, some 
of the more recent studies reported on these two specific variables only and not the broad 
definition of dyslipidemia.  
The review of literature yielded NAFLD rates from 19.8% to 75% among those 
with dyslipidemia. Li et al. (2009), in a large study compared those with NAFLD (N = 
1140) and without (N = 7954) and showed a significant difference in the prevalence. The 
results showed that the rates among those with NAFLD were 74.7 % versus 35.7% 
respectively (P  < 0.001) among those without NAFLD.  Lazo et al. (2013) in a study 
conducted in the U.S., after adjusting for confounders, reported that the presence of 
dyslipidemia increased the risk for NAFLD by 26% (OR 1.26, 95% CI [1.11, 1.42]). 
Even higher risk for NAFLD associated with hypercholesterolemia of 70% was reported 
in a study conducted in India by Mohan et al. (2009), with OR 1.7, 95% C.I. [1.1–2.7] p 
< 0.05). Dyslipidemia is a well recognized risk factor for NAFLD in the general 




Figure 16. NAFLD Prevalence Rate in the General Population (%): Dyslipidemia 
Hypertriglyceridemia and Low HDL Levels. High triglyceride levels along 
with low levels of HDL also are key predictors of NAFLD (Chalasani et al., 2012). 
Prevalence rates for NAFLD in the general population associated with 
hypertriglyceridemia ranged from 17% to 72% outside of the U.S. and a rate of 52% in 
the U.S. (see Figure 17). Mohan et al. (2009) reported that hypertriglyceridemia was 
associated with increased risk for NAFLD (OR 1.7, 95% C.I. [1.1–2.5], p < 0.05), after 
adjusting for age, gender and waist circumference. Dassanayake et al. (2009), also 
conducted a multivariate analysis and reported a significant association between elevated 
triglyceride and NAFLD  (OR 1.33, 95% CI [1.08,1.63], p 0.008). Similar findings were 
also reported by Chen, et al. in 2006; Jimba et al. in 2005; and  Li et al. in 2009. 
Elevations in triglyceride levels is recognized in the guidelines as a significant risk factor 
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for NAFLD and remained a consistent finding in this literature review (Chalasani et al., 
2012). 
Low levels of HDL are also a significant risk factor associated with the 
development of NAFLD.  Prevalence rates NAFLD associated with low HDL in the 
general population ranged from 20.7% to 71.4%  (see Figure 17). In this review, studies 
reporting on the risk for NAFLD associated with low HDL after adjusting for 
confounders were mixed, though more studies reported an increased risk for NAFLD. 
Several studies indicated significant risk that ranged from 40% to 70% as shown in 
Figure 17. Mohan et al. (2009) reported OR 1.7, 95% C.I. [1.1, 2.6], p < 0.05); also by 
Kim et al. (2004) with OR of 1.41 95% C.I. [1.01, 1.97], p < 0.05); Park et al. (2006) 
reported OR 1.61 95% C.I. [1.14, 2.28], p < 0.05).  Whereas, Li et al. (2009) after 
adjusting for confounders reported a 33% reduced risk for NAFLD associated with low 
HDL levels (OR 0.342, 95% C.I. [0.23, 0.50]). Dassanayake et al. also reported similar 
findings in 2009. Despite these mixed results, it is generally accepted that those with low 






    
 
Figure 17. NAFLD Prevalence Rate in the General Population: Hypertriglyceridemia & Low 
HDL Levels (%)  
In Summary, NAFLD is a chronic condition that is emerging as a public health 
challenge in the U.S. (Argo & Caldwell, 2009). The presence of other prevalent 
conditions associated with NAFLD, such as obesity and metabolic syndrome, diabetes, 
CVD, and dyslipidemia appears to accelerate the development of NAFLD (Argo & 
Caldwell, 2009). Patients with RA also have similar risk factors (Chung et al., 2008; 
Crowson et al., 2011). These factors are prevalent in the RA population with obesity rates 
as high as 65% (see Figure2), MetS rates up to 42% (see Figure 3); hypertension around 
80% (See Figure 4); hypertriglyceridemia about 30% and low HDL of 35% (see Figure 
5), and diabetes of 16% (see Figure 6). Use of MTX for the treatment of RA has been 
associated with increased elevation of liver enzymes and fibrosis of the liver ( Arena et 
al., 2012; Sakthiswary et al., 2014). Hence, this study hypothesized that NAFLD is also 
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prevalent in patients with RA, given the overlap of several NAFLD related risk factors 
and exposure to MTX.  
 Theories related to NAFLD are complex and appear to be linked to chronic 
inflammation affecting the liver. The two hit theory postulated by Day & James (1998) is 
the most frequently referenced theory to explain NAFLD (Lim, et.al., 2010). Obesity and 
metabolic dysfunction are central to the development of NAFLD due to systemic 
inflammation (Fabbrini et al.,2010). RA is also a disease associated with systemic 
inflammation with similar risk factors as NAFLD (Ahmed, 2006), along with liver 
enzyme elevation due to MTX (Visser & Heijde (2009). It is most likely that the 
development of NAFLD maybe due to the confluence of several factors related to 
inflammation and for patients with RA the use of MTX. 
Only one small study in the U.S. reported on the prevalence of NAFLD in the RA 
population (Bhambhani, et.al., 2006). However, prevalence rate in the general population 
was as high as 46% in the U.S. (see Figure 7). No studies reported the incidence rates for 
NAFLD in the RA population, whereas the rate was about 20% in the general population 
(see Figure 10). Risk factors associated with NAFLD in the general population were age, 
gender, and race/ethnicity along with clinical features such as metabolic syndrome, 
obesity, diabetes mellitus, and dyslipidemia (Chalasani et al., 2012). In the general 
population, NAFLD increased with age and peaked in the middle ages of life (Chalasani 
et al., 2012;  Frith, et.al 2009; Hu et al., 2012; Vernon et al., 2011; Wong et al., 2011;Yan 
et al., 2013). Men appeared to be at a higher risk than women for NAFLD in the general 
population (see Figure 11). Hispanics had a greater risk for NAFLD followed by 
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Caucasians, with African Americans having the lowest risk for NAFLD (see Figure 12). 
In the U.S. general population, more studies reported NAFLD rates >65% among the 
obese (see Figure 13) and for those with MetS the rate was as high as 80% (see Figure 
14). NAFLD was reported for those with dyslipidemia (high as 92%), 
hypertriglyceridemia (high as 70%) and 50% for those with low HDL was seen in the 
general population (see Figure 16 and Figure 17).  
Given the emerging prevalence of NAFLD, there is a need to identify patients at 
risk using non-invasive tools such as FIB-4 index (McPherson et al., 2010; Shah et al., 
2009a).This study used retrospective data collected from an observational cohort of 
patients with RA in the U.S. to determine the incidence, prevalence, and factors 
associated with NAFLD using FIB-4. The next chapter details the methods used to 




Chapter 3: Research Method 
The primary objective of this study was to determine if there are significant 
factors that predict the development of NAFLD after adjusting for relevant confounders. 
All patients who met the eligibility criteria and did not have NAFLD at the index baseline 
visit were included in the incident cohort analysis. However, if the sample size was not 
adequate for an incident cohort analysis then the alternate objective was the prevalence 
analyses and a cross sectional cohort would be identified. 
With these objectives in mind, this chapter covers the methodological approach 
taken to address the study objectives and includes: research design, the rationale for the 
approach, the criteria used to select the population, the setting for the study, assumptions 
used to estimate the sample size and power calculation, the statistical analysis plan, and 
description of the dataset. Also presented is the process that was taken to collect the data 
by the registry, specifications and procedures taken to access the study dataset, and 
operationalization of the study variables. Finally, the steps taken to protect and maintain 
the ethical standards for the participants in the registry are also included.   
Research Design and Rationale 
This was a quantitative, nonexperimental, retrospective cohort study that sought 
to answer the following research questions:  
RQ1 Quantitative: What is the incidence rate of NAFLD among patients with RA 




RQ2 Quantitative: What is the prevalence of NAFLD among patients with RA for 
one year (e.g. from January 2012-December 2012) in a RA registry in the U.S. 
determined by using the FIB-4 test? 
RQ3: Among patients in the RA incident cohort, what are the baseline differences 
in clinical and demographic characteristics among those with NAFLD compared 
to those without? 
RQ H0: Among patients in the RA incident cohort, there are no significant 
baseline differences in the clinical and demographic characteristics among those 
with NAFLD compared to those without. 
RQ3 Ha: Among patients in the RA incident cohort, there are significant 
differences in the baseline clinical and demographic characteristics among those 
with NAFLD compared to those without. 
RQ4 Quantitative: For the RA incident cohort, what are the significant baseline  
factors (clinical and demographic) that predict the development of NAFLD after  
adjusting for relevant confounders? 
RQ4 H0: For the RA incident cohort, there are no significant baseline factors   
(clinical and demographic) that predict the development of NAFLD after 
adjusting for relevant confounders. 
RQ4 Ha: For the RA incident cohort, there are significant factors (clinical and  





NAFLD was the dependent variable for this study. The presence of NAFLD was 
determined using FIB-4 score, a tool that measured the various stages of NAFLD. Based 
on the literature review presented in Chapter 2, the independent predictor variables 
included demographic characteristics such as age, gender, and race/ethnicity) as well as 
clinical risk factors such as metabolic syndrome, obesity, diabetes, dyslipidemia, and 
MTX use. Potential confounders associated with NAFLD, but not considered as 
independent risk factors, were liver enzyme elevation, alcohol use, and liver disorders. 
These were risk factors identified in the general population; as such information in the 
RA population was not available in the literature. 
This was a non-experimental research study that used data collected from a 
historical, concurrent cohort of patients with RA and was designed to determine the 
incidence, prevalence, and factors associated with NAFLD. Thus, this study included a 
cohort with longitudinal data for the incidence analysis and a cross sectional data set to 
determine the NAFLD prevalence rate. The primary objective was the incident cohort 
analysis, allowing the opportunity to assess the development of NAFLD, and the ability 
to compare the prevalence of risk factors among those with and without NAFLD and also 
the opportunity to establish the temporal association between the risk factors and the 
onset of disease.  A retrospective cohort and cross-sectional methodology was a rational 
approach to answer these questions as it permits one to evaluate the association between 
the environmental exposures, subject characteristics, and disease risk. Such data would 
have to be collected over many years and would not be realistically feasible or ethical 
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using alternative approaches, such as a randomized study or a prolonged prospective 
observational study (Forthofer, Lee, Hernandez, 2007, pp. 134-166) 
There were other reasons for using a retrospective cohort study design. It allowed 
for the calculation of incidence rates, as information about temporality was available, 
specifically the time sequence between exposure and the outcomes (Szklo & Nieto, 2014, 
pp. 1-7). Additionally, a retrospective cohort study allowed the inclusion of many 
possible exposure measures of association with the outcomes. Taking this approach 
accommodated an important element in the study: the ability to measure risk factors that 
would take many years to develop and also the ability to measure the effect of them over 
a long period of time, key to identifying the predictors of NAFLD. Taking this 
longitudinal approach efficiently aligned with several research objectives of this study 
using the Kaplan Meier and Cox proportional hazard analysis. Information about the time 
to development of NAFLD is limited and therefore answering this question prospectively 
would be cost prohibitive and resource intensive due to the years and vastness of data 
needed to complete the study. Aside from the practical and logistical issues, it would not 
be ethical to knowingly allow those with risk factors associated with NAFLD to continue 
to be exposed without appropriate and timely interventions. 
From an epidemiological perspective, a prospective cohort study is considered 
ideal, provided it is unbiased and reflects the real life temporal association of cause and 
effect for the event under study (Szklo & Nieto, 2014, pp. 1-7). This study was similar to 
several population level cohort studies that were presented in Chapter 2; for example, the 
studies conducted using NHANES data to determine the prevalence of NAFLD in the 
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general population  (e.g. Lazo et al., 2011, Lazo et al., 2013, Stepanova & Younossi, 
(2012), and Smits et al., 2013). This study was similar to a study conducted by Xu et.al in 
2013 to determine the prevalence and risk factors associated with the development of 
NAFLD in a non-obese cohort. Several epidemiological studies were also published 
using cohorts from the RA registry, by Fisher et.al (2012) and Greenberg et.al (2011).  
Risk for NAFLD has not been documented or well characterized in the literature 
for this potentially at risk population with RA. Thus, determining the incidence, 
prevalence, and factors associated with the development of NAFLD was an important 
unanswered question. The approach of answering these questions was based on 
information learned from the literature review and also included important pragmatic 
consideration: the feasibility of conducting the study, availability of a concurrent cohort 
of patients with RA, with data collected over many years, and also having access to a 
large enough sample size with specific data points to reasonably answer the research 
questions.  
Methodology 
Setting and Sample 
Data used for this study were from the Corrona registry. Corrona is an 
independent, prospective, observational cohort registry of adult patients with RA 
recruited from roughly 160 private and academic practice sites across 40 states in the 
U.S., with > 600 participating rheumatologists (Corrona Rheumatoid Arthritis, 2015). 
Approvals for data collection and research were obtained from local institutional review 
boards of participating academic sites and a central institutional review board for private 
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practice sites. Clinical, laboratory, imaging, medication, and drug toxicity data reflecting 
routine care has been collected since 2001(Corrona Rheumatoid Arthritis, 2015). Follow-
up assessments are reported every four months and completed as part of routine clinical 
encounters. Data are collected from both patients and their treating rheumatologists using 
questionnaires and include physician and patient reported information on disease severity 
and activity measures, disease duration, medical comorbidities, use of medications, 
laboratory values, and adverse events (Corrona Rheumatoid Arthritis, 2015). ). It has 
been previously established that the results from studies conducted in this registry is 
generalizable to a national U.S. population of patients with RA (Curtis. J., Chen, L., Yun, 
H., et al, 2013). A sample of patients that met study requirements, as outlined below was 
selected for the study from this registry. A descriptive analysis was also conducted to 
determine comparability of NAFLD study population and the overall registry population 
(see sample Table 9).  
Population 
All adults with a diagnosis of RA and 18 years of age in the registry with 
information necessary to determine the presence of NAFLD (FIB-4 criteria - age, AST, 
ALT and platelets) were included in the study.  Excluded were those for whom the FIB-4 
information was not available or those with secondary causes of NAFLD collected in the 
registry, such as Hepatitis C, B, and polycystic ovarian disease. As of December 2014, 
data was amassed on more than 40,300 patients, with approximately 265,250 patient 
visits, and 107,650 patient years of follow-up observation time. Based on a preliminary 
feasibility assessment, approximately 20,000 patients were eligible for this study. 
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Sample and Sampling Procedures  
Based on a retrospective analysis of a cohort of RA patients and the specific 
research questions, the only option was to use a purposive sample of convenience; only 
patients meeting certain inclusion and exclusion criteria were selected for the study 
(Frankfort-Nachmias, & Nachmias, 2008, pp. 213-24 8). To answer the specific research 
questions, an incident cohort with FIB-4 data to determine the presence of NAFLD was 
identified during the study period (January 2001 - November 2014).  The incident cohort 
was defined as the group without NAFLD at the baseline visit; they also must have at 
least one or more follow-up visit. To increase the robustness of the analysis and reduce 
the possibility of misclassification those with at least two follow up visits with FIB-4 data 
were included in the analysis.  
Sample size for the research questions was estimated using G*Power software 
and inputs for effect size were based on information from studies reviewed in Chapter 2. 
Research questions R1 and R2 were questions related to proportions specifically to 
determine the rates of incidence and prevalence rate. Incidence in the RA population in 
the U.S. was not available, however, cumulative rates in the general population ranged 
from 9.3 to 36.5% over a period of 5 to 8 years (See Figure 10). More studies reported 
cumulative rates of 15% to 20% (see Figure 10). Assuming that the rates in the RA 
population were similar, an average rate of 17% was used for the sample and power 
calculation for the incident cohort analysis. Using a two-sided test of significance with 
alpha of 0.05 and power of 80%, a sample of 640 patients was sufficiently large to detect 
a similar incidence rate of 17%. To increase precision and minimize chance, with 100% 
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power and two-sided alpha of 0.01, the study required a sample of 1913 patients.  Thus, 
to detect an incidence rate of 17%, a minimum sample of 640 was sufficient and a sample 
of 1913 patients increased the power and robustness of the analysis given the fact that 
rates in the RA population were not known (See Figure 18). 























Exact -  Proport ion: Dif erence from constant (binomial test. one sample case)
Tail(s) =  Two. Constant proportion =  0.17. α err prob =  0.05. Ef ect size g =  - 0.04
Power (1-β err prob)
 
        G*Power estimated effect size based sample size assumptions 
Figure 18. Sample Size and Power Calculation for NAFLD Incidence Rate 
Studies about NAFLD in the RA population are few, only one study reported 
prevalence rates in the RA population. This was a small study of 100 patients that 
reported a prevalence rate of 23% (Bhambhani, et.al., 2006), however slightly higher 
rates  (30%) were reported in the general population (Vernon et al., 2011). Assuming a 
prevalence rate of 23%, using a two-sided test of significance with alpha of 0.05 and 
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power of 80%, a sample of 325 was sufficient to detect a similar prevalence rate of 23%. 
To increase the power and robustness of the analysis given the fact that rates in the RA 
population was unknown, sample size was calculated with a power of 100% and two-
sided alpha of 0.01; a sample of 730 was sufficiently large (See Figure 19). 
 
G*Power estimated effect size based sample size assumptions 
Figure 19.  Sample Size Calculation for NAFLD Prevalence Rate 
A power calculation was also estimated for RQ4, which addressed the question: if 
there were significant factors that predict the development of NAFLD (incident cohort) 
after adjusting for relevant confounders. For the incidence cohort, Cox proportional 
hazard models yielded the hazard rates and hazard ratio for developing NAFLD. The 
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independent predictor variables were gender, age, race/ethnicity, metabolic syndrome, 
obesity, diabetes, hypertriglyceridemia and low HDL. There is limited information in the 
RA population and a wide range of rates was reported in the general population for the 
various independent risk factors. No single study reported all the relevant risk factors; 
hence information from several studies was used to determine the sample size. The effect 
size for each of the parameters was derived from several studies as outlined in Table 5. 
For each of the risk factors, power was calculated with 95% CI using the proportion of 
participants at risk for being exposed and unexposed. Assuming a sample size of 640 for 
the incident cohort, using a two tailed-test with alpha of 0.05, power was estimated for 
each of the factors. Overall all the variables considered were sufficiently powered for the 
bivariate analysis as shown in Table 5.  For the multivariate analysis, a small effect size 
of 0.02 (Cohen, 1988, p. 412) was assumed to minimize chance for the eight key 




Table 5  
Power Analysis of NAFLD and Independent Risk Factors 








Gender  Chen et.al., 
(2006) 
Men 30.4% 66.3% 4.5 100% 
Age Chen et al., 
(2007) 
40-64 yrs. 33.7% 66.3% 3.9 100% 
≥ 65 yrs. 32.6% 67.4% 4.3 100% 




Hispanic 58.3% 41.7% 0.5 98% 
Caucasian 44.4% 55.6% 1.6 80% 
African 
American 





Zelber-Sagi et al., 
(2012)  
 29% 8% 3.51 100% 
Mohan (2009);  48.6% 26.1% 2.0 99% 
Ong 2008  43.5% 56.5 1.7 90% 
Obesity Dassanayake 
(2009) 
 38% 62% 2.7 99% 
Chen et al., 
(2007) 
 48.9% 51.1% 1.09 86% 
Diabetes Mellitus Mohan et al. 
(2009 
 54.5% 45.5% 2.9 99% 
Lazo (2011),  15.8% 5.4% 0.3 99% 
Ong 2008  12.2% 87.8% 51 100% 
Hypertriglyceridemia Chen et al., 
(2007) 
 41.8% 58.2% 1.9 98% 
Mohan (2009)  23.9 26.1 1.2 85% 
Dassanayake 
(2009) 
 30% 70% 5.4 100% 
Lazo 2011  52.6 23.8 0.30 100% 
Low HDL Mohan (2009)  29.9 70.1% 5.4 100% 
Kim (2004)  42.3 50.7 0.7 57% 
Dassanayake 
(2009) 
 20% 80% 16 100% 




Taking into consideration the known rates of NAFLD and the effect size of its 
associated risk factors, with a power of 80% and alpha of 0.05, a sample size of 759 was 
sufficiently large to detect the incidence rates and the study was also adequately powered 
for the multivariate analysis.  
Data Collection 
This was a retrospective study that used observational data. Patients with RA 
were recruited into the Corrona RA registry (Corrona Rheumatoid Arthritis, 2015; 
Kremer, 2005). Corrona RA is a disease-based registry that systematically collects and 
documents the effectiveness and safety of disease modifying anti-rheumatic drugs, 
biologic agents, and other treatments used in the management of patients with RA 
(Corrona Rheumatoid Arthritis, 2015; Curtis et. al, 2010). The information is maintained 
in a comprehensive database (the CORRONA Database) which then can be used for drug 
safety, clinical outcomes, and marketing related research. Corrona only provides de-
identified aggregate reports to subscribers (Corrona Rheumatoid Arthritis, 2015).  
According to Corrona RA registry (2015), registry patients must be ≥ 18 years of 
age with a diagnosis with RA, or started on approved biologic or small molecule 
medication for the treatment of RA. Patients must be able and willing to provide written 
consent for participation in the registry, collection of protected health information (PHI) 
and access to their medical record as needed. Health care providers recruit patients from 
their own practice and are encouraged to include vulnerable subject populations, such as 
elderly or economically disadvantaged persons reflective of disease and or population 
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demographics at the participating sites (Corrona Rheumatoid Arthritis, 2015). Patients are 
enrolled during regularly scheduled office visits. At the site, healthcare providers, as well 
as patients, complete the registry questionnaires during the course of regularly scheduled 
office visits, about 2 to 4 times per year (Corrona Rheumatoid Arthritis, 2015). Patients 
remain in the registry until they are lost to follow-up or withdraw consent, at which time 
a subject exit questionnaire is completed (Corrona Rheumatoid Arthritis, 2015). Protocol 
and case report forms may be requested directly from the registry 
(http://www.corrona.org). 
A registry protocol is made available to the sites that outline the process for data 
collection During routine clinical care, providers perform assessments according to 
standard clinical practice; the registry does not mandate specific visits or tests (Corrona 
Rheumatoid Arthritis, 2015). The provider questionnaire form is used to collect routine 
physician related information, which includes laboratory, imaging or other clinical data. 
Patient recorded information, including demographic information, experience with 
prescribed treatments, functional status, and self- assessment of their disease activity is 
captured using the subject questionnaire forms (Corrona Rheumatoid Arthritis, 2015).  
Subsequently, the data is entered into the registry database or alternatively, de-
identified data can also be faxed to Corrona and then entered into the EDC system by the 
registry staff (Corrona Rheumatoid Arthritis, 2015). According to Corrona rheumatoid 
arthritis registry (2015), quality of the data is controlled by using edit checks that are built 
into the on-screen data entry forms to promote completeness and accuracy of the 
submitted data. Additionally, the registry conducts random checks and remote inspections 
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of the data received from sites to ensure consistency and completeness of the data, and, to 
ensure quality, on-site monitoring is conducted as needed to inspect source 
documentation, to ensure adherence to good clinical practice, protocol compliance, and 
accuracy of data reported (Corrona Rheumatoid Arthritis, 2015). 
The Corrona Foundation is a non-profit entity whose primary purpose is to 
promote research in the areas of rheumatic diseases and other conditions (Corrona 
Rheumatoid Arthritis, 2015). Permission was granted to access a limited, de-identified 
data set required to answer the research questions for this study. The scope and terms of 
the data for research and publication was outlined in the foundation sublicense data 
agreement and available upon request. 
Operationalization of Variables 
The NAFLD dataset retrieved from the RA registry for this analysis was limited 
to answer the specific objectives for this study. The NAFLD dataset included 
demographic information, RA specific information about the disease activity, duration of 
disease, and RA specific medications, along with data relevant to determine the 
incidence, prevalence, and factors associated with NAFLD. The dependent and key 
NAFLD related independent predictor variables are specified in Table 6. Operational 




Table 6  
Variable Characteristics  
Variable Type Variable Name Data Source Level of Measurement 
Dependent NAFLD Clinical (laboratory) Nominal 
Predictor 
 
Age Demographic Continuous 
Ordinal 
 Gender Demographic Nominal 
 Race/ Ethnicity Demographic Nominal 
 Metabolic Syndrome  Clinical Nominal 
 Obesity  Clinical Nominal 
 Diabetes  Clinical Nominal 
 Dyslipidemia Clinical Nominal 
Potential Predictors MTX Clinical Nominal 
 Liver Enzyme Elevation Clinical Nominal 
 Liver Disorders Clinical Nominal 
 Alcohol Use Clinical Nominal 
MTX- Methotrexate     
Dependent Variable  
The dependent variable was defined as the presence or absence of NAFLD using 
the FIB-4 score, a validated noninvasive tool described in detailed in Chapter 2. FIB-4 
score was calculated by using the following formula: age [years] × AST [U/L]) / (platelet 
[109] × √ALT [U/L] (Shah et al., 2009a). FIB-4 score was divided into three categories to 
match the various progressive stages of NAFLD (see Table 7). FIB-4 score of  <1.3 
corresponds to fibrosis stage 0 and indicates the absence of fibrosis or advanced disease; 
FIB-4 score of ≥ 1.3 but < 2.67 = stage 1 with early changes in perisinusoidal or portal 
changes and also includes stage 2 – perisinusoidal, portal and periportal changes 
suggestive of mild to moderate disease; and score ≥ 2.67 encompasses advanced disease 
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with stage 3 with septal or bridging fibrosis or stage 4 which includes cirrhosis or 
advanced disease (Kleiner et al., 2005; Vallet-Pichard et.al 2007; Shah et.al, 2009a). As 
described above, there are four possible stages of NAFLD. For this analysis, the primary 
outcome of interest was to determine the presence or absence of NAFLD.  A FIB-4 score 
of  <1.3 indicates the absence of advanced disease and the presence of NAFLD with a 
score of ≥ 1.3. However, additional analyses was planned to ascertain the presence of the 
other two categories of secondary interest, mild/moderate NAFLD (score ≥ 1.3 but < 
2.67) and advanced disease (score ≥ 2.67),   
Table 7 
Relationship between NAFLD Score of Stages of Disease  
NAFLD FIB-4 Score NAFLD Stages Disease Definition 
<1.3 Stage 0 Absence of fibrosis or advanced disease 
≥ 1.3 but < 2.67 Stage 1: with early changes in 
perisinusoidal or portal changes 
Mild to moderate disease 
Stage 2: perisinusoidal, portal and 
periportal changes 
≥ 2.67 Stage 3 and Stage 4 with septal or 
bridging fibrosis, cirrhosis 
Advanced disease 
Independent Variables  
The independent predictor variables identified were a combination of 
demographic and clinical risk factors for NAFLD. These variables are collected in the 
registry and defined for the analysis was based on information learned from the review of 
literature presented in Chapter 2. Operational definitions for each of the variables are 




 Variables, Operational Definitions, and Codes 
Variable Type Variable Name Responses Categories/Code 
Dependent  NAFLD  FIB-4 score  
• <1.3 - no advanced disease (= 0) 
• ≥ 1.3 - positive for NAFLD (=1) 
• ≥ 1.3 but < 2.67 = mild/moderate (= 2) 
• ≥ 2.67 = advanced disease (=3) 
Predictor 
 
Age at baseline • Younger = ≥ 18 years < 39 years (= 1) 
• Middle age  =≥ 40 - 59 years (=2) 
• Elderly ≥ 60 years (=3) 
Predictor 
 
Gender at baseline • Male (=1) 




Race at baseline 
• Hispanic (yes=1, no=0) 
• Caucasian (=1) 
• African American (=2) 
• Asian (=3) 
• Other (=4) 
• Multiracial (=5) 
Predictor 
 
Obesity at baseline • BMI Underweight  <18.5 (=1) 
• BMI Normal weight 18.5–24.9 (=2) 
• BMI Overweight 25–29.9 (=3) 
• BMI Obesity 30 or > (=4) 




 Variables, Operational Definitions, and Codes 
 
(table continues) 
Variable Type Variable Name Responses Categories/Code 
Predictor 
 
Metabolic Syndrome at 
baseline 
Meets any three of the following criteria 
(yes=1, no=0) 
• BMI  >25 (yes=1, no=0) 
• Elevated TG level is defined as levels 
≥150 mg/dL (yes=1, no=0) 
• HDL <40 mg/dL in men and  <50 mg/dL 
in women (yes=1, no=0) 
• Use of lipid lowering medications 
(yes=1, no=0) 
• History of dyslipidemia (yes=1, no=0) 
• Elevated blood pressure is defined as 
≥130 mm Hg systolic blood pressure or 
≥85 mm Hg diastolic blood pressure 
(yes=1, no=0) 
• Use of antihypertensive drug treatment 
(yes=1, no=0) 
• History of hypertension (yes=1, no=0) 
• Use of drug treatment for elevated 
glucose (yes=1, no=0) 
• History of diabetes (yes=1, no=0) 
Predictor Diabetes at baseline Yes=1, No=0 
Predictor  Dyslipidemia at baseline Yes=1, No=0 for any one of these criteria 
Total cholesterol > 200 (mg/dL) or LDL > 
130 (mg/dL) or HDL <40 mg/dL in men and  
<50 mg/dL in women, or TG >150 mg/dL 
Predictor MTX at baseline Yes=1, No=0 
Predictor Liver Enzyme Elevation* Yes=1, No=0 
Predictor Liver Disorders at baseline Yes=1, No=0 
Predictor Alcohol use at baseline Yes =1, No =0 
0=No, Daily = 2, Weekly =3,1 Daily = 2, 
Occasional 3, Monthly= 4 
BMI- Body Mass Index; TG- Triglyceride; HDL- High Density Lipids: LDL- Low Density Lipids; 
*ULN > Upper limit of normal at baseline 
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Age, gender and race/ethnicity are self-reported demographic measures collected 
in the registry. Age is a continuous variable and reported in years in the registry. For this 
study, similar to studies conducted by Lazo et al. (2013), Yan et al. (2013) and Chen et.al. 
(2006), age was categorized into three groups: younger, middle age and elderly. Gender 
indicates the reported sex of the patient and captured as male or female. Race is another 
self -reported measure captured in the registry as Caucasian, African American, Asian, 
other or mixed race, and ethnicity grouped as Hispanic or non Hispanic. 
Clinical risk factors for NAFLD are metabolic syndrome, obesity, diabetes, 
hypertriglyceridemia and low HDL, and are physician reported measures. Obesity for this 
study was assessed using BMI score, calculated for each patient using height weight, age 
and gender. BMI was then categorized into four groups: underweight, normal weight, 
overweight and obese using the Centers for Disease Center BMI criteria (CDC [BMI], 
(2014). Metabolic syndrome was defined as the presence of any three of the following 
obesity related risk factors: elevated waist circumference, elevated triglycerides (TG), 
blood pressure, glucose and reduced HLD (Alberti et al., 2009; Grundy et al, 2005). 
Specific criteria recommended for each of these measures were used in this analysis to 
determine the presence of metabolic syndrome (Grundy et al., 2005).  
Waist circumference is the preferred measure to determine metabolic syndrome, 
however, it was not collected in the registry and was substituted with BMI score ≥ 25 
(overweight/obese) in this analysis. BMI is an appropriate substitute as it has been used 
in several studies and shown to be an independent risk factor for NAFLD (e.g. Smits et 
al. 2013, Wong, et al. 2011, and Mohan et al. 2009).  Operational definitions for elevated 
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TG are: TG levels ≥150 mg/dL, the use of lipid lowering medications, history of 
dyslipidemia, elevated blood pressure of ≥130 mm Hg systolic blood pressure or ≥85 mm 
Hg diastolic blood pressure, the use of antihypertensive drug treatment,  a history of 
hypertension and reduced high HDL levels <40 mg/dL in men and  <50 mg/dL in women 
or the use of lipid lowering medication or history of dyslipidemia.  Fasting glucose levels 
are not captured in the registry; hence the presence of elevated fasting glucose was 
defined as the use of drug treatment for elevated glucose or history of diabetes.  
The variable diabetes was defined as those patients with a reported history of 
diabetes or use of drug treatment for elevated glucose. Dyslipidemia was defined as 
altered lipid levels (total cholesterol, low density cholesterol (LDL), HDL, and TG), as 
outlined in the ATP III guidelines, (NCEP, 2002) or taking lipid lowering medications. 
Potential predictors in the study are MTX use (as yes or no), liver enzyme elevation (as 
yes or no above upper limit of normal), alcohol use, and liver disorders. These variables 
are captured in the registry. For this analysis, presence of liver disorders included 
reported hepatic events, liver disorders and also those with history of liver biopsy. 
Alcohol use is captured in the registry as none, daily, weekly, or occasional use. 
Statistical analyses for this study were conducted using the Statistical Package for 
Social Sciences (SPSS 22.0). The registry statistician extracted the dataset.  Included in 
the dataset were adult RA patients who met the inclusion criteria and also had the 
measurements to calculate FIB-4 score (age, AST, ALT and platelets) during the period 
of January 2001 to November 2014. For the incident cohort analysis, the index baseline 
visit included those without NAFLD (calculated FIB-4 score <1.30) at or after date of 
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enrollment into the registry and must have had at least two or more follow-up visits. An 
incident case of NAFLD was defined when there was at least two follow up visits with 
FIB-4 ≥1.30.  These were consecutive visits; the incident event occurred at the second 
visit with FIB-4 ≥1.30. However, should there not be sufficient sample size to conduct 
the analysis, then a more lenient criterion where patients with only one follow-up visit 
with FIB-4 ≥1.30 would be included for analysis. RA patients with one or more visits in 
the period of one year (e.g. from January 2012 - December 2012) would be included in 
the prevalent dataset. NAFLD (FIB-4 ≥1.30) must be present at two consecutive visits. 
Again, should sample size not be sufficient then only one follow-up visit would be used 
for the analysis.  
Statistical Analysis and Tests 
The following section outlines the statistical plan for each of the research 
questions and, wherever appropriate, shell output tables are provided, for example see 
table 9. This was a quantitative study that included descriptive and multivariate analysis. 
In preparation for these analyses using SPSS, measures of central tendency, distribution, 
and dispersion of data was assessed. The impact of missing data was evaluated along 
with assumptions for parametric tests and the appropriate use of nonparametric tests. 
Kaplan Meier survival and Cox proportional hazard analysis was used to determine the 
factors that predict the development of NAFLD. This approach allows one to estimate 
risk of an event (i.e. development of NAFLD) after adjusting for predictor or explanatory 
variables (Tabachnick & Fidell 2012, pp. 510-570) While satisfying assumptions of 
distribution for descriptive analyses and assessing for linearity, normality, and 
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homoscedasticity among covariates, are not necessarily required for survival analysis, 
however, assessing them would enhance the robustness of the analysis, additionally there 
are other factors and assumptions that must be evaluated and addressed when conducting 
survival analysis (Tabachnick & Fidell (2012, pp. 510-570). I used the checklist provided 
by Tabachnick & Fidell (2012) as my guide for conducting survival analysis. While 
satisfying assumptions of distribution for descriptive analyses and assessing for linearity, 
normality, and homoscedasticity among covariates, are not necessarily required for 
survival analysis, however, assessing them would enhance the robustness of the analysis, 
additionally there are other factors and assumptions that must be evaluated and addressed 
when conducting survival analysis (Tabachnick & Fidell (2012, pp. 510-570). I used the 
checklist provided by Tabachnick & Fidell (2012) as my guide for conducting survival 
analysis. I evaluated the adequacy of sample size, missing data, normality of distribution, 
proportionality of hazard assumption and multicollinearity.  I also addressed issues with 
missing data, outliers, and difference between withdrawn and remaining cases, and 
changes in survival experience over time. The details and results of these evaluations are 
presented in the following sections. For inferential testing, a two- sided test with 95% 
confidence interval, and hazard ratios were used. Ratio analysis with results that do not 
include 1 or analysis with p-value < .05 was considered significant unless otherwise 
specified. 
Descriptive Analysis 
Several descriptive analyses were conducted pertaining to each of the research 
questions: continuous variables means, medians, and interquartile ranges were 
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determined. A descriptive analysis was conducted to determine comparability of NAFLD 
study population and the overall registry population (see sample Table 9). This 
information was provided by the registry and enabled the comparison of the NAFLD 
study cohort with core registry population. 
Table 9  
NAFLD Study Cohort Compared to Overall Registry Patients (sample) 





Age (years)    
Gender (female) (n, %)    
Race (n, %)    
 
RQ1 Quantitative: What is the incidence rate of NAFLD among patients with RA 
from 2001 -2015 in a RA registry in the U.S. using the FIB-4 test? 
The incident cohort dataset was used to determine the incidence rates and time to 
using Kaplan Meier survival analysis. The results of the analysis included time to event, 
person years, absolute number and percent of incident cases, rate per 1000 patient years 
with 95% CI, and the overall cumulative incidence rates during the study period. Rates of 
NAFLD by the key significant risk factors were identified in the study, and were also 
analyzed and reported (see Table 10). 
RQ2 Quantitative: What is prevalence rate of NAFLD among patients with RA 
for one year  (e.g. from January 2012 - December 2012) in a RA registry in the U.S. 
determined by using the FIB-4 test? 
Similar analysis was conducted to determine the prevalence rates using the 
prevalent cohort. The results of the analysis include absolute number, percent of 
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prevalent cases, and prevalence per 1000 patients with 95% CI during the study period. 
Prevalence of NAFLD by the key significant risk factors identified in the study are also 
summarized and reported (see Table 10). 
Table 10  












(1000 PY) 95% CI 
Overall NAFLD       
Mild/Moderate 
NAFLD 
     
Advanced NAFLD      
Age      
Younger      
  Middle Aged      
Elderly      
Gender                        
Male  
     
Female      
Race/ Ethnicity        
Caucasians       
Hispanic      
African American      
Asian      
Obesity (BMI)      
Metabolic 
Syndrome  
     
Diabetes      
Dyslipidemia      
MTX Use       
Liver Enzyme 
Elevation 
     
Liver Disorders      
Alcohol use      
Daily     
Weekly     
Monthly      




RQ3: Among patients in the RA incident cohort, what are the baseline differences 
in clinical and demographic characteristics among those with NAFLD compared to those 
without? 
RQ Ho: Among patients in the RA incident cohort, there are no significant 
baseline differences in the clinical and demographic characteristics among those with 
NAFLD compared to those without. 
RQ3 Ha: Among patients in the RA incident cohort, there are significant 
differences in the baseline clinical and demographic characteristics among those with 
NAFLD compared to those without. 
Baseline characteristics for those with NAFLD were compared to those without 
for the incident cohort in the format shown in the sample table (see sample Table 11). 
Chi-square and independent t-test were used to determine if there are statistically 
significant differences between these two groups. 
Table 11  
Comparison of Baseline Factors: Patients with vs. without Incident NAFLD  











Age (mean, years)     
Gender (female) (n, %)     
Race (n, %)     
P value = With Incident NAFLD vs. Without Incident NAFLD 
RQ4 Quantitative: For the RA incident cohort, what are the significant baseline 
factors (clinical and demographic) that predict the development of NAFLD after 
adjusting for relevant confounders? 
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RQ4 Ho: For the RA incident cohort, there are no significant baseline factors 
(clinical and demographic) that predict the development of NAFLD after adjusting for 
relevant confounders. 
RQ4 Ha: For the RA incident cohort, there are significant factors (clinical and 
demographic) that predict the development of NAFLD after adjusting for relevant 
confounders. 
Cox proportional hazard analysis was used to determine the factors that predict 
development of NAFLD for the incident cohort analysis. The results were reported as 
hazard rates and ratios. The following known predictors of NAFLD were included in the 
model apriori regardless of the significance, including: age, gender, race/ ethnicity, 
obesity, metabolic syndrome, diabetes, dyslipidemia, MTX, liver enzyme elevation, liver 
disorders, and alcohol use. 
Bivariate and Multivariate Analysis 
Prior to conducting the multivariate analysis, a bivariate analysis was conducted 
to determine the effect of each of the factors associated with the outcome variable (see 
sample Table 12). The results from the unadjusted analysis were used to inform 




Table 12  
Unadjusted Analyses of Baseline Predictors for Incidence of NAFLD 
Variable Hazard Ratio 95% CI P-value 
Overall NAFLD    
Mild/Moderate 
NAFLD 
   
Advanced NAFLD    
Age    
Younger      
Middle Aged    
Elderly    
Race/Ethnicity    
Caucasians    
African American    
Asian    
Other    
Hispanic    
Obesity BMI    
Underweight    
Normal Weight    
Overweight    
Obesity (BMI ≥ 25)    
Metabolic Syndrome    
Diabetes    
Dyslipidemia    
MTX Use    
Liver Disorders    
Alcohol use    
Daily    
Weekly    
Monthly    
BMI- Body Mass Index; MTX- Methotrexate 
A multivariate analysis was conducted to determine if there are significant 
baseline factors that predict the development of NAFLD after adjusting for relevant 
predictors or explanatory variables among patients with RA (see sample Table 13). Cox 
proportional hazards analysis was used to identify factors associated with the 
development of NAFLD (Tabachnick, B. & Fidell, L., 2012. Ch. 11). An unadjusted and 
adjusted Cox proportional model was run to determine the effect of the confounders on 
the outcome variable. While p-values can assess differences, however, it is also important 
to ascertain the impact or magnitude of the change so as to avoid overestimation or 
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underestimation of the association of these factors and the outcome variable (Grayson, 
1987). Factors with ratios that changed by 10% or more were included in the multivariate 
model as potential confounders (Grayson, 1987; Hernán, et al., 2002).  
All factors identified apriori and significant factors from the bivariate analysis 
were entered into the model simultaneously. Several models were run to identify the most 
parsimonious model, and also evaluate the effect of the predictor variables: age, gender, 
race/ ethnicity, obesity, metabolic syndrome, diabetes, dyslipidemia, MTX use, liver 
enzyme elevation, liver disorders, and alcohol use as defined and categorized in Table 8. 
For example, one of the models would be adjusted for key demographic variables (e.g. 
age, gender, race/ethnicity). Then a second model could be adjusted for these key 
demographic variables as well as for factors associated with MetS. The risk over time 
was assumed to remain proportionally constant; this assumption was checked using 
Kaplan Maier analysis. Should the survival curves for each of these combinations cross, 
then the assumption of proportionality would be violated (Tabachnick, B. & Fidell, L., 
2012. Ch. 11). Should this assumption be violated then diagnostic analysis would be 
conducted to determine the causes, such as outliers, highly influential variables, or 
inclusion of appropriate covariates in the model (Wilson, 2013). Incidence (hazard) rates 
and ratios were reported with 95% confidence interval and factors that do not include 1 




Table 13  
Adjusted Analyses of Baseline Predictors for Incidence of NAFLD 
Variable Hazard Ratio 95% CI P-value 
Overall NAFLD    
Mild/Moderate 
NAFLD 
   
Advanced NAFLD    
Age    
Younger      
Middle Aged    
Elderly    
Race/Ethnicity    
Caucasians    
African American    
Asian    
Other    
Hispanic    
Obesity BMI    
Underweight    
Normal Weight    
Overweight    
Obesity (BMI ≥ 25)    
Metabolic Syndrome    
Diabetes    
Dyslipidemia    
MTX Use    
Liver Disorders    
Alcohol use    
Daily    
Weekly    
Monthly    
BMI- Body Mass Index; MTX- Methotrexate; Adjusted for age, gender, race/ethnicity, BMI, 
metabolic syndrome, diabetes, dyslipidemia, MTX use, Liver Disorder, Alcohol use 
Threats to Internal and External Validity 
The main threat to internal and external validity for this study was the design. A 
valid study is unbiased, one that is designed and data collected fit for purpose in a reliable 
and valid manner such that the overall results of the study are closer to the truth ( Szklo & 
Nieto, 2014. pp. 109-150). 
As this was a non-randomized study that used secondary data and utilized a non-
probability sample of convenience there were inherent threats to both internal and 
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external validity (Szklo & Nieto, 2014, pp. 109-150).  Systematic selection bias was a 
potential issue in this study, as the sample was selected primarily based on availability of 
laboratory parameters (liver enzyme and platelet counts); there is a potential for 
differences among this group and the rest of RA patients in the registry. Comparing the 
study cohort and the registry population assessed this threat of potential bias. Significant 
differences could be indicative of systematic selection bias (Szklo & Nieto, 2014, pp. 
109-150). 
There are other limitations of using secondary data, as the collected data may not 
be a good fit for the research question, there maybe systematic missing variables, or key 
variables may not be available at certain time points (Hofferth, 2005). Hence this 
analysis, using secondary data, may not be conducive to establishing causality (Smith et 
al., 2011). Given that this was a retrospective study, misclassification of either the 
exposure or the outcome was also a potential risk. This limitation was addressed during 
the data collection phase of the study, however, since this was a retrospective study. 
Conducting sensitivity and specificity analysis was not feasible; hence the magnitude of 
misclassification is unknown. Alternatively, additional sensitivity analysis was conducted 
under varying plausible assumptions to estimate the influence on the effect size. When 
these results are directionally consistent one can be assured that the results are from the 
effect of treatment rather than due to systematic errors (Szklo & Nieto, 2013, pp. 391-
426). While this was a large registry of RA patients across the U.S., patients volunteered 
to participate in the registry, also not all patients at a site were entered into the registry; 
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leading to variation as to how sites select patients for the registry and may pose a 
potential threat to the generalizability of the results (Curtis, et al., 2013). 
Using real world data increases the external validity, however, there remain many 
unmeasured confounders that threaten internal validity and thereby diminishing the 
inferential power of the study (Frankfort-Nachmias & Nachmias, 2008). This was an 
exploratory hypothesis-generating study and some of the limitations of observational data 
can be addressed by adjusting for confounders and assessing interactions along with sub 
group analysis; these are potential options to consider in order to increase the robustness 
of the study results (Frankfort-Nachmias & Nachmias, 2008). Thus, results can only be 
interpreted under the conditions study was conducted, as alternative explanations cannot 
be ruled out or cannot be adequately explained through statistical analysis (Szklo &Nieto, 
2013, pp. 391-426). 
Ethical Procedures 
This was a retrospective study where a limited dataset with pertinent information 
for the analysis was retrieved from the registry. To ensure that the registry is operating in 
an ethical and compliant manner, it has institutional review board (IRB) approval in place 
and also has obtained participants’ consent for the use of their clinical data for research. 
The registry has safeguards in place that includes obtaining the appropriate consent for 
accessing the data from the participants as well as from the sites for the use of their data 
in a Health Information Portability and Accountability Act (HIPPA) compliant manner 
(Corrona Rheumatoid Arthritis, 2015). Thus, the use of data for this study retrieved from 
the registry was within the scope of the consent (i.e. for research). To ensure 
110 
 
confidentiality was maintained, only the needed de-identified data was extracted and 
subsequently stored in a secure and protected place on my computer. A mutual agreement 
about rights, use, and storage of the data is specified in a data use agreement and 
available upon request. To protect against potential human rights violation and to ensure 
confidentiality was maintained, the study protocol, original IRB approval for the registry, 
and data sharing agreement was approved by Walden University’s IRB (# 06-19-15-
0335302).  
Summary 
This was a retrospective cohort study of patients with RA to determine the 
incidence, prevalence, and factors associated with NAFLD.  Secondary data from an 
established RA registry was used to identify a cohort with longitudinal data for the 
incidence analysis. The primary objective of the study was to determine incidence rates, 
time to event and the factors that predict the development of NAFLD after adjusting for 
relevant confounders such as age, gender, race/ ethnicity, obesity, metabolic syndrome, 
diabetes, dyslipidemia, MTX, liver disorders, and alcohol use. Alternatively, analyses 
using a prevalent cohort were planned in the event an adequate sample for the primary 
objective was not available. Descriptive analysis, Kaplan Meier survival and multivariate 
Cox proportional hazard analysis was conducted using SPSS. Processes and approvals 
were in place to ensure that patients were protected in an ethical and compliant manner.  
As this was a non-randomized study that used secondary data and utilized a non-
probability sample of convenience there were inherent threats to both internal and 
external validity (Szklo & Nieto, 2014, pp. 109-150).  Additionally, this study did not 
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that collected fit for purpose data in a reliable and valid manner ( Szklo & Nieto, 2014. 
pp. 109-150). Systematic selection bias was a potential issue in this study, as the sample 
was selected primarily based on availability of laboratory parameters (liver enzyme and 
platelet counts); there is a potential for differences among this group and the rest of RA 
patients in the registry. Comparing the study cohort and the registry population assessed 
this threat of potential bias. Significant differences could be indicative of systematic 
selection bias (Szklo & Nieto, 2014, pp. 109-150). 
There are other limitations with using secondary data for example there maybe 
missing data for key variables, or key variables may not be available at the pertinent time 
points (Hofferth, 2005). This was a retrospective study; there is potential risk of 
misclassification of either the exposure or the outcome. This was a large registry of RA 
patients across the U.S., who volunteered to participate in the registry. Additionally not 
all patients at a site were entered into the registry. Thus there was a potential threat to the 
generalizability of the results (Curtis, et al., 2013). 
Using real world data increases the external validity, however, there remain many 
unmeasured confounders that threaten internal validity and thereby diminishing the 
inferential power of the study (Frankfort-Nachmias & Nachmias, 2008). This was an 
exploratory hypothesis-generating study and some of the limitations of observational data 
can be addressed by adjusting for confounders and assessing interactions along with sub 
group analysis; these are potential options to consider in order to increase the robustness 
of the study results (Frankfort-Nachmias & Nachmias, 2008). Thus, results can only be 
interpreted under the conditions study was conducted, as alternative explanations cannot 
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be ruled out or cannot be adequately explained through statistical analysis (Szklo &Nieto, 
2013, pp. 391-426). The next chapter will present the results of the analysis plan outlined 




Chapter 4: Results 
The purpose of this research study was to determine the presence and factors 
associated with the development of NAFLD using registry data collected from a cohort of 
adult RA patients in the U.S. The primary objective of this study was to determine the 
incidence rate and the factors that predict the development of NAFLD after adjusting for 
relevant confounders. The contingency plan was to conduct analyses using a prevalent 
cohort if the sample size was not adequate for the incident cohort analysis. Since the 
incident cohort sample was sufficiently large the alternate objective to conduct analysis 
using the prevalent cohort was abandoned. Thus this chapter will focus on the results of 
the incident analyses. To achieve these objectives an incident cohort was utilized. All 
patients who met the eligibility criteria without NAFLD (FIB-4 score <1.3) at the index 
baseline visit were grouped into the incident cohort.  
This chapter also includes the results from the descriptive analysis, bivariate 
analysis, and factors selected for the multivariate analysis. I will summarize the results 
for each the following research questions. 
RQ1 Quantitative: What is the incidence rate of NAFLD among patients with RA 
from January 2001 - November 2014 in a RA registry in the U.S. using the FIB-4 
test? 
RQ2 Quantitative: What is the prevalence of NAFLD among patients with RA for 
one year (e.g. from January 2012-December 2012) in a RA registry in the U.S. 
determined by using the FIB-4 test? 
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RQ3: Among patients in the RA incident cohort, what are the baseline differences 
in clinical and demographic characteristics among those with NAFLD compared 
to those without? 
RQ H0: Among patients in the RA incident cohort, there are no significant 
baseline differences in the clinical and demographic characteristics among those 
with NAFLD compared to those without. 
RQ3 Ha: Among patients in the RA incident cohort, there are significant 
differences in the baseline clinical and demographic characteristics among those 
with NAFLD compared to those without. 
RQ4 Quantitative: For the RA incident cohort, what are the significant baseline  
factors (clinical and demographic) that predict the development of NAFLD after  
adjusting for relevant confounders? 
RQ4 H0: For the RA incident cohort, there are no significant baseline factors   
(clinical and demographic) that predict the development of NAFLD after 
adjusting for relevant confounders. 
RQ4 Ha: For the RA incident cohort, there are significant factors (clinical and  
demographic) that predict the development of NAFLD after adjusting for relevant  
confounders. 
As mentioned above, since the sample size was sufficiently large to answer the 
primary objective of this research study, the incident analysis, the alternative research 
questions that relate to the prevalent analyses was dropped and the results will focus on 
the primary objective only. Chapter 3 outlined a priori the statistical analysis plan. In this 
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chapter, I describe the methods used to select the incident dataset, statistical analysis and 
also describe any deviations from the plan and the rationale for the modifications. 
Dataset Collection and Preparation 
This study used retrospective data from an established RA registry. Recruitment 
and details about data collection are outlined in Chapter 3.  The registry statistician 
extracted limited, de-identified, patient level data from the registry and only included the 
pre-specified clinical and demographic data points needed for this study. This included 
data about demographic and clinical information for the predictor variables; gender, age, 
race/ethnicity, metabolic syndrome, obesity, diabetes, dyslipidemia, liver enzyme 
elevation, liver disorders and alcohol use. Factors related to RA were disease duration, 
disease activity and the RA related medication.  All adult patients with a diagnosis of RA 
of more than 18 years of age in the registry with information necessary to determine the 
presence of NAFLD (FIB-4 criteria) were included in the study.  
The registry statistician extracted the information for the incident cohort and also 
provided information needed to determine comparability of the NAFLD study cohort and 
the overall registry population (Table 14). The study period for the incident cohort was 
from January 2001 to November 2014.  Excluded were those for whom the FIB-4 
information was not available or those with secondary causes of NAFLD collected in the 
registry such as Hepatitis C, B, and polycystic ovarian disease, yielding a sample of 
17,481 patients for the incident cohort analysis as shown in Figure 20.  
The incident cohort included those with an index baseline visit without NAFLD 
(calculated FIB-4 score <1.30) at or after date of enrollment into the registry and had a 
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minimum of one or more follow-up visits. An incident case of NAFLD was defined when 
there was at least two consecutive follow up visits with FIB-4 scores to determine the 
presence of NAFLD. The dataset for the incident cohort and the data requirements was 
extracted as planned and described in Chapter 3. 
 
Figure 20. Flow chart of Study Participants  
Transforming Data 
The independent predictor variables identified were a combination of 
demographic and clinical risk factors for NAFLD. Raw data were transformed and 
operationalized for analysis as previously outlined in Table 8.  Frequency tables were 
then run on each of the variables. Several of the categories had to be further collapsed 
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due to infrequency of data. Race was collapsed from eight categories into four: 
Caucasian, African American, Asian and “Other” which included multiracial, Pacific 
Islander, and unknown. Marital status was collapsed into three groups (single or 
widowed; married or partnered; divorced or separated). Given the prevalence of obesity 
in this cohort, this category was collapsed into obese (BMI ≥ 25) and non-obese groups. 
Smoking status was combined from four into two categories, nonsmokers and smokers; 
the latter included both former and current smokers. 
Diabetes included those with a diagnosed history of diabetes or those currently 
taking diabetic medications. Liver disorders included those with a diagnosis of hepatic 
disease, or hepatic disease with or without biopsy. Dyslipidemia for the analysis included 
those with a history of dyslipidemia or using lipid lowering medication. Also included 
were those with high triglyceride levels, low HDL, high cholesterol, or high LDL. 
Disease duration categories were classified into clinically meaningful categories of those 
with early RA with less than 2 years, 2 to 5 years, 5 to 10 Years and those with greater 
than 10 years of disease (Anderson, Wells, Verhoeven, & Felson, 2000). MTX use 
included those currently using MTX; conventional diseases modifying antirheumatic 
drugs (cDMARD) included those on any other RA medications other than MTX. Those 
on TNFs and non-TNFs were combined into one group of biologic users. Alcohol was 
collapsed from four categories into two groups; alcohol users (which included those who 
used alcohol daily, weekly, occasionally, and monthly) and nonusers. Smoking status was 
combined into two groups; nonsmokers and smokers, the latter included those with 
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current or past history of smoking. Exercise was divided into two groups: those who 
exercise and those who do not. 
Descriptive Statistics of the Entire NAFLD Cohort    
A descriptive analysis was conducted to determine comparability of the NAFLD 
study cohort and the overall registry population (see Table 14). The primary purpose of 
this descriptive analysis was to evaluate the generalizability of the findings from this 
study, given that a sample of convenience was used. Specifically, to determine if there 
were clinically relevant differences between the incident cohort compared to the overall 
registry population. The overall registry had 40,300 RA patients with almost half of them 
(17,481) meeting the eligibility criteria to be included in the NAFLD analysis. There was 
statistically significant difference between those in the NAFLD cohort compared to those 
remaining in the registry for all the variables except for Hispanic ethnicity and liver 
disorders. However, the significant p values seen in this analysis were driven mainly 
from the large sample size. Even though there were statistically significant differences 
the clinical relevance was minimal since the numerical values were similar for most of 
the variables.  For example, the absolute values for many of the factors were similar e.g., 
three fourth of the cohort were females (74% in overall registry vs. 79% in the NAFLD 
cohort). However there were some notable absolute differences: the NAFLD cohort was 
younger (54.2 years vs. 61.1 years); was more likely to have insurance (79.2 % vs. 
66.9%); used MTX (70.2% vs. 58.3%); fewer reported CVD history (6.4% vs. 11.6%); 





Overall Registry Patient Compared to NAFLD Study Cohort  





 n % N %  
Gender (Female) 22436 74.4% 17481 78.7% < .001 
Race  22,819  17,481  < .001 
Asian  1.4%  1.6%  
 African American  8.1%  6.3% 
 Other Race 1   5.2%  3.5% 
Caucasians   85.0%  88.5% 
Ethnicity Hispanic  1792 7.8% 14199 8.17% 0.363 
Marital Status 22,819  17,481  < .001 
Single /Widowed  22.9%  19.6%  
Married /Partnered  61.0%  66.7%  
 Divorced /Separated  12.1%  12.3% 
Educational Status 22,819  17,481  < .001 
Primary  4.8%  3.7%  
High School  40.1%  36.6% 
College/University   48.3%  55.5% 
Insurance Status (Yes) 19,768 66.9 % 15612 79.2 < .001 
MTX Use  22,819 58.3% 17481 70.2% < .001 
cDMARD Use 22,819 32.0% 17481 29.5% < .001 
TNF Use 22,819 32.3% 17481 37.2% < .001 
NonTNF Use  22,819 5.8% 17481 6.7% < .001 
Cardiovascular History  22,819 11.6% 17481 6.4% < .001 
Diabetes 22,819 9.7% 17481 8.1% < .001 
Dyslipidemia 22,819 26.3% 17481 21.8% < .001 
History Cancer  22,819 8.0%) 17481 5.4% < .001 
Liver Disorders 22,819 2.4% 17481 2.2% 0.174 
Liver Enzyme 
Elevation  
13,832 22.0% 17481 8.2% < .001 
Metabolic Syndrome  22,819 22.9% 17481 18.9% < .001 
Alcohol Use (Yes)  19,087 36.3% 15026 39.8% < .001 
Smoker (Yes) 21,254 15.0% 16228 17.4% < .001 
Exercise (Yes) 21,404 68.5% 16795 70.3% < .001 
 n M (SD) N M (SD) p-value* 
Age yrs.  22363 61.1 (13.8) 17481 54.2 (12.4) < .001 
Disease Duration yrs.  22,469 9.2 (10.2) 17242 8.2 (8.9) < .001 
CDAI Score  21,352 14.8 (13.2) 16818 13.8 (13.0) < .001 
Body Mass Index  21,277 29.1 (7.2) 17481 29.6% (7.2) < .001 
M= mean; SD = Standard Deviations; CDAI= Composite disease activity index; MTX = Methotrexate; 
cDMARDs = conventional disease modifying antirheumatic drugs; TNF = Tumor Necrotic Factor; 1= 





Upon receipt of data, I conducted a detailed analysis of the dataset to ensure there 
was sufficient sample size and that the relevant variables were included. Then the 
NAFLD analytic data set was prepared for descriptive and multivariate analyses. Several 
analyses for measures of central tendency, distribution, and dispersion of data were 
assessed. The impact of missing data was evaluated along with assumptions for 
conducting the Kaplan Meier and Cox proportional analysis.  Details and results from 
these evaluations are provided later in this section. 
Data Preparation for Analysis 
I used the checklist provided by Tabachnick & Fidell (2012, pp. 510-570) as my 
guide for conducting survival analysis. I evaluated the adequacy of sample size, missing 
data, normality of distribution, proportionality of hazard assumption and 
multicollinearity.  I also addressed issues with missing data, outliers, and difference 
between withdrawn and remaining cases, and changes in survival experience over time. 
The details and results of these evaluations are presented in the following sections. 
Adequacy of Sample Size 
Sample size estimations and considerations are described in detail in Chapter 3. 
Based on the literature review, taking into consideration the known rates of NAFLD and 
the effect size of its associated risk factors, with a power of 80% and alpha of 0.05, a 
sample size of 759 participants would have been sufficient to detect the incidence and 
prevalence rates and the study would also be adequately powered for the multivariate 
analysis. The final sample size for this study was 17,481 RA patients with data collected 
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over a period of 14 years (January 2001 to November 2014), thus sufficiently large to 
conduct the incident analysis. Additionally, when certain categorical data was collapsed 
based on the frequency analysis, the analysis was sufficiently powered for the chi-
squared test. The assumption was also met of having expected frequencies of greater than 
five in each of the cells (Field, 2009). 
Assessing Missing Data 
I used missing variable analysis (MVA), a SPSS test to determine if there were 
identifiable patterns of missing data. The result of this analysis using the Little's MCAR 
test was not significant (χ2  (24176) = 1317.39, p = 1.000). Thus it can be assumed that 
the likelihood of systematically missing values potentially leading to bias was low. In 
addition, visual outputs and variable summary statistics were generated to determine the 
number of cases. The impact of missing variables on the outcome variable was assessed 
as shown in Table 15. The minimum percentage of missing values for a variable to be 
included in the analysis was set at 1.0%. Among the missing values:  ethnicity (Hispanic) 
had the highest number with 19% with missing values, followed by alcohol use with 
14%, and diabetes with 1.4%. These were important variables as they were key predictor 
variables identified a priori. The approach to address these missing values is described in 





Missing Variable Analysis 
 
Missing 
Valid N N Percent 
Ethnicity (Hispanic) 3282 18.8% 14199 
Alcohol Use (yes) 2455 14.0% 15026 
Private insurance 1869 10.7% 15612 
Exercise (yes) 1108 6.3% 16373 
Diabetes 238 1.4% 17243 
Marital Status 223 1.3% 17258 
Addressing Missing Data 
With retrospective, secondary data collected over many years, missing data are 
inevitable and can be a major challenge. There are no firm guidelines for how much 
missing data can be allowed, allowable tolerance also hinges upon the sample size 
(Tabachnick & Fidell, 2012, Ch. 4). There are several analytical approaches to address 
this issue of missing values. All have limitations and none of them are able to produce 
unbiased estimates with certainty. For this analysis I selected the multiple imputation 
approach. It is considered one of the more robust analytic approaches to reduce 
uncertainty (Tabachnick & Fidell, 2012. Ch.4). One of the strengths of multiple 
imputations is that sampling variability is retained. It can be used with data from a single 
observation and more importantly it accommodates the use of longitudinal data 
(Tabachnick & Fidell, 2012, Ch. 4).  Additionally, this approach makes no assumptions 
about randomly missing variables. It generates a mean estimate for each variable from 
multiple imputation data sets while taking into account variance within and between these 
datasets. Thus this approach is able to account for the true uncertainty in the data 
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(Tabachnick & Fidell, 2012, Ch. 4).  Most of the key variables selected apriori did not 
require imputation except for diabetes and ethnicity. For this analysis using the multiple 
imputation function available in SPSS, five other imputation datasets were produced in 
addition to the original data. Given the large sample size and the use of multiple 
imputations, any substantial impact of missing data was sufficiently mitigated 
(Tabachnick & Fidell, 2012, pp. 60-116).  
Normality of Distributions 
For continuous variables, the independent-samples t-test was used to determine if 
there was a statistically significant difference between mean baseline among those with 
NAFLD versus those without the disease. The factors evaluated were age, BMI, duration 
of disease and disease activity. Prior to conducting the t-test analysis, I evaluated the 
normality of distribution and impact of outliers in these two groups in relationship to the 
dependent variable. I used several analytical approaches including histograms, box-plots, 
normal Q-Q plots to assess normal distribution and detrended normal Q-Q plot to assess 
differences between the observed and expected values (data not shown). Age was 
normally distributed. However, there were a few cases at the very low end and the very 
high end that deviated from the expected distribution. Similar results were seen for 
disease duration and disease activity, with outliers at both ends of the distribution. For 
BMI, the normal distribution as well as expected distribution was deviated, with a large 
number of cases with very high values. To address this issue of outliers, these variables 
were transformed into categorical variables for the multivariate analysis. The impact of 
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these variables was assessed using Mahalanobis regression analysis and presented below 
(see Table 16). 
Assumptions for Chi-Square 
The chi-square test was used to evaluate if there was a significant association for 
dichotomous variables. In order to use this test, the sample size should be large and 
expected frequencies in each cell must be greater than five (Field 2009). For this study 
both these requirements were met.  The sample was sufficiently large (17,481 
participants) and the outputs from the analysis showed that none of the cells had less than 
the expected count of less than five. Strength of relationship or effect size was tested 
using Cramer’s V test (Field, 2009). 
Assessment for Outliers 
Outliers were assessed using Mahalanobis regression analysis. This analysis 
creates a center point from which the intersection of the means of all the variables and 
then determines the distance a case is from this center (Tabachnick & Fidell, 2012, pp. 
60-116). Outliers were identified by first creating Z score for each covariate’s lowest and 
highest scores. Then Mahalanobis distance was computed using SPSS regression 
analysis. The impact of the outliers using a multivariate model was assessed and 
summary statistics for the original as well as for each of the imputed datasets was 
produced. The outputs showed deviation from normality and were positive for skew and 
kurtosis (see Table 16). Results for the overall summary Mahalanobis distance analysis 
showed that only 694 (4%) were identified as outlier cases out of 17481cases after 
imputation (see Table 17). The issue with multivariate outliers is that cases are discrepant 
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as a result of combination of outlier scores of one or more variables and not any one 
score. It is anticipated that the number of possible multivariate outliers was substantially 
reduced after transformation. There is no clear guidance for allowable missing values, 5% 
is often an acceptable level (Tabachnick & Fidell, 2012, pp. 60-116).  In summary, there 
were only few outlier cases in this large sample and the data was imputed. Since 
normality of data is not integral for survival analysis, the inclusion of these outlier cases 
is not expected to be influential in the multivariate analysis (Tabachnick & Fidell, 2012, 
pp. 60-116). 
Table 16 
Descriptive Mahalanobis Distance 
  N Mean SD Skew SE Kurtosis SE 
Original 
data 
Mahalanobis Distance 9381 28.99 13.91 1.50 .025 3.47 .051 
Valid N (listwise) 9381       
1 Mahalanobis Distance 16786 28.99 14.12 1.66 .019 4.53 .038 
Valid N (listwise) 16786       
2 Mahalanobis Distance 16787 28.99 14.14 1.65 .019 4.39 .038 
Valid N (listwise) 16787       
3 Mahalanobis Distance 16790 28.99 14.14 1.67 .019 4.55 .038 
Valid N (listwise) 16790       
4 Mahalanobis Distance 16786 28.99 14.10 1.65 .019 4.38 .038 
Valid N (listwise) 16786       
5 Mahalanobis Distance 16787 28.99 14.13 1.66 .019 4.43 .038 
Valid N (listwise) 16787       









Included Excluded Total 
N Percent N Percent N Percent 
Original data Mahalanobis Distance 9381 53.7% 8100 46.3% 17481 100% 
1 Mahalanobis Distance 16786 96.0% 695 4.0% 17481 100% 
2 Mahalanobis Distance 16787 96.0% 694 4.0% 17481 100% 
3 Mahalanobis Distance 16790 96.0% 691 4.0% 17481 100% 
4 Mahalanobis Distance 16786 96.0% 695 4.0% 17481 100% 
5 Mahalanobis Distance 16787 96.0% 694 4.0% 17481 100% 
 
For survival analysis, it was assumed that the censored cases and the ones lost 
during the course of study would not be systematically different from those with an event 
at the end of the study. Differences would inevitably result in nonrandom loss of cases, 
violating this assumption would bias the results of the study (Tabachnick & Fidell, 2012, 
pp. 60-116). This was a retrospective study that used a sample of convenience, selected 
only patients who met the inclusion criteria. These patients were then followed over time 
to determine the rate and time to development of NAFLD. Unlike prospective studies 
where information and reasons for withdrawal would be collected, this information is 
unknown particularly for the lost cases over time in the registry. Thus in the absence of 
information, it can only be assumed that the reasons for lost cases would be similar for 
those censored and those with an event. I conducted an analysis and visually inspected 
the pattern over time for the event cases and the censored cases. The patterns appear to be 





Figure 21- Event Cases      Figure 22 - Censored Cases  
Changes in Survival Experience Over Time 
This assumption is important for survival analysis in that it assumes that factors 
that would affect survival in the beginning would be the same factors affecting survival at 
the end of the study (Tabachnick & Fidell, 2012, pp. 510-570). Since this was not a 
prospective study, I was not able to test this assumption. This study used secondary data 
collected over a period of 14 years and pertinent information to evaluate this assumption 
is not routinely collected as part of patient care. Thus it can only be assumed that 
environmental factors and other conditions for survival would be similar over time and 
these factors would be the same for both the event and censored group.  For example, it is 
assumed that factors such as participants remaining in the registry, treatment of RA, or 
having laboratory levels measured needed to calculate the FIB-4 score were similar over 
time. 
Multicollinearity 
Survival analysis is inherently protected against issues with multicollinearity 
(Tabachnick & Fidell, 2012, pp. 510- 570). However, investigating its impact is 
Overall dataset= light blue and cases = grid pattern; X axis = study period in years; Y axis = proportions 
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recommended using the FACTOR analysis function; results with greater than 0.90 maybe 
indicative of multicollinearity. The results of this analysis are presented in Table 18. All 
the variables had values were less than 0.90, ranging from .22 to the highest value of .76 
for metabolic syndrome (See Table 18), indicating no significant multicollinearity.  
Table 18 
Factor Analysis Communalitiesa 
 Initial Extraction 
Age categories 1.000 .528 
Gender 1.000 .424 
Race group 1.000 .404 
Ethnicity/Hispanic 1.000 .420 
Marital Status 1.000 .410 
Education 1.000 .441 
Insurance Status 1.000 .482 
Smoking Status 1.000 .449 
Alcohol Use (yes) 1.000 .450 
Exercise (yes) 1.000 .354 
Hypertension  1.000 .493 
CVD 1.000 .277 
Dyslipidemia 1.000 .494 
Cancer History 1.000 .467 
Diabetes  1.000 .325 
Liver Disorders History 1.000 .549 
Liver Enzyme Elevation 1.000 .424 
BMI categories 1.000 .455 
Metabolic Syndrome 1.000 .768 
Disease Duration Categories 1.000 .419 
CDAI Categories 1.000 .354 
MTX use  1.000 .384 
Extraction Method: Principal Component Analysis.a; a. Imputation Number = 5 
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Proportionality of Hazards 
Proportionality of hazards is a major assumption for the Cox proportional hazards 
model. This assumption assumes that the effect of the given set of covariates is the same 
over time or that the shape of the survival function is the same for all cases or groups 
over time (Tabachnick & Fidell, 2012, pp. 510-570). I visually assessed this assumption 
by generating Kaplan Meier plots for each of the variables similar to the plot shown for 
age and gender (see Figure 23 and 24). Similarly, survival plots were assessed using the 
regression analysis where the mean of the covariates was used, the results were 
significant; χ2 (21) = 2719.82, p < .001. This meant that the relationship between the 
covariates survival lines was proportional over time and were significantly different, they 
did not cross each other for the original as well as the imputed data sets (see Table 19, 
Figure 23 and Figure 24). 
Table 19 






Chi-square Df Sig. 
Original data 54714.825 1830.40 21 .000 
1 90843.581 2719.22 21 .000 
2 90876.081 2717.95 21 .000 
3 90841.775 2720.68 21 .000 
4 90881.167 2722.44 21 .000 
5 90857.972 2719.82 21 .000 




Figure 23. Survival Function: Gender and Age       Figure 24. Survival Function: Mean of Covariates  
I also tested for proportionality of hazards using SPSS COXREG -TIME 
PROGRAM function. In this analysis, all the covariates were entered into this regression 
model simultaneously to analyze their effects on survival over time. A non significant 
result is required to meet the proportionality hazard assumption, meaning that that none 
of the covariates significantly interacted over time (Tabachnick & Fidell, 2012, pp. 510-
570). The results of this analysis was non significant; p = .709 (see Table 20). 
Table 20 
Test for Proportionality of Hazards- Time with All Covariates 
 
Wald df Sig. Exp (B) 95.0% CI for Exp (B) 
Lower Upper 
T_COV_ .139 1 .709 1.000 1.000 1.000 
b. Df= degrees of freedom 
In summary, using Tabachnick & Fidell’s, guidelines for conducting survival 
analysis each of the issues and assumptions associated with survival analysis was 
evaluated and addressed. The study was more than adequately powered with a sample 
size of 17,481 patients with RA with about 14 years of observation time. Missing data 
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were addressed using the multiple imputation method, an optimal approach that preserved 
sampling variability of the original data. The large sample size helped minimize the 
impact of the outliers. Outliers were transformed into categorical variables to further 
reduce the impact. Impact of outliers was also evaluated by conducting the Mahalanobis 
distance analysis and it showed that over 96% of cases was included in the analysis and 
thus not significantly affected by outliers. Multicollinearity was evaluated and all 
variables were below the accepted threshold of .90. Evaluations of differences between 
withdrawn and remaining cases, and changes in survival experience over time are 
important issues for prospective studies designed to evaluate differences between 
treatments. However, treatment effectiveness was not an objective for this study, and 
limited information about the survival experience was collected in the registry. Hence it 
is not known if this assumption was violated and thus the implications are not self-
evident. Proportionality hazard assumption was evaluated using Kaplan Meier plots and 
regression analysis. These analyses showed that none of the covariates or groups 
significantly interacted with each other over time. Overall, after transforming variables 
and having adequately met all of the assumptions for survival analysis, this dataset was 
sufficiently prepared and powered to conduct the ensuing survival analysis. 
Research Question 1  
Results of Incidence Rates and Time to Development of NAFLD 
Research question 1 (RQ1) was to determine the incidence rate of NAFLD among 
patients with RA from 2001 -2014 in the U.S. using the FIB-4 test. Incidence rate was 
determined using the incident cohort dataset with 17,481 RA patients. Chi-square test 
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was used to compare frequencies among the categorical variables. The sample was 
sufficiently large and none of the cells had less than the expected count less than five 
(Field, 2009). Kaplan-Meier survival analysis was conducted to determine rate and time 
to development of NAFLD. Breslow (Generalized Wilcoxon) test was used to determine 
if there were differences in the survival distribution for the categorical variables (Field, 
2009). The results of the analysis included the overall cumulative incidence rate during 
the study period for the cohort, absolute number of incident cases, percent of incident 
cases, and incidence rate per 1,000 person years (PY) along with 95% confidence 
intervals.  
For this incident cohort of 17,481 patients with RA, data were available for a 
period of 13.2 years.  As shown in Table 21, the overall NAFLD cumulative incidence 
over this period was 31%, 95%, CI [29.82, 31.18%], with an incidence rate of 95 cases 
per 1,000 patient years, 95% CI [92.60, 97.45]).  The mean overall time to the 
development of NAFLD was 7.2 years, 95%CI [7.07, 7.29]. Similar results were seen for 
patients developing mild/moderate NAFLD. Only 249 patients (1.4%), developed 
advanced NAFLD; however, the mean time to event was longer (12.8 years). 
Table 21 
NAFLD Rates: Overall Incidence Rates and Time to Event 
Variable N (%) Incidence Cases 
n (%) 
Incidence Case /1000PY 
[95% CI] 
































Table 22 shows the absolute number and percent of overall incident cases, 
incidence rate (per 1,000 patient years with 95% CI), and time to event for each of the 
demographic factors. In the overall cohort, baseline age was categorized into three 
groups; 12% were in the younger group, half of them were middle aged and a third were 
elderly. In the group of patients that developed NAFLD, most were elderly (56.0%), 
followed by middle aged (42.1%) and a few were younger (1.7%). Similar results were 
seen for NAFLD incidence rates, with higher rates for the elderly and middle age group 
as shown in Table 22. The elderly group developed NAFLD in the shortest mean time of 
4.5 years, followed by the middle-aged group with 8.1 years whereas time to incidence of 
NAFLD was the longest in the younger group (11.6 years).  The difference in the mean 
time to event among the three age categories was statistically significant, χ2 (2) = 
1994.83, p < .001. This overall cohort consisted mostly of women (79%). The proportion 
of patients developing NAFLD and also the incidence rate were three times higher among 
women then men as shown in Table 22. However, men developed NAFLD in a shorter 
mean time of 6.4 years compared to 7.4 years for women. There was a statistically 
significant difference in the time to development of NAFLD by gender, χ2 (1) = 57.69, p 
< .001.  
In the overall cohort most of the patients were Caucasians (89%), with 6.4% 
African Americans, 1.6% Asians and 3.5% in the “other” race category. The proportion 
of patients developing NAFLD and also the incidence rate were significantly higher for 
Caucasians (89.9% and 85.41 cases per 1,000 patient years, 95% CI [83.10, 87.73] 
respectively) compared to other race groups as shown in Table 22. There was a 
134 
 
statistically significant difference in the mean time to development of NAFLD by race, χ2 
(2) = 12.55, p < .006. . Although the absolute mean time to event across the racial/ethnic 
groups was relatively similar (7 years), the African-American group had a slightly earlier 
onset of disease in 6.7 years. In the overall cohort most reported not being Hispanic 
(91%). The proportion of patients developing NAFLD and a higher incidence rate were 
mostly seen among non Hispanics (93.0% and 88.41 cases per 1,000 patient years, 95% 
CI [86.06, 90.76] respectively) compared to Hispanics as shown in Table 22. The 
absolute mean time to event was similar at 7.1 years, 95% CI, [7.07, 7.27] for non 
Hispanics versus 7.4 years, 95% CI [7.07, 7.88] for Hispanics; however, the difference 
was statistically significant; χ2 (1) = 6.76, p < .009. 
Table 22 
NAFLD Rates: Incidence Rates by Demographic Factors 












Age     1994.8 
< .001 Younger 2133 (12.2%) 92 (1.7 %) 1.64 [1.31,1.98] 11.62 [11.36, 11.88] 
 Middle Aged 9360 (53.5%) 2251 (42.1%) 40.15 [38.52, 41.77] 8.15 [8.09, 8.31] 
Elderly 988 (34.3%) 2985 (56.0%) 53.24 [51.38, 55.10] 4.56 [4.44, 4.61] 
Gender     57.69 
< .001 Male 3707 (21.2%) 1351 (25.4%) 24.10 [22.83, 25.37] 6.42 [6.21, 6.64] 
Female 13774 (78.8%) 3977 (74.6%) 70.93 [68.81, 73.06] 7.39 [7.27, 7.52] 
Race      12.55 
< .006 Caucasians 1546 (88.5%) 4789 (89.9%) 85.41 [83.10, 87.73] 7.18 [7.09, 7.29] 
African American 1116 (6.4%) 316 (5.9%) 5.64 [5.02, 6.26] 6.76 [6.20, 7.25] 
Asian 286  (1.6%) 68 (1.3 %) 1.21 [0.92, 1.50] 7.53 [6.78, 8.29] 
Other 614 (3.5%) 155 (2.9%) 2.76 [2.33, 3.20] 7.71 [7.20, 8.30] 
Ethnicity                                           6.76 
< .009 Hispanic 1442 (8.2%) 371 (7.0%) 6.62 [5.95, 7.29] 7.45 [7.07, 7.88] 
Not Hispanic 16039 (91.2%) 4957 (93.0%) 88.41 [86.06, 90.76] 7.16 [7.04, 7.27] 
* p-value across categories; PY= Patient Years; CI- Confidence Interval; CV = Cramer’s V 
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Incidence Rates and Time to Event by NAFLD Risk Factors 
The pre-identified or known risk factors for NAFLD were baseline obesity, 
metabolic syndrome, diabetes and dyslipidemia. Included in the analysis were also other 
potential predictors including liver enzyme elevation, MTX use, liver disorders and 
alcohol use. Overall rate and time to event for each of these factors are presented in Table 
23. 
In this cohort 72% of the patients were obese (BMI ≥ 25). The proportion of 
patients developing NAFLD and also the incidence rate were higher among patients with 
obesity (72% and 68.38 cases per 1,000 patient years, 95% CI [66.29, 70.47) respectively 
compared to the non obese group as shown in Table 23. The average time to development 
of NAFLD was similar for both BMI groups, 7 years; (χ2 (1) = .061, p = <. 805). In this 
overall cohort, 18% had metabolic syndrome. Nearly, 20% of patient with metabolic 
syndrome developed NAFLD, however, the rates for NAFLD were much higher for those 
with metabolic syndrome, 115.3 per 1000 PY, CI 95% [112.72, 118.00] compared to 45.4 
per 1000 PY, CI 95% [43.76, 47.21] among those without metabolic syndrome (see Table 
23). There was a statistically significant difference in the time to development of NAFLD 
for those with metabolic syndrome. This group had an earlier onset of disease with an 
average of 5.1 years, 95% CI [4.95, 5.43] compared to an average of 7.4 years, 95% CI 
[7.36, 7.59] for those without (30%); χ2 (1) =305.309, p < .001. 
In this cohort, 6.9% of patients had diabetes. The proportion of patients 
developing NAFLD and also the incidence rate were significantly higher among the non 
diabetics (91.7% and 87.14 cases per 1,000 patient years, 95% CI [84.81, 89.48] 
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respectively) compared those with diabetes as shown in Table 23. However, the mean 
time to development of NAFLD for those with diabetes was significantly shorter 
compared to those without diabetes, in 6.1 years, 95% CI [5.77, 6.46] compared to 7.2 
years, 95% CI [7.14, 7.37]; χ2 (1) = 27.78, p < .001. Likewise for those with dyslipidemia 
the mean time to development of NAFLD was significantly sooner, 5.0 years, 95% [CI 
4.86, 5.22] compared to 7.5 years, 95% CI [7.47, 7.71] for those without; χ2 (1) = 351.56, 
p < .001. In this study population only 22% had dyslipidemia. The proportion of patients 
developing NAFLD and also the incidence rate were about threefold higher among those 
without a history of dyslipidemia compared to those with dyslipidemia as shown in Table 
23. 
Only 8% of the cohort had liver enzyme elevation. The proportion of patients 
developing NAFLD and also the incidence rate were significantly higher for those with 
normal liver enzyme levels (92.1% and 87.14 cases per 1,000 patient years, 95% CI 
[85.21, 89.89] respectively) compared to those with liver enzyme elevations as shown in 
Table 23. There was no difference between these two groups in the mean time to event at 
7.1 years (χ2 (1) p= .141). Similar results were seen for those with a history of liver 
disease at baseline, the difference in mean time to event was not statistically significant 
with 7.2 years, 95% CI [7.10, 7.32] for those without a history compared to 6.0 years 
(95% CI, 5.59, 6.49); χ2 (1) = .972, p = .324. Only 2% reported a history of liver 
disorders in this cohort. In the group that developed NAFLD most patients did not have a 
history of liver disorder (97.2%) compared to 2.8% with a history of liver disorder. The 
overall incidence rate for NAFLD was low for both groups, but slightly higher for those 
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without a history of liver disease 4.2, per 1000 PY, CI 95% [3.74, 4.82] and 2.6 per 1000 
PY, CI 95% [2.26, 3.12] for those with a history of liver disease.  
About 40% of the overall cohort reported they were currently or had a history of 
using alcohol. The proportion of patients developing NAFLD and also the incidence rate 
were higher for nonusers of alcohol (62.5% and 89.80 cases per 1,000 patient years, 95% 
CI [87.44, 92.17] respectively) compared to alcohol users as shown in Table 23. There 
was also a significant difference in the time to development of NAFLD. Those not using 
alcohol had an earlier onset of NAFLD with a mean time of 6.9 years, (95% CI, 6.79, 

















Incidence Rates and Time to Event by NAFLD Risk Factors 
Variable N (%) Incidence 
Case n=5328 
Incidence Rates Cases/ 
1000 PY [95% CI] 
Time to Event 
(Years) [95% CI] 
χ2* 
p Value 
Obesity              Yes  12639 (72.3%) 3834 (72.0%) 68.38 [66.29, 70.47) 7.17 [7.04, 7.30] .061 
.805 
No 4842 (27.7%) 1494 (28.0%) 26.65 [25.31, 27.98] 7.22 [7.02, 7.42] 
Metabolic          Yes 
Syndrome          
2229 (18.3%) 1078 (20.2%) 115.36 [112.72, 118.00] 5.19 [4.95, 5.43] 305.309 
< .001 
 No 14174 (81.7%) 4250 (79.8%) 45.48 [43.76, 47.21] 7.28 [7.36, 7.59] 
Diabetes            Yes 1208 (6.9%) 442 (8.3%) 7.88 [7.15, 8.62] 6.11 [5.77, 6.46] 27.787 
< .001 
No 16273 (93.1) 4886 (91.7%) 87.14 [84.81, 89.48] 7.25 [7.14, 7.37] 
Dyslipidemia     Yes 3824 (21.9%) 1378 (25.9%) 24.58 [23.30, 25.86] 5.04 [4.87, 5.22] 351.565 
< .001 
No 13657 (78.1%) 3950 (74.1%) 70.45 [68.33, 72.57] 7.59 [7.47, 7.71] 
Liver Enzyme    Yes 





7.47 [6.76, 8.19] 
 
7.11 [6.78, 7.48] 2.169 
.141 
No 16041 (91.8%) 4909 (92.1%) 87.14 [85.21, 89.89] 7.19 [7.08, 7.30] 
Liver Disorders Yes 391 (2.2%) 151 (2.8%) 2.69 [2.26, 3.12] 6.04 [5.59,6.49] .972 
.324 
No 17090 (97.8%) 1517 (97.2%) 4.28[3.74, 4.82] 7.21 [7.10, 7.32] 
Alcohol use       Yes 7027 (40.2%) 1997 (37.5%) 35.62 [34.08, 37.15] 7.51 [7.33, 7.69] 59.989 
< .001 
No 10453 (59.8%) 3331 (62.5%) 89.80 [87.44, 92.17] 6.92 [5.59, 6.49] 
p-value across categories; PY= Patient Years; CI- Confidence Interval; CV = Cramer’s V 
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Incidence Rates and Time to NAFLD by RA Related Factors 
Included in the incident NAFLD rate analysis were baseline factors related to RA; 
disease duration, disease activity and use of medication including MTX, conventional 
synthetic disease modifying antirheumatic drugs (cDMARD), steroids and biologics. 
Rate and time to event for each of these factors are presented in Table 24.  
Most patients had early disease (33%) or greater than 10 years of disease (29.2%). 
The proportion of patients developing NAFLD and also the incidence rate were the 
highest among patients with disease duration greater than10 years followed by those with 
early RA, however, the proportion and rates for the group with 5 to 10 years and 2 to 5 
years of disease duration were similar as shown in Table 24. Those with the longest 
duration of disease (>10 years) developed NAFLD sooner with a mean time of 6.8 years, 
95% CI [6.71, 7.07], whereas for the other duration of disease categories the mean time 
to event ranged from 7.1 years to 7.4 years (see Table 24). These differences in the mean 
time to development of NAFLD were also statistically significant; χ2 (3) = 24.16, p < 
.001 among the groups.  
In the cohort at baseline about 18% were in remission, 31% had low disease 
activity, 28% had moderate disease activity and 22% had high disease activity. As shown 
in Table 24, the proportion of patients developing NAFLD and also the incidence rate 
was highest among patients with low disease activity, followed by those with moderate 
disease activity and then among those with high disease activity. The proportion of 
patient with NAFLD and incidence rates was the lowest among patients in remission. The 
mean time to development of NAFLD was statistically significantly different (χ2 (3) = 
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20.28, p < .001, although the absolute mean time to event does not vary greatly across the 
various disease severity categories (7.0 years to 7.3 years). Time to development of 
NAFLD was longer for those in remission at 7.3 years, (95% CI, 7.09, 7.61). 
Most of the patients in this cohort were currently taking MTX (70.2 %). The 
proportion of patients developing NAFLD and also the incidence rate was higher among 
MTX users (72.7% and 69.1 cases per 1000 PY, CI 95% [67.03, 71.23] respectively) 
compared to nonusers as shown in Table 24. The absolute mean time to event was similar 
but was statistically different; in 7.0 years, 95% CI [6.96, 7.21] for MTX users versus 7.4 
years, 95% CI [7.24, 7.64] for the nonusers; χ2 (1) = 13.62, p <  .001.  
About 30% of the overall cohort was on cDMARDs. The proportion of patients 
developing NAFLD and also the incidence rate was about higher among cDMARDs 
nonusers (69.2% and 65.78 cases per 1000 PY, CI 95% [63.73, 67.83] respectively) 
compared to nonusers as shown in Table 24.There was no statistically significant 
difference in the mean time to development of NAFLD (7.35 years for the users of 
cDMARDs vs. 7.09 years for nonusers); χ2 (1) = 27.49, p = .596. About 30% of patients 
were currently taking steroids. The proportion of patients developing NAFLD and also 
the incidence rate was higher among steroid nonusers (68.2% and 62.74 cases per 1000 
PY, CI 95% [58.66, 66.82] respectively), compared to user as shown in Table 24. Mean 
time to development of NAFLD for those using steroids was also significant (7.0 years 
for steroid users vs. 7.1 years for the nonusers); χ2 (1) =20.153, p < .001.  
The proportion of patients developing NAFLD and also the incidence rate was 
higher among non biologic users (58.5% and 55.56 cases per 1,000 patient years, 95% CI 
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[53.66, 57.45 respectively] compared to biologic users as shown in Table 24. There was a 
statistically significant difference in the mean time to event, biologic nonusers developed 
NAFLD in 7.05 years, 95% CI, [6.90, 7.19] years versus 7.35 years, 95% CI,  [7.18, 7.52] 
for biologic users; χ2 (1) = 58.88, p < .001. 
 
Table 24 
NAFLD Incidence Rates by RA Factors 










RA Disease      
Early RA (< 2yrs) 5735 (32.8%) 1556 (29.2%) 27.75 [26.39, 29.11] 7.12 [6.91,7.33] 24.16 
(3) 
< .001 2 to 5yrs 3276 (18.7%) 938 (17.6%) 16.73 [15.67,17.79] 7.48 [7.22, 7.73] 
5 to 10yrs 3340 (19.1%) 978 (18.4%) 17.44 [16.36, 18.53] 7.44 [7.20, 2.69] 
> 10yrs 4990 (28.9%) 1852 (36.2%) 33.03 [31.55, 34.51] 6.89 [6.71, 7.07] 
RA Disease Activity      




Low Disease  5480 [31.4%] 1678 (31.5) 29.93 [28.52, 31.34] 7.12 [7.03, 7.40] 
Moderate 4935 [28.2%] 1569(29.5%) 27.98 [26.62, 29.35] 7.11 [6.09, 7.31] 
High  3835 [21.9%] 1213 (22.8%) 21.63 [20.43, 22.84] 7.01 [6.78, 7.24] 
MTX Use      13.62 
(1) 
< .000 Yes 12274 (70.2%) 3876 (72.7%) 69.13 [67.03, 71.23] 7.08 [6.96, 7.21] 
No 5207 (29.8%) 1452 (27.3%) 25.90 [24.58, 27.21] 7.44 [7.24, 7.64] 
cDMARD      .281 
(1) 
.596 
Yes 5183 [29.6%] 1640 [30.5%] 29.25 [27.86, 30.64] 7.35 [7.16, 7.45] 
No 12298 (70.4%) 3688 (69.2%) 65.78 [63.73, 67.83] 7.09 [6.95, 7.22] 
Steroids     20.153 
< .001 
 
Yes 5199 (29.7%) 1696 (31.8%) 30.25 (28.83, 31.67) 7.01 [6.82, 7.20] 
No 12282 (70.3%) 3632 (68.2%) 62.74 [58.66, 66.82] 7.24 [7.12, 7.38] 
RA Medication     27.492 
< .001 Biologics (Yes) 
 
7688 (44.0%) 2213 (41.5%) 39.47 [37.86, 41.08] 7.35 [7.18, 7.52] 
Biologics (No) 9793 (56.0) 3115 (58.5%) 55.56 [53.66, 57.45] 7.05 [6.90, 7.19]  
* p-value across categories; PY= Patient Years; CI- Confidence Interval; CV = Cramer’s V;  cDMARD= Conventional  
Disease-modifying antirheumatic drugs 
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Incidence Rates and Time to NAFLD by Other Factors 
Also of interest were other relevant comorbidities often associated with the 
development of NAFLD. These factors included assessing NAFLD rates and time to 
event for CVD, hypertension, smoking, and exercise and are presented in Table 25. Only 
6.5 % of this population had a history of CVD. The proportion of patients developing 
NAFLD and also the incidence rate was significantly higher among those without CVD 
(90.3% and 85.79 cases per 1,000 patient years, 95% CI [83.47, 88.11] respectively) 
compared to those with CVD as shown in Table 25. There was a statistically significant 
difference in the mean time to NAFLD, those with a history of CVD were likely to 
develop NAFLD significantly sooner, in 4.6 years, 95% CI [4.29, 4.90] compared to 7.3 
years, 95% CI, [7.24, 7.47] for those without a history; χ2 (1) = 183.64, p < .001.  
About 37% of the overall cohort reported a history of hypertension. The 
proportion of patients developing NAFLD and also the incidence rate was marginally 
higher for those without hypertension (58.5%, 55.63 cases per 1,000 patient years, 95% 
CI [53.73, 57.53] respectively) compared to those with hypertension as shown in Table 
25. However, there was a statistically significant difference in the mean time to event for 
those with a history of hypertension developed NAFLD in 5.9 years, (95% CI, 5.82, 6.16) 
compared to those without hypertension with 7.7 years, (95% CI, 7.61, 7.88); χ2 (1) = 
313.26, p < .001.  
About 41% of this cohort reported to be a current smoker or had a history of 
smoking. The proportion of patients developing NAFLD and also the incidence rate was 
marginally higher for non smokers (59.1% and 55.95 cases per 1,000 patient years, 95% 
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CI [54.05, 57.85] respectively) compared to smokers as shown in Table 25. There was a 
statistically significant difference in the mean time to event; smokers had an earlier onset 
of NAFLD with 6.9 years, (95% CI, 6.73, 7.103) versus to 7.37 years, (95% CI, 7.23, 
7.51) for nonsmokers; χ2 (1) =22.73, p < .001.  
About 70 % of this cohort reported that they exercised once or more during the 
week. The proportion of patients developing NAFLD and also the incidence rate was 
higher for patients that reported that they exercised (79.5% and 66.97 cases per 1,000 
patient years 95% CI [64.90, 69.04] respectively) compared to the group that did not 
exercise as shown in Table 25. The mean time to development of NAFLD was not 
significant with 7.3 years (95% CI, 7.11, 7.49) for the group that did not exercise 











Overall NAFLD Incidence by Comorbidities and Other Factors 










CVD                Yes 1129 (6.5%) 518 (9.7%) 9.24 [8.45, 10.03] 4.60[4.29, 4.90] 183.64 
< .001 
No 16352(93.5%) 4810 (90.3%) 85.79 [83.47, 88.11] 7. 36 [7.24, 7.7.47]  
Hypertension   Yes 
 
6518 (37.3) 2209 (41.5%) 39.40 [37.79, 41.01] 5.99 [5.82, 6.16] 313.26 
< .001 
No 10963 (62.7%) 3119 (58.5%) 55.63 [53.73, 57.53] 7.75 [7.61, 7.88]  
Smoking Status  
Yes  
7208 (41.4%) 2171 (40.9%) 38.72 [37.12, 40.32] 6.91 [6.73, 7,10] 22.73 
< .001 
No 10193 (58.6%) 3137 (59.1%) 55.95 [54.05, 57.85] 7.37 [7.23, 7.51]  
Exercise          Yes 12171 (69.9%) 3755 (70.5%) 66.97 [64.90, 69.04] 7.13 [7.00, 7,26] 1.07 
.299 
No 12171 (69.6%) 1573 (29.5%) 28.05 [26.69, 29.42] 7.30 [7.10, 7.9]  
* p-value across categories; PY= Patient Years; CI- Confidence Interval; CV = Cramer’s V 
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Research Question 2 
Research question 3 was to determine the prevalence of NAFLD among patients 
with RA during the course of one year (e.g. 2012) in the U.S. using the FIB-4 test. As 
previously mentioned, answering this research question was contingent on not having a 
sufficiently large sample size to conduct the incident cohort analysis. Since the incident 
dataset was of sufficient size, data to conduct the prevalence analysis were not included 
in the dataset provided by the registry for the analysis. 
Research Question 3 
RQ3 was the subgroup analysis to determine the differences in baseline 
characteristics (clinical and demographic) for the incident cohort in those with NAFLD 
compared to those without. I compared baseline characteristics between the groups, those 
with NAFLD to those without using the t-test for continuous variables. Chi-square test 
was used for categorical variables, and effect size was estimated using Cramer’s V value. 
The overall effect size for these variables was small to moderate. Cramer’s V results 
ranged from 6% to 33%. 
Comparison of Baseline Demographic Factors  
In the overall study cohort about 31% (n= 17,481) developed NAFLD during the 
study period (see Table 26). The mean age for the overall cohort with NAFLD was 54 
years (SD = 12.45). The NAFLD group was older by 9.8 years; this difference was 
statistically significant [t (11934) = - 44.48, p < .001]. The proportion of patients in the 
NAFLD group compared to those without NAFLD across the age categories was lower 
except for the elderly (see Table 26.). The difference between the two subgroups was 
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statistically significant; χ2 (2) = 11593.16, p <. 001; the strength of association was 
moderate (Cramer’s V value = .32). In the overall cohort there were more women (79%). 
As shown in Table 26, there were more men in the NAFLD group compared to the group 
without NAFLD. The difference between the two subgroups was statistically significant; 
χ2 (1) = 474.12, p = <. 001, however, the strength of association was weak with Cramer’s 
V = .06. 
The majority of this cohort were Caucasians (89%), with 6% of African 
Americans, 4% falling into the other race category and less than 2% Asians. The 
proportion of patients in the NAFLD group compared to those without NAFLD across 
the race categories was lower except for Caucasians as shown in Table 26. The difference 
between the two subgroups was statistically significant; χ2 (3) = 109,23, p = <. 001, 
however, the strength of association was weak (Cramer’s V = .03).  Similar results were 
seen when comparing the two subgroups by ethnicity. The proportion of patients in the 
NAFLD group compared to those without NAFLD was higher among the non Hispanics 
than the Hispanic group as shown in Table 26.There was statistically significant 
difference between the two subgroups; χ2 (3) = 88.53, p = <. 001, the strength of 
association was weak (Cramer’s V value = .03). 
Most of the overall cohort were married (67%), with 20% single or widowed and 
13% were divorced or separated. The proportion of patients in the NAFLD group 
compared to those without NAFLD across the various marital status categories was lower 
except for the married/partnered group as shown in Table 26. There was statistically 
significant difference between the two subgroups; χ2 (2) = 59.82, p = <. 001, the strength 
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of association was weak (Cramer’s V value = .02).  In the overall cohort about 56% were 
college/university educated, 37% with high school education and about 4% had primary 
education. The proportion of patients in the NAFLD group compared to those without 
NAFLD across the various educational categories was lower except for the group with 
high school education as shown in Table 26. There was a statistically significant 
difference between the two groups; χ2 (3) = 604.76, p = <. 001; the strength of association 
was weak (Cramer’s V value = .07). In the overall cohort most had insurance (80%). The 
proportion of patients in the NAFLD group compared to those without NAFLD was 
higher among those without insurance as shown in Table 26. There was a statistically 
significant difference between the two groups; χ2 (3) = 732.59, p = <. 001; however, the 
strength of association was weak (Cramer’s V value = .08). 
Table 26   
Comparison of Demographic Factors: Patients with vs. without NAFLD Incidence 
Baseline Variable   All Patients 
N 17,481) 
Without NAFLD  
N=12153  
With NAFLD  
N=5328 
χ2  [CV] 
p-value* 
Age yrs. M (SD) 54.28 (12.45) 51.27 (12.14) 61.16 (10.23) 9.89 ** [-10.24, 9.54] 
  Younger (18 - <40) 2133 (12.2%) 2041 (16.8%) 92 (1.7%) 1932,19 
[.33] 
< .001 Middle Age (40 -<60) 9360 (53.5%) 7109 (58.5%) 2251(42.2%) 
Elderly (>=60) 5988 (34.3%) 3003 (50.2%) 2985 (56.6%) 
Gender                     Male  3707 (21.2%) 2356 (19.4%) 1351 (25.4%) 474.12 
[.67] 
< .001 Female  13774 (78.8%) 9797 (80.6%) 3977 (74.6%) 
Race                        Asian 286 (1.6%) 218 (1.8%%) 68 (1.3%) 109.23 
[.03] 
< .001 African American  1116 (6.4%) 800 (6.6%) 316 (5.9%) 
Other1 614 (3.5%) 459 (3.8%) 155 (2.9%) 
Caucasians 15465 (88.5%) 10676 (69.0%) 4789 (89.9%) 
Ethnicity    Non-Hispanic 16039 (91.8%) 11082 (91.2%) 4957 (93.0%) 88.53 
[.03] 
< .001   Hispanic  1442 (8.2%) 1071(8.8%) 371 (7.0%) 
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Comparison of Baseline RA Factors 
In the overall cohort, about 33% had early RA, 19% for those with 2 to 5 years 
and 5 to 10 years disease duration and 29% for those with > 10 years of disease duration. 
The proportion of patients in the NAFLD group compared to those without NAFLD 
across the various categories of disease duration was lower except for the category with 
greater than10 years of disease as shown in Table 27. There was a statistically significant 
difference between the two subgroups; χ2 (3) = 703.34, p = <. 001, but the strength of 
association was weak (Cramer’s V value = .08).  
In the overall cohort about 18% were in remission, 31% were in low disease 
activity, 28% moderate disease and 22% with high disease activity. The proportion of 
patients in the NAFLD group compared to those without NAFLD was higher across the 
various categories of disease severity except for remission as shown in Table 27. There 
was a statistically significant difference between the two subgroups; χ2 (3) = 150.03, p = 
<. 001, however, the strength of association was weak (Cramer’s V value = .03). 
Table 26   
 
(table continues) 
Comparison of Demographic Factors: Patients with vs. without NAFLD Incidence 
Variable   All Patients 
(N 17,481) 
Without NAFLD  
N=12153  

















`Married/Partnered 11787 (67.4%) 8111 (66.7%) 3676 (69.0%) 













High School 6406 (36.6%) 4222 (34.7%) 2184 (41.0%) 
 College/University 9702 (55.5%) 7059 (58.1%) 2643 (49.6%) 










< .001 Yes 13849 (79.2%) 9910 (81.5%) 3939 (73.9%) 
*P value = With Incident NAFLD vs. Without Incident NAFLD; **95% Confidence Interval; 1 - Other includes Mixed Race, 




Most of the overall cohort was currently using MTX (87%). The proportion of 
patients in the NAFLD group compared to those without NAFLD was slightly higher 
among the current MTX users (73% vs. 69% respectively) as shown in Table 27. There 
was a statistically significant difference between the two subgroups; χ2 (1) = 141.22, p = 
<. 001, but the strength of association was weak (Cramer’s V value = .03).  In the overall 
cohort, only 30% were using cDMARDs. The proportion of patients in the NAFLD group 
compared to those without NAFLD was marginally higher among the cDMARDs users 
(31% vs. 29%) as shown in Table 27. There was a statistically significant difference 
between the two subgroups; χ2 (1) =28.22, p = <. 001; however, the strength of 
association was very weak (Cramer’s V value = .01).  
In the overall cohort, only 30% were using steroids. The proportion of patients in 
the NAFLD group compared to those without NAFLD was slightly higher among the 
steroid users (32% vs. 28%) as shown in Table 27. There was a statistically significant 
difference between the two subgroups; χ2 (1) =16.03, p = <. 001; but the strength of 
association was weak (Cramer’s V value = .03). In the overall cohort, about 44% were 
using biologics. The proportion of patients in the NAFLD group compared to those 
without NAFLD was slightly lower among biologic users (41% vs. 45% respectively) as 
shown in Table 27. There was a statistically significant difference between the two 
subgroups; χ2 (1) = 11.47, p = <. 001, but the strength of association was weak (Cramer’s 




















Comparison of Baseline Comorbidities and Other Factors 
About 37% of this cohort had a diagnosed history of hypertension. The proportion 
of patients in the NAFLD group compared to those without NAFLD was slightly higher 
for those with hypertension (41% vs. 35% respectively) as shown in Table 28. There was 
Table 27  
Comparison of Baseline RA Factors: Patients with vs. without NAFLD Incidence 










Disease Duration yrs. M (SD) 8.29 (8.88) 7.74 (8.49) 9.53 (9.78) -1.79** (2.09- .14) 
Early RA 5735 (32.8%) 4179 (34.4%) 1556 (29.2%) 703.34 
[.08] 
< .001 2 to 5 years 3276 (18.7%) 2338 (19.2%) 938 (17.6%) 
5 to 10 years 3340 (19.1%) 2362 (19.4%) 978 (18.4%) 
>10 years 5109 (29.2%) 3257 (26.8%) 1852 (34.8%) 
 CDAI Score1 M (SD) 13.94 (12.88) 13.72 (12.83) 14.45 (13.00) -.73 ** (-1.14, -.31) 
Remission (≤ 2.8) 3223 (18.4%) 2358 (19.4%) 865 (16.2%) 150.03 
[.03] 
< .001 Low Disease (≤ 10) 5480 (31.3%) 3802 (31.3%) 1678 (31.5%) 
Moderate Disease (≤ 22) 4935 (28.2%) 3366 (27.7%) 1569 (29.5%) 
High Disease (> 22) 3835 (21.9%) 2622 (21.6%) 1213 (22.8%) 



















































Yes 7688 (44.0%) 5475 (45.1%) 2213 (41.5%) 
*P value = With Incident NAFLD vs. Without Incident NAFLD; **95% Confidence Interval;1- CDAI= Clinical 
Disease Activity Index; 2 -MTX= methotrexate; 3- cDMARD = conventional disease modifying disease-
modifying antirheumatic drugs; 4- Biologics – combined TNF = tumor necrosis factor & non TNFs 
149 
 
a statistically significant difference between the two subgroups; χ2 (1) =342.69, p = <. 
001, however, the strength of association was weak (Cramer’s V value = .05).  
In the overall cohort only 7% had a history of cardiovascular disease (CVD). The 
proportion of patients in the NAFLD group compared to those without NAFLD was two 
times higher among those with CVD (10% vs. 5% respectively) as shown in Table 28. 
There was a statistically significant difference between the two subgroups; χ2 (1) 
=810.79, p = <. 001, but the strength of association was weak (Cramer’s V value = .08).   
About 7% of this overall cohort had a history of diabetes. The proportion of 
patients in the NAFLD group compared to those without NAFLD was slightly higher 
among those with diabetes (8% vs. 6% respectively) as shown in Table 28. There was 
statistically a significant difference between the two subgroups for the diabetes; χ2 (1) 
=137.80, p = <. 001; the strength of association was very weak (Cramer’s V value =  .03).   
In the overall cohort, about 22% of this cohort had a reported history of 
dyslipidemia. The proportion of patients in the NAFLD group compared to those without 
NAFLD was marginally higher among those with dyslipidemia (26% vs. 20% 
respectively) as shown in Table 28. There was a statistically significant difference 
between the two subgroups; χ2 (1) =427.96, p = <. 001, however, the strength of 
association was weak (Cramer’s V value = .06).   
About 6% of the cohort had a history of cancer excluding non melanoma skin 
cancer (NMSC).  The proportion of patients in the NAFLD group compared to those 
without NAFLD was marginally higher among those with a history of cancer  (7% vs. 5% 
respectively) as shown in Table 28.There was a statistically significant difference 
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between the two subgroups; χ2 (1) =272.89, p = <. 001, but the strength of association 
was weak (Cramer’s V value = .05).  
Only a small proportion of this cohort reported a history of liver disorders (2%). 
The proportion of patients in the NAFLD group compared to those without NAFLD was 
slightly higher among those with a history of liver disorders (7% vs. 5% respectively) as 
shown in Table 28. There was a statistically significant difference between the two 
subgroups; χ2 (1) =75.04, p = <. 001, but the strength of association was very weak 
(Cramer’s V value = .02).  
Overall, there was about 8% of the cohort that had liver enzyme elevation.  The 
proportion of patients in the NAFLD group compared to those without NAFLD was 
marginally higher among those with normal liver enzyme levels (92.1% vs. 91.6%) as 
shown in Table 28. There was a statistically significant difference between the two 
subgroups; χ2 (1) =8.42, p = .004, however, the strength of association was extremely 
weak (Cramer’s V value = .009). 
In the overall cohort, about 72% were obese. The mean BMI for the overall cohort 
was 30 (SD = 7.20) and was similar for those with and without NAFLD. The proportion 
of patients in the NAFLD group compared to those without NAFLD was also similar 
among those with and without obesity as shown in Table 28.The difference between the 
two subgroups was not statistically different; χ2 (1) = 2.68, p - .101, and the strength of 
association was extremely weak (Cramer’s V value = .005).  
About 19% of the overall cohort had metabolic syndrome. The proportion of 
patients in the NAFLD group compared to those without NAFLD was slightly higher 
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among those with metabolic syndrome (20% vs. 18% respectively) as shown in Table 28. 
There was a statistically significant difference between the two subgroups; χ2 (1) =51.84, 
p = <. 001, however, the strength of association was very weak (Cramer’s V value = .02).  
In the overall about 40% of the cohort reported using alcohol. The proportion of 
patients in the NAFLD group compared to those without NAFLD was slightly higher 
among the non alcohol users (62% vs. 59% respectively) as shown in Table 28. There 
was a statistically significant difference between the two groups for alcohol use: χ2 (1) = 
151.11, p = <. 001, but the strength of association was very weak (Cramer’s V value = 
.03).  
About 41% of the overall cohort were current smokers or had a history of 
smoking. The proportion of patients in the NAFLD group compared to those without 
NAFLD was similar among the smokers and non smokers as shown in Table 28. There 
was no statistically significant difference between the two subgroups; χ2 (1) =51.5, p = 
.023, and the strength of association was very weak (Cramer’s V value = .01).  
Most of this cohort reported exercising (70%). The proportion of patients in the 
NAFLD group compared to those without NAFLD was marginally higher among those 
who reported that they exercised (70% vs. 69% respectively) as shown in Table 28. There 
was a statistically significant difference between the two subgroups; χ2 (1) =17.15, p = <. 




Table 28  
Comparison of Baseline Comorbidities & Other Factors: Patients without and with 
NAFLD Incidence 
Variable All Patients 
(N 17,481) 







Hypertension                    No 10963 (62.7%) 7844 (64.5%) 3119 (58.5%) 342.60 
[.05] 
< .001 Yes 6518 (37.3%) 4309 (35.5%) 2209 (41.5%) 
Cardiovascular Disease    No 1635 (93.5%) 11542 (95.0%) 4810 (90.3%) 810.79 
[.088] 
< .001 Yes 1129 (6.5%) 611(5.0%) 518 (9.7%) 
Diabetes                           No 16273 (93.1% 11387 (93.7%) 4886 (91.7)%) 137.80 
[.03] 
< .001 Yes 1208 (6.9%) 766 (6.3%) 442 (8.3%) 
Dyslipidemia                    No 13657 (78.1%) 9707 (79.9)%) 3950 (74.1%) 427.96 
[.06] 
< .001 Yes 3824 (21.9%) 2446 (20.1%) 1378 (25.9%) 
History Cancer                 No 16527 (94.5%0 11583 (95.3%) 4944 (92.8%) 272.89 
[.05] 
< .001 Yes 954 (5.5%) 570 (4.7%) 384 (7.2%) 
Liver Disorders                 No 17090 (97.8%) 11913 (98.0%) 5177 (97.2%) 75.04 
[.02] 
< .001 Yes 391 (2.2%) 240 (2.0%) 151 (2.8%) 
Liver Enzyme Elevation   No 16041 (91.8%) 11132 (91.6)%) 4904 (92.1%) 8.42 
[.009] 
.004 Yes 570 (4.7%) 1021 (8.4%) 419 (7.9%) 
Obese (BMI) M (SD) 29.66 (7. 20) 29.85 (7.43) 29.22 (6.65) .62 **[.40, .84] 
No 4842 (27.7%) 3348(27.5%) 1494 (28.0%) 2.68 
[.005] 
.101 Yes 12639 (72.3%) 8805(72.5%) 3834 (72.0%) 
Metabolic Syndrome        No 14174 (81.1%) 9924 (81.7%) 4250 (79.8%) 51.84 
[.022] 
< .001 Yes 3307 (18.9%) 2229 (18.3%) 1078 (20.2%) 
Alcohol Use                  None 10449 (59.8%) 7118 (58.6%) 3331 (62.5%) 151.11 
[.03] 
< .001 Yes 7032 (40.2%) 5035 (41.5%) 1997 (37.5%) 
Smoking Status           Never 10193 (58.3%) 7056 (58.3%) 3137 (59.1%) 5.15 
[.007] 
.023 Smoker 7208 (41.2%) 5037 (41.7%) 2171 (40.9%) 
Exercise                        None 5310 (30.4%) 3737 (30.7%) 1573 (29.5%) 17.15 
[.01] 
< .001 Yes 12171 (69.6%) 8416 (69.3%) 3755 (70.5%) 
*P value = With Incident NAFLD vs. Without Incident NAFLD; **95% Confidence Interval; SD = Standard Deviation; 





Research Question 4 
Research question 4 was to determine the significant baseline factors (clinical and 
demographic) that predicted the development of NAFLD after adjusting for relevant 
confounders. Prior to conducting the multivariate analysis, I conducted a bivariate 
analysis to determine the effect of each of the predictor and the outcome variables. The 
results from the unadjusted analysis were used to inform the multivariate model.  
Unadjusted Analyses of NAFLD Predictors: Baseline Demographic  
The unadjusted analyses of baseline demographic predictors for developing 
NAFLD are presented in Table 29. In this unadjusted analysis there was a significant 
increased risk for NAFLD with increased age (the middle-aged and elderly) NAFLD risk 
was lower for women, African American, Caucasians, Hispanics, for those with 
college/university education, and also for those with insurance. 
Table 29 
Unadjusted Analyses of NAFLD Predictors: Baseline Demographic  
Variable   Hazard Ratio [95% CI] p-value 
Age      Younger (18-<40) Referent   
Middle Age (40 -<60) 5.37 4.36, 6.62 < .001 
Elderly (>=60) 16.03 13.02, 19.73 < .001 
Gender                      Male Referent   
Female 0.76 0.71, 0.81 < .001 
 Race                        Asian Referent   
  African American 0.78 0.61, 0.99 .050 
 Other1 1.10 0.98, 1.24 .080 
  Caucasians  0.79 0.67, 0.92 .004 
 Ethnicity    Non-Hispanic Referent   
Hispanic  0.88 0.79, 0.98 .021 
Single or Widowed Referent   
Married or Partnered 0.96 0.90, 1.03 .308 
Divorced or Separated 0.91 0.82, 1.01 .078 
Education             Primary Referent   
High School 1.04 0.91, 1.19 548 
College/University 0.78 0.69, 0.89 < .001 
Insurance Status       None Referent   
Yes 0.62 0.58, 0.66 < .001 




Unadjusted Analyses of NAFLD Predictors: RA Related Factors 
The unadjusted analyses for baseline RA related predictors are presented in Table 
30.  In the unadjusted analysis, there was a statistically significant decreased risk for 
NAFLD for those with 2 to 5 years and 5 to 10 years of disease duration, and also for 
those using biologics. Baseline moderate and high disease severity was associated with 
















Unadjusted Analyses of NAFLD Predictors: Baseline RA Factors  
Variable Hazard Ratio [95% CI] P-value 
Disease Duration     
Early RA Referent  
2 to 5 years 0.89 0.82, 0.96 .006 
5 to 10 years 0.90 0.83, 0.98 .015 
>10 years  1.06 0.99, 1.13 .072 
`CDAI Score     
 Remission (≤ 2.8) Referent  
Low Disease (≤ 10) 1.06 0.97, 1.15 .152 
Moderate Disease (≤ 22) 1.12 1.03,1.22 .007 
High Disease (> 22) 1.16 1.06, 1.27 .001 
MTX use     
None Referent  
Yes  1.12 1.03, 1.21 .007 
cDMARD Use     
None Referent  
Yes .96 0.91, 1.02 .235 
Steroids Use    
No Referent  
Yes 1.11 1.04, 1.17 < .001 
Biologics Use    
No Referent  
Yes 0.88 0.83, 0.93 < .001 
1- CDAI= Clinical Disease Activity Index; 2 -MTX= methotrexate; 3- cDMARD = conventional disease 
modifying disease-modifying antirheumatic drugs (other than MTX) 
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Unadjusted Analyses NAFLD Predictors: Comorbidities and Other Factors  
The results of unadjusted analyses by baseline comorbidities and other potential 
predictors are presented in Table 31. Most of the comorbidities in the model were 
associated with increased risk for NAFLD except for liver enzyme elevation, obesity, and 
exercise. The highest increased risk was seen for those with CVD, followed by those with 
dyslipidemia, metabolic syndrome, and those with hypertension. Other factors associated 
with increased risk for NAFLD, include liver disorders and smoking. However, alcohol 
use was associated with decreased risk for NAFLD. 
Table 31 
Unadjusted Analyses of NAFLD Predictors: Comorbidities & Other Factors  
Variable   Hazard Ratio 95% CI P-value 
Hypertension                        No Referent   
Yes 1.67 1.58, 1.77 < .001 
Cardiovascular Disease        No Referent   
Yes 2.09 1.90, 2.29 < .001 
Diabetes                                No Referent   
Yes 1.32 1.20, 1.45 < .001 
Dyslipidemia                        No Referent   
Yes 1.93 1.8, 2.05 < .001 
Cancer History                      No Referent   
Yes 1.51 1.36, 1.67 < .001 
Liver Disorder                      No Referent   
Yes 1.19 1.01, 1.40 .032 
Liver Enzyme Elevation       No Referent   
Yes 0.96 0.87, 1.06 .479 
Obesity (BMI ≥ 25)              No Referent   
Yes 1.06 .99, 1.04 .211 
Metabolic Syndrome            No Referent   
Yes 01.89. 1.77, 2.03 < .001 
Alcohol Use                          No Referent   
Yes 0.83 0.78, 0. 87 < .001 
Smoking Status                     No Referent   
Yes 1.16 1.10, 1.22 < .001 
Exercise                               No Referent   





Multivariate analysis was conducted to determine the significant baseline factors 
that independently predicted the development of NAFLD after adjusting for relevant 
predictor or explanatory variables. Cox proportional hazards survival analysis was used 
to identify factors associated with the development of NAFLD (Szklo & Nieto, 2014, pp. 
229-305). I ran the unadjusted and adjusted Cox proportional model to determine effect 
of the confounders on the outcome variable. Incidence (hazard) rates and ratios (HR) are 
reported with 95% confidence interval and factors that do not include 1 and a p-value < 
.05 were considered significant. While p-values can assess differences, however, it is also 
important to ascertain the impact or magnitude of the difference to avoid overestimation 
or underestimation of the associations (Grayson, 1987). I identified factors with 
significant p-values or those with ratios that changed by 10% or more and included them 
in the multivariate model as potential confounders (Grayson, 1987; Hernán, Hernández-
Díaz, Werler, & Mitchell, 2002). I ran several multivariate models to evaluate the effect 
of the various predictor variables using the imputed incident data set as well as the 
original dataset. Multivariate models were analyzed by entering the predictor variables 
simultaneously into the model. Additionally, I also evaluated the impact on the HR using 
the original data without imputation. 
The process taken to select the variables for the final primary model was as 
follows. I used the imputed dataset and included all the available demographic, RA 
related, comorbidities and other relevant variables into the model as described in the 
bivariate analysis. The outputs were compared to the unadjusted bivariate analysis for 
each of these variables and then I identified factors that were significant using p value of 
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0.05 as well those variables that changed by 10% or more. The variables selected a priori 
were age, gender, race/ ethnicity, obesity, metabolic syndrome, diabetes, dyslipidemia, 
MTX use, liver enzyme elevation, liver disorders, and alcohol; these were included 
regardless of significance as they are established clinical risk factors. The variables 
education, insurance, smoking, exercise, hypertension, cardiovascular, cancer, disease 
duration, and disease activity were included based on a significant p value or based on 
change of 10% or more.   
I also ran a model where only significant factors and variables selected a priori 
were included. The results of this analysis were consistently significant for all the 
variables except in this model, factors such as marital status and exercise were also 
significant. Included in the multivariate analysis were the original data along with the 
imputed datasets. The results were similar to the primary model presented in Table 32. 
Since information about risk factors associated with the development of NAFLD has not 
been characterized in the RA population, it is important to include as much of the 
available information as possible to increase robustness of the model to identify 
predictors of NAFLD.  Based on extensive evaluation and consistency of the results for 
the key predictor variables regardless of the model used, I elected to include all the 
available variables. They were either selected a priori or were significant. The final 
model also met the requirements for goodness of fit for model selection and thus enabled 




In the adjusted analyses age a significant independent predictor for NAFLD. HR 
was 5.16, 95% CI [4.16, 6.40] for the middle aged group (p < .001). Similarly there was a 
significant increased risk for the elderly group with HR of 13.94, 95% CI [11.22, 17.31], 
p < .001. Women were at lower risk for developing NAFLD compared to men, with HR 
0.81, 95% CI [0.76, 0.86]; p < .001. Race and ethnicity (Hispanics) were not significant 
predictors for the development of NAFLD. In the adjusted analysis, those who were 
divorced or separated were at a lower risk of developing NAFLD, HR 0.87, 95% CI 
[0.79, 0.97], p = 0.010. As was those with insurance, with a lower risk for NAFLD (HR 
0.89, 95% CI [0.83, 0.95], p < .001). Factors such as education, smoking, and use of 
alcohol were not significant predictors for the development of NAFLD. However, there 
was an increased risk for NAFLD in the group that exercised (HR 1.09, 95% CI [1.02, 
1.16], p = .009) in the adjusted analysis.  
Those with hypertension, cardiovascular disease and dyslipidemia were at a 
statistically significant increased risk for NAFLD in the adjusted analysis. Hazard ratios 
were 1.11, 95% CI [1.04, 1.19], p < .003 for hypertension; HR of 1.19, 95% CI [1.08, 
1.31], p < .001 for cardiovascular disease; and HR 1.31, 95% CI [1.20, 1.42], p < .001 for 
dyslipidemia. Diabetics were at reduced risk for developing NAFLD, HR was 0.87, 95% 
CI [0.78, 0.98], p < .020. The risk for NAFLD was significantly lower for the obese, with 
a HR= .84, 95% CI [0.79, .90], p <. 001. Comorbid conditions such as history of cancer, 
liver disorders, and liver enzyme elevation groups were not significant predictors for 
NAFLD after adjusting for confounders. 
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In the adjusted analysis for RA related factors, all categories of disease duration 
were associated with lower risk for NAFLD. Those with 2 to 5 years and 5 to 10 years of 
disease were at lower risk of NAFLD with HR of 0.87, 95%CI [0.80, 0.94], p = .001, and 
HR of 0.87, 95%CI [0.80, 0.95], p = .001 respectively. The results were similar for those 
with longer duration of disease greater than10 years; HR 0.88, 95%CI [0.82, 0.95], p = 
.001. In the adjusted analysis, baseline disease activity was not associated with increased 
risk for NAFLD. MTX use remained significant predictor in the adjusted analysis with an 
increased risk for NAFLD, HR 1.08, (95% CI 1.01, 1.15), p = .021. Similar results was 
seen for cDMARDs use, which was also associated with significant increased risk for 
NAFLD, HR 1.08, (95% CI 1.01, 1.15), p = .027. The use of steroids and biologics were 
not associated with increased risk for the development of NAFLD in the adjusted 
analysis. 
Table 32 
Adjusted Analyses of NAFLD Predictors  
Baseline Factors Hazard Ratio 95.0% CI p Value 
Age*    
Younger (18-<40) Referent   
Middle Age (40 -<60) 5.16 4.16, 6.40 < .001 
Elderly (>=60) 13.94 11.22, 17.31 < .001 
Gender (Female) 0.81 0.76,0.86 < .001 
Race *    
Asian Referent   
African American 1.15 0.87, 1.51 0.323 
Other1  0.94 0.70, 1.27 0.703 
Caucasians 1.05 0.82, 1.35 0.677 









Adjusted Analyses of NAFLD Predictors                                     (table continues) 
Baseline Factors Hazard Ratio 95.0% CI p Value 
Marital Status    
Single or Widowed Referent   
Married or Partnered 0.96 0.89, 1.03 0.279 
Divorced or Separated 0.87 0.79, 0.97 0.010 
Education**    
Primary Referent   
High School 1.00 0.87, 1.16 0.939 
 College/University 0.98 0.85, 1.12 0.780 
Insurance ** 0.89 0.83, 0.95 0.001 
 Smokers**  0.99 0.93, 1.04 0.597 
Alcohol Use* 0.97 0.91, 1.03 0.278 
Exercise (Yes) 1.09 1.02, 1.15 0.009 
Hypertension ** 1.11 1.04, 1.19 0.003 
Cardiovascular Disease** 1.19 1.08, 1.31 0.001 
Dyslipidemia * 1.31 1.20, 1.42 0.001 
Cancer ** 1.07 0.96, 1.20 0.195 
Diabetes • 0.87 0.78, 0.98 0.019 
Liver Disorders * 1.18 0.99, 1.39 0.061 
Liver Enzyme Elevation* 1.05 0.95, 1.17 0.331 
Obese (BMI >=25) * 0.84 0.79, 0.90 < .001 
Metabolic Syndrome* 1.21 1.09, 1.35 0.001 
Disease Duration**    
Early RA Referent   
2 to 5 years 0.87 0.80, 0.94 0.001 
5 to 10 years 0.87 0.80, 0.95 0.001 
>10 years  0.88 0.82, 0.95 0.001 
Disease Activity (CDAI) **    
Remission (≤ 2.8) Referent   
Low Disease (≤ 10) 0.98 0.90, 1.07 0.685 
Moderate Disease (≤ 22) 1.03 0.95, 1.12 0.484 
High Disease (> 22) 1.08 0.98, 1.18 0.111 
MTX use * 1.08 0.01, 1.16 0.021 
cDMARD Use** 1.08 1.01, 1.15 0.027 
Biologics Use** 1.04 0.98, 1.10 0.230 
Steroid Use ** 0.98 0.92, 1.04 0.553 
BMI = Body Mass Index; CDAI = Clinical Disease Activity Index; MTX= Methotrexates; cDMARD = 
Conventional disease modifying antirheumatic drugs (excluding MTX).  * - Identified apriori; ** met significance (p 




In this chapter I described the methods used to select the incident cohort and the 
steps taking to prepare for analysis. Several variables were transformed, analyses for 
measures of central tendency, distribution, and dispersion of data were assessed. For the 
Kaplan Meier and Cox proportional survival analysis, the adequacy of sample size was 
evaluated, impact of missing data, normality of distribution, proportionality of hazard 
assumption and multicollinearity were assessed. I also evaluated and addressed issues 
with missing data, outliers, and difference between withdrawn and remaining cases, and 
changes in survival experience over time. Missing data were addressed using the multiple 
imputation method, an optimal approach that preserved sampling variability of the 
original dataset. The large sample size of 17,481 participants helped minimize the impact 
of outliers, and was further reduced by transforming them into categorical variables. 
Since the incident sample size was sufficiently large, the alternative research questions 
related to the prevalent analysis previously embedded in RQ3 and RQ4 were abandoned. 
Descriptive analysis, and bivariate analysis were conducted to inform the model for the 
multivariate analysis. 
A descriptive analysis was conducted to determine if the NAFLD cohort was 
similar to the overall registry, but given the large sample size it was difficult to evaluate 
using the p values. The numerical values were similar for most variables, however, there 
were some notable absolute differences. The NAFLD cohort was younger, more of this 
cohort had insurance, and more of them were taking MTX, with fewer reporting CVD 
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history and liver enzyme elevations. Generally for most of the clinical variables, the 
NAFLD cohort appears to be mostly similar to the overall registry.  
RQ1 was to determine the incidence rate and time to development of NAFLD in 
this cohort of RA patients. There were about 17,481 patients in the incident cohort with 
data collected over a period of 13.2 years. The cumulative overall incidence rate over this 
period was 31%, with a mean overall time to event of 7.1 years, with most developing 
mild to moderate NAFLD (29%) and only 1.4% had advanced disease.  
Research question 2 was to determine the prevalence of NAFLD among patients 
with RA during the course of one year (e.g. 2012) in the U.S. using the FIB-4 test. As 
previously mentioned answering this research question was contingent on not having a 
sufficiently large sample size to conduct the incident cohort analysis. Thus this analysis 
was not pursued. 
RQ3 compared the clinical and demographic variables among those with and 
without NAFLD. Overall there were statistically significant differences for all of the 
factors when the two groups of those with and without the disease were compared except 
for smoking and obesity. The prevalence of demographic factors was lower in the 
NAFLD group except for the elderly, gender (men). The prevalence of Caucasians, non 
Hispanics, those married/partnered, those with high school education and those without 
insurance were higher in the NAFLD group. 
The prevalence of RA related factors was lower in the NAFLD group for disease 
duration except for those with greater than 10 years of disease. Slightly higher prevalence 
was seen across all disease severity categories with the exception of those in remission. 
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There was higher prevalence of MTX users, the cDMARDs users, steroid users, and also 
the users of biologics in the NAFLD group. The prevalence of comorbidities and other 
factors was higher in the NAFLD group also for hypertension, CVD, diabetes, metabolic 
syndrome, history of cancer, liver disorders, among those with normal liver enzymes, non 
users of alcohol and among those who reported that they exercised. The prevalence of 
obesity and smokers were similar among those with and without NAFLD. 
RQ4 identified significant baseline factors (clinical and demographic) that 
predicted the development of NAFLD after adjusting for relevant confounders. In the 
bivariate analysis, the following demographic factors were statistically significant for 
increased risk; age (middle age and elderly), whereas women, race and ethnicity (African 
Americans, Caucasians, and non-Hispanics), college/university education and having 
insurance were associated with reduced risk for NAFLD.  Among the RA related 
variables, disease duration (2 to 5 years and 5 to 10 years) was associated with reduced 
risk. Moderate and high disease activity was associated with increased risk for NAFLD. 
Use of RA medications including MTX and steroids were associated with increased risk 
for NAFLD and the use of biologics was associated with lower risk for NAFLD. In the 
unadjusted analyses of comorbidities such as, hypertension, CVD, diabetes, dyslipidemia, 
cancer history, history of liver disorders, metabolic syndrome, and smoking were all 
associated with increased risk. Alcohol use was associated with a reduced risk for 
NAFLD.  
In the multivariate analysis the following variables were statistically significant 
predictors for increased risk for NAFLD, middle age, elderly, exercise, hypertension, 
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CVD, dyslipidemia, and metabolic syndrome. Factors associated with statistically 
significant reduced risk included gender (female), diabetes, obesity, disease duration, 
being divorced or separated, and having insurance. The relevance and implications of 
these newly identified predictors for NAFLD in the RA population are elaborated in the 
next chapter. 
In Chapter 5, I provide a summary of findings, interpretation of the results in 
context of the theoretical framework and current understanding of NAFLD compared to 
the general population. I discuss the strength and limitations of the study and propose 
suggestions for future research. I also will review potential impact for social change and 




Chapter 5: Discussion, Conclusions, and Recommendations 
The purpose of this quantitative research study was to determine the incidence 
and factors associated with NAFLD using longitudinal retrospective data collected from a 
cohort of adult RA patients in the U.S. The primary objective of this study was to first 
establish the occurrence of NAFLD by using FIB-4, a noninvasive tool in this population. 
A second goal was to determine if there were significant clinical and demographic factors 
that independently predict the development of NAFLD using Kaplan Meier and Cox 
proportional hazard survival analysis.   
The finding from this study established for the first time that roughly 31% of 
patients with RA developed NAFLD (FIB-4 score ≥ 1.3).  A large registry dataset with 
longitudinal data collected over a period of 14 years was used to determine the 
cumulative incidence rates. About 29% of this cohort had mild to moderate NAFLD and 
about 1.4% had advanced disease. The overall mean time to event was about 7 years.  At 
baseline, the mean age of this cohort was about 54 years and over 80% of these 
individuals were Caucasian females. These patients had RA for about 8 years, had 
moderate disease activity, and over three fourths of them were obese and were currently 
using MTX. Less than half of this cohort had hypertension, reported using alcohol, or 
were smokers. About a fourth of these patients had dyslipidemia, metabolic syndrome. 
Less than 10% had diabetes, cardiovascular disease, and liver enzyme elevation. Very 
few had a history of liver disorders.  
The two subgroups of those with and without NAFLD were compared to 
determine the differences in baseline clinical and demographic characteristics. There was 
166 
 
a statistically significant difference between the two subgroups of those with and without 
NAFLD except for obesity and smoking. For the clinical characteristics, prevalence was 
higher for the known risk factors such as age, gender, and race/ethnicity. In the NAFLD 
group, the prevalence of RA related factors was higher for those with more than 10 years 
of disease duration, across all disease severity categories with the exception of those in 
remission. The prevalence was higher in the NAFLD group for MTX users, cDMARDs 
users, steroid users, and also for the users of biologics. The prevalence of comorbidities 
and other factors was higher in the NAFLD group for hypertension, CVD, diabetes, 
metabolic syndrome, history of cancer, liver disorders, among those with normal liver 
enzymes, non users of alcohol and among those who reported that they exercised. There 
were no differences in the prevalence of obesity and smokers among those with and 
without NAFLD. 
Adjusted and unadjusted cox regression analysis was conducted to determine 
factors associated with the risk of developing NAFLD. In the unadjusted analysis, age 
(middle age and elderly), baseline moderate and high disease activity, MTX use and 
steroid use were associated with increased risk for NAFLD. Factors associated with 
reduced risk for developing NAFLD were gender (women), African Americans, 
Caucasians, ethnicity (non-Hispanics), disease duration (2 to 5 years and 5 to 10 years), 
biologic use, alcohol use, college/university education, and having insurance. In the 
adjusted analysis, age (middle age, elderly), hypertension, cardiovascular disease, 
dyslipidemia, exercise, metabolic syndrome, MTX use and cDMARDs were significant 
independent predictors for developing NAFLD. Gender (women), diabetes, obesity, 
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disease duration, divorced or separated, and having insurance were significant 
independent predictors for reduced risk for NAFLD  
In summary, the results from the bivariate as well as the multivariate results were 
consistent for most the key variables, except for race and ethnicity, cancer, liver disorder 
and alcohol use with loss of significance in the adjusted model. Being divorced or 
separated and having insurance were associated with reduced risk, while diabetes 
reversed from increased risk to lower risk. The relevance and implications of these newly 
identified predictors for NAFLD in the RA population will be elaborated in the following 
section. 
Discussion of Findings 
The results of this study agreed with previous NAFLD research in the general 
population. Finding hypertension, cardiovascular disease, dyslipidemia, metabolic 
syndrome, and the use of MTX were identified as independent predictors for the 
development of NAFLD in the RA population. However development of NAFLD was 
not associated with liver enzyme elevation in this population. 
Theories, pathways, and relationships related to the development of NAFLD are 
still evolving (Erickson, 2009). The conceptual framework for this study was based on 
the hypothesis that NAFLD and RA would have shared risk factors and the confluence of 
these factors could contribute to the development of NAFLD. This study further 
confirmed this framework as metabolic syndrome, dyslipidemia, MTX use, along with 
hypertension and cardiovascular disease was prevalent in this cohort with RA and all 
were found to be independent predictors for the development of NAFLD. Interestingly, 
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the known factors among the general population for increased risk for NAFLD, such as 
gender, obesity, and diabetes, were associated with decreased risk in the RA population.  
Exercise was associated with increased risk in the RA population. These findings may be 
unique to patients with RA, as this population is aggressively treated with anti-
inflammatory medications and potentially could alter inflammatory pathways related to 
obesity, metabolic dysfunction, and lipid metabolism, key precursors to the development 
of NAFLD (Fabbrini, et.al., 2010). 
Overall NAFLD Incidence Rates  
This is the first study that reports on the incidence rates and time to development 
of NAFLD for patients with RA using FIB-4. This was a large study of 17,481 patients 
with RA in the U.S. with data collected over 14 years. During this period, 31% of this 
cohort developed NAFLD; the rate was 95 cases per 1,000 patient years. The mean time 
to event was 7 years. Most of the patients that developed NAFLD had mild to moderate 
NAFLD (29%), while incidence of advance NAFLD was very low (1.4%).  The overall 
incidence rate in the RA population was much higher than the incidence rate reported in 
the general population of 15% to 20%, and 18 to 31 per 1000 PY (Vernon et al., 2011). 
The incidence rate was also higher then the only previously reported NAFLD rate for 
patients with RA with a prevalence of 23% in the U.S. (Bhambhani et al., 2006), 
however, that study used ultrasound to determine the presence of NAFLD (Chalasani et 
al., 2012). There are significant variations in the rates of NAFLD depending on the tools 
used; the rates reported in this study is similar to rates reported when FIB-4 score was 
used (Eguchi et al., 2012), and also similar to rates several studies that used ultrasound 
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(Chalasani et al., 2012). Time to development of NAFLD for the RA population was 
about 7 years and seems to be similar to the general population of 7 to 8.5 years (Zelber-
Sagi et al., 2012). 
Risk Factors Associated with Nonalcoholic Fatty Liver Disease 
Overall results of this study showed that age, hypertension, cardiovascular 
disease, dyslipidemia, metabolic syndrome exercise, MTX use and cDMARDs were 
significant independent predictors for increased risk for developing NAFLD in persons 
with RA. Some of these factors (age, hypertension, cardiovascular disease, dyslipidemia, 
and metabolic syndrome) were similar to the risk factors identified in the NAFLD 
guidelines for the general population, however, there were other risk factors in the 
guidelines such as gender, obesity, and diabetes (Chalasani et al., 2012). 
Unlike in the general population, race and ethnicity were not significant predictors 
of NAFLD in the RA population (Chalasani et al., 2012). In the general population, 
hypertension, presence of cardiovascular disease, and liver enzyme elevation were 
associated with NAFLD but were not identified as independent risk factors (Lonardo et 
al., 2015; Chalasani et al., 2012). However in the RA population, all of except for liver 
enzyme elevation were independent predictors for the development of NAFLD. Unlike 
the general population, being female, having diabetes, and being obese were independent 
predictors for reduced risk for NAFLD in the RA population (Chalasani et al., 2012), 
Among the demographic variables, age and gender were significant independent 
predictors for NAFLD in the RA population. Incidence was the highest for the elderly 
group, with about half developing NAFLD, followed by the middle age group. The 
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incidence for NAFLD was less common among those less than 40 years of age. There 
was roughly a 13 fold increased NAFLD risk for the elderly, where the increased risk was 
five fold for the middle age group. These findings are similar to risk seen in the general 
population, where the risk for NAFLD increased over time, peaking in the middle and 
latter ages of life (Lonardo, et al., 2015; Chalasani et al., 2012; Vernon et al., 2011). 
Being male was also a significant independent predictor for NAFLD in the general 
population as was for the RA population (Chalasani et al., 2012; Vernon et al., 2011).   
In the general population, prevalence and risk for NAFLD differed by race and 
ethnicity in the U.S., with increased risk for Hispanics, followed by Caucasians, with 
African Americans consistently having the lowest risk for NAFLD (Stepanova & 
Younossi, 2012; Vernon et al., 2011, Williams et al., 2011). However in this analysis of 
RA patients, in the group that developed NAFLD, almost 90% were Caucasians. Race 
and ethnicity were not significant independent risk factors for NAFLD in the adjusted 
analysis for patients with RA, though the rates were directionally increased for risk, 15% 
for African Americans, 5% for Caucasians and 4 % for Hispanics.  This discrepancy 
could be attributed to Caucasians with RA, however, a few studies in the general 
population also reported increased risk for Caucasians compared to other races 
(Stepanova & Younossi, 2012; Ong et al., in 2008). 
Obesity is a significant risk factor for NAFLD and some studies suggest increased 
risk even among those with normal BMI. Studies in the U.S. reported overall prevalence 
rates for NAFLD of more than 65% for the obese (Chalasani et al., 2012; Lazo & Clark, 
2008a; Vernon et al., 2011). The results in this study were consistent with these reports, 
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among the obese about 72 % developed NAFLD, compared to 28% in the non-obese 
group. Interestingly, in the adjusted analysis obesity was associated with a 16% decreased 
risk for NAFLD, unlike studies in the general population where the risk was an 
independent predictor for increased risk (Lazo et al. in 2013). Perhaps this unexpected 
reversal could be explained by the fact that BMI was used in this study instead of waist 
circumference, a more sensitive measure for central obesity and a measure recommended 
by the NAFLD guidelines (Alberti et al., 2009; Crowson, Matteson, Davis,  & Gabriel, 
2013). This paradoxical finding related to obesity has also been previously reported in the 
RA literature, where overweight and obesity were associated with reduced relative risk 
for of all-cause and cardiovascular mortality and this was regardless of age and disease 
duration (Wolfe & Michaud (2012). As alluded previously, this may be an unique finding 
related to patients with RA, with chronic inflammation linked to adipose tissue (obesity), 
some have even reported that there maybe some protective effect with increasing body 
mass among patients with RA instead of the known harmful effect of obesity (Crowson, 
et. al, 2013). 
In this study about 19% of patients with RA had metabolic syndrome.  Among 
patient with RA metabolic syndrome was identified as an independent NAFLD predictor, 
with an increased risk of 21%. The proportion of metabolic patients that developed with 
NAFLD was about 20% and was similar to the findings in the general population with 
prevalence rates that ranged from 20.5% to 43.%  in the U.S. (Smits et al., 2013;  Ong et 
al., 2008).  However, unlike the general population, where the risk for NAFLD was 
associated with the presence of any and all factors related to metabolic syndrome 
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(Vernon et al., 2011), in this study about 80% of patients without metabolic syndrome 
developed NAFLD, conceivably another finding unique to patients with RA. This 
phenomena maybe related to other comorbid conditions prevalent among patients with 
RA such as insulin resistance, hypertension and increased waist circumference, a measure 
not available in this study (Ferraz-Amaro, González-Juanatey, López-Mejias, Riancho-
Zarrabeitia & González-Gay, 2013).  
Similar results were seen for patients with dyslipidemia, more RA patients (74%) 
without dyslipidemia developed NAFLD.  In this study 25 % of patients in the overall 
cohort developed NAFLD and was within the range of prevalence reported in the U.S. 
(See Figure 16), Similar to the risk for NAFLD seen in the general population (Chalasani 
et al., 2012). This study also found dyslipidemia to be an independent predictor for 
NAFLD with an increased risk of 31%.  
Only 7% had diabetes in this study. The NAFLD rate among the diabetics (8.3%) 
was lower then the prevalence rates reported for the general population in the U.S. of 
15.8% to 26.3% (Lazo et al., 2011; Williams et al., 2011). Unlike studies in the general 
population where diabetes was associated with increased risk for NAFLD (Chalasani et 
al., 2012),  in this study diabetes was an independent predictor for lower risk for NAFLD 
(16%). It is unknown if this is another unique finding for patients with RA, or perhaps 
related to underlying insulin resistance, a measure that was not available in this study 
(Ferraz-Amaro et. al., 2013). 
Potential confounders associated with NAFLD were hypertension, cardiovascular 
disease, liver enzyme elevation, alcohol use, and liver disorders. In the general population 
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these factors have been associated with NAFLD but are not recognized as independent 
risk factors for NAFLD by the guidelines  (Chalasani et al., 2012). The overall 
prevalence of these factors was less than 10% for liver enzyme elevation, 37% for 
hypertension, and 40% for alcohol use in this study. After adjusting for confounders, 
hypertension and a history of cardiovascular disease were found to be independent 
predictors for the development of NAFLD for patients with RA. There was an 11% 
increased risk for NAFLD for those with hypertension and 19% for those with 
cardiovascular disease.  
Only about 8% of this cohort with RA had liver enzyme elevation developed 
NAFLD. A similar rate was seen in the general population (Chalasani et al., 2012). In the 
adjusted analysis there was increased risk for NAFLD (5%) for patients with RA but was 
not statistically significant. More patients not using alcohol developed NAFLD (63%) in 
the RA population. Unlike the general population where there was an association for 
increased risk for NAFLD (Chalasani et al., 2012). In the adjusted analysis use of alcohol 
was not a significant predictor for NAFLD, but had a small risk reduction of 3%.  Similar 
non-significant results were seen for those with a history of liver disorders and history of 
cancer with an increased risk for NAFLD of 18% and 7% respectively. Additionally, in 
this study those with education and insurance had a reduced risk for NAFLD. 
Inexplicably, exercise was associated with increased risk for NAFLD by 9%; this finding 
is contrary to the NAFLD guidelines, where exercise along with diet was recommended 
to reduce risk for NAFLD (Chalasani, 2012). 
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As previously stated, information about risk factors in the general population has 
been well characterized; however, such information related to RA is not available in the 
literature. Among those with NAFLD, 35% had disease duration of 10 years or more, 
29% had early RA and 18% had disease duration of 2 to 10 years. Inclusion of RA related 
factors in the model showed that baseline disease duration was an independent predictor 
for lower risk for NAFLD (12%) and this was regardless of the category of disease 
duration.  Implication of these findings warrants further exploration to understand the 
impact of disease duration, changes in disease severity, influence of medication and 
development of comorbidities over time (Ferraz-Amaro et. al., 2013). 
Among those with NAFLD, the proportion of patients in low disease activity 
(32%), moderate activity (30%) and high disease activity (29%) were similar but lower 
for those in remission (16.2%). It appears that there may be a dose type association with 
increased baseline disease activity and risk for NAFLD. Baseline disease activity was not 
a significant independent predictor for the development of NAFLD, although there was 
an increased risk for NAFLD for those with moderate and high disease activity (3% and 
8% respectively), and a reduced risk (2%) for those with low disease activity.  
As hypothesized, use of MTX was an independent predictor of development of 
NAFLD, with an 8% increased risk. Most of this cohort was currently using MTX (70%), 
and almost three fourths of them developed NAFLD. A similar result was seen with those 
using cDMARD also with an increased risk of 8%. Other drugs used for RA, including 
biologics and steroid use were not statistically significant risk factors for NAFLD, 
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however there were directional changes; steroids were associated with an increased risk 
of 4% and biologics with a reduced risk of 2%.  
In summary, as postulated patients with RA developed NAFLD similar to the 
rates seen in the general population. A priori it was hypothesized that the following 
factors would be predictors for the development of NAFLD, these included age, gender, 
race/ ethnicity, obesity, metabolic syndrome, diabetes, and dyslipidemia. As expected, 
they were significant independent predictors for increased risk for the development of 
NAFLD except for obesity and diabetes were associated with reduced risk, and 
race/ethnicity was not a significant factor. MTX use, liver enzyme elevation, liver 
disorders, and alcohol use were identified as potential predictors for NAFLD apriori, 
however, among these factors only current use of MTX was identified as a significant 
predictor for increased risk for NAFLD. In this population with RA, comorbidities such 
as hypertension and CVD were found to be independent predictors for increased risk for 
NAFLD as was disease activity, where as diseased duration was associated with 
decreased risk. 
Study Limitations 
This was a non-randomized study that used secondary data and utilized a non-
probability sample of convenience. Threats to internal and external validity were 
previously outlined in Chapter 1. The data used for this analysis were retrieved from a 
large U.S. registry of RA patients. It has been previously established that the results from 
this registry is generalizable to a national U.S. population of patients with RA (Curtis. J., 
Chen, L., Yun, H., et al, 2013). One of the strengths of this study is its large sample size 
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and longitudinal data collected over 14 years. However, pertinent to this study is the 
potential for systematic selection bias, since the cohort was primarily selected based on 
availability of laboratory parameters (liver enzyme and platelet counts), measures 
available in the registry. Thus there could be selection bias potentially leading to 
systematic differences between the study cohort and the rest of the patients in the 
registry. The impact of this limitation was evaluated by comparing the NAFLD cohort 
with the overall registry population. There was a statistically significant difference 
between those in the NAFLD cohort compared to those remaining in the registry for all 
the variables except for ethnicity and liver disorders. These differences were mainly 
driven by the large sample size. The overall registry had 40,300 RA patients and almost 
half of this population was included in the NAFLD cohort. Upon further evaluation, 
clinically and numerically the NAFLD cohort appeared to be mostly similar to the overall 
registry for most of the variables, however this may still pose some limitations in terms of 
generalizability of the results. 
Another limitation with this study was related to missing data. It is not known if 
these values were missing due to loss of follow up or underreporting and thus could 
potentially lead to bias.  This limitation was addressed statistically using the multiple 
imputations to increase the precision and robustness of the results. There were some other 
limitations to note related to assumptions associated with survival analysis. For this 
analysis, I assumed that the censored cases and the ones lost during the course of study 
were not systematically different from those with an event at the end of the study, as this 
would inevitably result in nonrandom loss of cases potentially leading to bias. Since this 
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was a retrospective study that used a sample of convenience such data and reasons for 
loss were not collected so I can only assume that the reasons for lost cases was similar for 
those censored and or those with an event. I used the Breslow test to address this issue 
analytically, as this test weights the differences in survival according to the number at risk 
at each time point, and showed there was no difference between the cases, thus 
statistically addressing issues with systematic loss of cases. 
Another potential limitation related to survival analysis is the assumption that 
factors that would affect survival in the beginning would be the same factors affecting 
survival at the end of the study also. For this study in the absence of data, I assumed that 
environmental factors and other conditions for survival would be similar over time and 
these factors would be the same for both the event and censored group.  Thus the results 
of this exploratory hypothesis-generating study using observational data can only be 
interpreted under the conditions the study was conducted, and thus alternative 
explanations cannot be completely ruled out (Szklo &Nieto, 2013, pp. 391-426). 
Recommendations for Future Research 
The strength of this study was the large sample size and access to data that was 
collected over a period of 14 years. The findings from this study identified for the first 
time the incidence and factors associated with the development of NAFLD among 
patients with RA.  Most of the findings were generally consistent with what is known in 
the general population. The rate of 31% was similar to the rate seen in the U.S. general 
population, however there were some notable unique differences for the predictors of 
NAFLD in the RA population. In this study, I did not directly compare the rates between 
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the RA population and the general population. Such a comparison would be useful from a 
clinical perspective, particularly to understand if the RA population known to have 
systemic inflammation would be potentially at higher risk for NAFLD then the general 
population. In this study among those who developed NAFLD, most developed mild to 
moderate NAFLD and only a few had advanced disease. Additional long term studies are 
needed to determine rate and time to progression of advanced disease. 
The cohort in this study included mostly Caucasians; further studies are needed to 
better understand incidence and factors associated with the development of NAFLD in 
other minority race and ethnic groups. Unlike the general population, in this study 
patients with diabetes and obesity appeared to have reduced risk for NAFLD. Additional 
research is needed to better understand if this phenomenon is unique to RA patients with 
NAFLD having these comorbidities (metabolic syndrome, insulin resistance) or perhaps 
these patients are affected by the chronic use of immunosuppressants (e.g. anti TNF-
alpha) used for the treatment of RA (Ferraz-Amaro et. al., 2013) . 
Also, confirmed in this study was that patients treated with MTX are at increased 
risk for the development of NAFLD; however further studies are needed to identify 
alternative RA treatments that may reduce the risk for NAFLD. The dataset did not 
support assessing the effect of time varying variables on the outcome, as only baseline 
factors were available. It would have been particularly interesting to understand the 
impact of factors related to RA, such as change in duration and severity of disease, or 
changes in RA treatment and the impact on NAFLD. These are areas that warrant further 
exploration. Finally, additional studies using the FIB-4 score are warranted to further 
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confirm the utility of this tool for the early diagnosis and management of NAFLD. 
Social Change Implications 
This study further confirmed existing theories related to NAFLD in another 
chronic condition, RA. The findings from this study supports previous hypotheses related 
to the complex relationship between chronic inflammation affecting the liver, factors 
such as obesity, metabolic dysfunction, altered lipid metabolism and that these factors 
remain central to the development of NAFLD in the RA population also. Thus this study 
had some novel findings and adds to the body of knowledge to further the advancement 
of science but more importantly provides insights for better care of patients with RA.  
The findings of this study provide a unique opportunity for social change 
including the early diagnosis of NAFLD using a novel, less expensive, noninvasive tool. 
This study used FIB-4, a diagnostic tool that can be used to identify mild/moderate and 
advanced NAFLD and can easily be incorporated into routine care. Thus FIB-4 is a 
practical tool for the early diagnosis and management of NAFLD among patients with 
RA. 
The results of this study helps inform future studies as it identified independent 
predictors for the development of NAFLD among patients with RA, along with providing 
rates of prevalence of these risk factors.  It also sheds light on the time to development of 
NAFLD for patients with RA. About a third of the RA population developed NAFLD, 
highlighting the need for policies that support surveillance programs and also those that 
foster interdisciplinary approaches to identify and manage these interrelated chronic 
conditions. Predictors and factors associated with the development of NAFLD are useful 
180 
 
information for public health practitioners and clinicians. Such evidence can be used to 
inform practice, policy, particularly for a newly identified population with NAFLD, 
patients with RA. The findings of this study and ensuing publications can add substantive 
evidence to the body of literature and thus can enable increased public awareness of 
NAFLD among patients with RA. 
Conclusion 
The results of this study established for the first time that about 31% of RA 
patients are at risk for developing NAFLD and the mean time to event was about 7 years. 
A novel non-invasive tool (FIB-4 score) was used to identify the various stages of 
NAFLD. Of note was that most developed mild to moderate NAFLD (30%) and only 
about 1.4% had advanced disease. Overall there were statistically significant differences 
for all of the clinical and demographic variables when the two subgroups of those with 
and without NAFLD were compared, except for smoking and obesity where there was no 
difference. The prevalence of several key comorbidities was higher in the NAFLD group 
such as hypertension, CVD, diabetes, and metabolic syndrome. Patients with these 
conditions, nonusers of alcohol and smokers were more likely to develop NAFLD 
significantly sooner.  However there were some unique unexpected findings for RA 
patients with obesity and diabetes, unlike the general population these factors were 
associated with reduced risk for NAFLD. 
The results from the bivariate as well as the multivariate analysis were consistent 
for most the key variables, except for race and ethnicity, cancer, liver disorder and 
alcohol use with loss of significance in the adjusted model. Factors such as being 
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divorced or separated, and having insurance were associated with reduce risk and 
diabetes reversed from increased risk to lower risk in the adjusted model.  This study 
using a large dataset with longitudinal data collected over period of 14 years identified 
for the first time the following variables as independent predictors of increased risk for 
NAFLD. The risk factors are age (middle age, elderly), exercise, hypertension, 
cardiovascular disease, diabetes, dyslipidemia, metabolic syndrome and MTX use. 
Predictors associated with statistically significant reduced risk for NAFLD were gender 
(female), diabetes, obesity, disease duration, divorced or separated, and having insurance.  
Thus this study has identified yet another population at risk for NAFLD those 
with RA and further confirms its association with other chronic conditions such as 
dyslipidemia, metabolic syndrome, hypertension and cardiovascular disease. This study 
furthermore highlights the need for early diagnosis and management of NAFLD, which 
can be accomplished by using an easily available a noninvasive tool, FIB-4 score.  The 
ubiquitous prevalence of NAFLD continues to be an emerging public health challenge 
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